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Chapter 1
General introduction
“Between the health care we have
and the care we could have
lies not just a gap, but a chasm.”
(Institute of Medicine)

Chapter 1
11
General introduction
bACkGroUnD
Genetics is a rapidly developing field of science. Just the last decade has seen its evolu-
tion from the first complete sequencing of a single reference human genome in 20031 
to next generation sequencing nowadays allowing individual genome-wide analysis in 
clinical diagnostics.2 Genetic counseling acts as its clinical counterpart, guiding both 
patients and families in the translation of their genetic information to day-to-day life.3 
Novel technological advancements and increased public awareness of genetic aspects 
of disease, as well as the growing call for more patient participation in medical decision-
making4 frequently lead to new models of genetic services.5
The focus of this thesis is the evaluation of patient experiences with innovations in 
genetic testing and counseling, mainly regarding hereditary cancer. The goal is to give 
further insight to both genetic and non-genetic health care professionals to provide 
appropriate support in the context of the new developments and to assess needs for 
further innovation regarding genetic counseling and clinical follow-up. This chapter first 
describes the standard cancer genetic diagnostic process6 and how the evaluation of 
patient experiences has already helped shape this process. Next, the current theoretical 
models and literature regarding psychological effects of conventional genetic testing 
and counseling are summarized. Finally, research needs in each stage of the genetic di-
agnostic process are discussed within the context of two well-known hereditary cancer 
syndromes, followed by an overview of the thesis chapters.
Genetic Diagnostic Process
The standard process surrounding the diagnosis of hereditary cancer can be split into 
three stages:
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1. recognition & referral: Patients at high risk for hereditary cancer are selected by 
non-genetic health care professionals (e.g. general practitioners, medical oncologists, 
surgeons, gynecologists) for referral to and further evaluation at a human genetics 
department.
2. Genetic testing & Counseling: Clinical geneticists and genetic counselors provide 
in-depth counseling regarding the possibility and consequences of hereditary 
cancer. Patients may be offered genetic testing in this stage. The current standard 
generally includes two face-to-face genetic counseling sessions: pre- and post-test.5
3. follow-up & Prevention: Should hereditary cancer be confirmed by genetic testing, 
these mutation carriers are recommended intensive surveillance or prophylactic 
measures for early cancer detection and prevention. Family relatives are also eligible 
for testing or surveillance.
impact of patient experiences
Dissemination of health care innovations into clinical practice is a long standing chal-
lenge. Involved parties may be hesitant to adopt innovations when uncertain about 
the consequences7 which may include the psychological impact on patients. Evaluat-
ing outcomes reported by patients themselves may reduce this uncertainty, therefore 
increase adoption of novel strategies experienced as beneficial.
Patient experiences have already influenced cancer genetic counseling, originally 
based on the genetic diagnostic process for Huntington’s disease, a neurodegenerative 
disease without treatment options.8 This Huntington protocol included two mandatory 
pre-test counseling sessions to ensure proper decision-making to start genetic testing, 
followed by a post-test session to discuss test results. Contrary to Huntington’s disease, 
hereditary cancer syndromes are often actionable: prevention measures can be taken 
to effectively lower cancer mortality.9,10 Therefore patients may feel empowered by 
this knowledge: they can take action i.e. control these high cancer risks.11 Research 
confirmed that patients tested for hereditary cancer reported no long-term increase in 
psychological distress12, leading to hereditary cancer clinics making the second pre-test 
session optional.8
However, considering increasing awareness therefore demand for cancer genetic test-
ing, even this two visit model may hamper patient access to cancer genetic services. 
Alternative models must be developed and evaluated for their beneficial as well as 
adverse effects.5
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Psychological effects of Genetic testing
Two main motivations were expressed by patients regarding their wish to start genetic 
testing: the need for information and the need for control11: once patients know that 
they are at an increased risk for developing cancer, they can take preventive measures.9,10 
But the possibility or presence of increased cancer risks may have a psychological im-
pact in itself. This is demonstrated by a recent review13 which identified six overarching 
themes as specific psychosocial issues of these patients:
1. Coping with cancer risk, such as reassessing their life and priorities after genetic 
counseling, but also positive thinking and changing lifestyle behavior;
2. Practical issues, including concerns about access to health or life insurance, negative 
effects on employment and the burden of waiting times in the genetic diagnostic 
process;
3. Family-related problems, mainly revolving around communication, from finding sup-
port to start genetic testing to disclosure of the test result to family members;
4. Children-related problems, such as worries that their children (mainly daughters) may 
be at an increased risk of cancer, as well as uncertainty how best to inform their 
children;
5. Living with cancer, fear and thoughts about the risk of developing cancer, side effects 
of preventive measures and the impact of cancer within their family;
6. Emotions, mainly in reaction to genetic test results, which can be both negative 
(distress, fear, anxiety) and positive (reassurance, relief, reduced anxiety).
These issues can be experienced by all individuals undergoing evaluation for hereditary 
cancer, allowing a normal range of psychosocial impact which is normally covered by 
standard genetic counseling.8 However, about a quarter of patients experiences serious 
(i.e. clinically relevant) levels of psychological distress coming forth from these issues, 
which may require additional psychosocial support.13 Therefore these six themes are 
also represented by the psychological outcomes used in many research studies to evalu-
ate patient experiences of the genetic diagnostic process.14
Models of psychological distress
To understand psychological distress in the context of genetic testing for hereditary 
cancer, several conceptual models from health psychology can be used. Van Oostrom 
e.a.15 previously applied Leventhal’s Common Sense model of Self-regulation and 
Psychological Adjustment. This model used the individual’s perception of illness as the 
basis for coping responses (monitoring i.e. actively seeking information about medical 
threats and blunting i.e. passively seeking distraction16) and psychological well-being. 
Pessimistic illness perception was related to high-risk perception (i.e. expectations), 
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causal attribution to genetic factors and passive coping, which in turn was related to 
hereditary cancer distress.15
An elaboration of the Common Sense model was proposed by Baum e.a.17 This Stress 
and Coping model also included the test result, disease characteristics and social sup-
port as factors playing into the extent of psychological distress triggered by genetic 
testing. If the individual experiences the test result as dangerous (dependent on risk/
illness perception and disease characteristics) or an excessive demand (dependent on 
coping style and social support), this leads to possibly serious stress.
The psychological studies described in this thesis are based on these conceptual models, 
evaluating characteristics such as coping style, risk perception and illness perception as 
possible influencing factors on the resulting level of psychological distress within the 
context of genetic testing.14
Psychological distress in hereditary cancer
Certain patients are at potential risk for serious psychological distress during genetic 
testing. A recent review of individuals tested for Lynch syndrome by Bleiker e.a.18 showed 
that this included: female patients, index patients (i.e. the first person in a family to un-
dergo genetic counseling/testing), patients with high cancer risk perception, high dis-
tress prior to counseling, a history of depression or professional psychological support, 
parental cancer during childhood or lack of social support. Most studies in this review 
focused on patients without a prior history of cancer (unaffected) who experienced clear 
psychological benefit (decreased cancer anxiety) if no mutation was identified, while 
those with mutations reported only short-term increases of distress without adverse 
long-term effects.18 Similar results were found in patients tested for hereditary breast 
cancer.12
Another review by Landsbergen e.a.19 focused specifically on patients already diagnosed 
with (colorectal) cancer: 25% of these already affected patients reported clinically rel-
evant distress. This dropped to 13% after genetic counseling. After result disclosure, mu-
tation carriers were more distressed than non-carriers, but their distress also returned to 
baseline levels over time.19
In summary, both affected and unaffected carriers may experience short-term psycho-
logical distress due to conventional genetic testing for hereditary cancer, but report no 
long-term effects. Innovations in cancer genetic testing and counseling discussed in 
this thesis are evaluated within this light, assessing whether patient experiences deviate 
from this known trend.
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Stage i: recognition & referral
Colorectal cancer (CRC) and breast cancer (BC) are two of the most common types of 
cancer worldwide.20 Both have well-known hereditary forms.21 But due to the common 
occurrence of CRC and BC in the general population, it may be difficult to recognize 
these families at risk for hereditary cancer. However, hallmarks of most hereditary can-
cers are an early age of onset and a positive family history.21 Syndrome specific clinical 
and family history criteria further help non-genetic clinicians determine the need for 
in-depth evaluation by a clinical genetic professional.
Colorectal cancer (CRC)
About 3% of CRC cases is estimated to be based on Lynch syndrome (LS) as the most 
common hereditary form of CRC.22 LS is caused by a mutation in one of the mismatch 
repair (MMR) genes: MLH1, MSH2, MSH6 and PMS2.22,23 Unaffected LS carriers are at 
increased cumulative lifetime risk primarily for developing CRC (25-70%) and, in women, 
endometrial cancer (30-70%).24 Age at diagnosis of LS-related CRC ranges from 41 to 
54 years, significantly lower than sporadic CRC at an average age of 70 years.25-28 While 
both sporadic and LS-related CRC arise from adenoma developing into carcinoma, this 
progression occurs more rapidly in LS patients.29 Clinical suspicion of LS is based on 
several clinical criteria such as the revised Bethesda guidelines shown in Table 1.30 CRC 
tumor material can be tested for molecular characteristics of LS, prior to DNA analysis 
for germline mutations.29
Breast cancer (BC)
Less than 10% of BC cases are estimated to be based on a genetic predisposition, most 
commonly a mutation in the BRCA1 or BRCA2 genes leading to hereditary breast/ovarian 
cancer (HBOC).21 Unaffected female BRCA-mutation carriers have a cumulative lifetime 
risk of BC up to 60-80% and an increased risk of ovarian cancer (OC) up to 20-60% for 
BRCA1 and 2-20% for BRCA231-33 with a younger age of onset than sporadic tumors.34 BRCA-
mutation carriers affected with BC have an additional increased risk of a second primary 
table 1: Revised Bethesda guidelines for testing colorectal cancer (CRC) tumors for Lynch syndrome (LS).30
CRC < 50 years.
Presence of synchronous, metachronous colorectal or other LS-associated tumors*, regardless of age.
CRC <60 years with microsatellite instability-high histology (≥2 of 5 markers).
CRC in 1 or more first-degree relatives with a LS-associated tumor, with one of the cancers <50 years.
CRC in 2 or more first- or second-degree relatives with LS-related tumors, regardless of age.
* LS-associated tumors: malignancies of the endometrium, stomach, small intestine, bile ducts, ovaries, up-
per urinary tract and adenoma or carcinoma of the sebaceous glands.
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BC up to 60%.35 Without preventive measures, the average survival until 70 years of age 
is 50% in BRCA1 and 70% in BRCA2.10 To identify patients at high risk for a BRCA-mutation, 
the Dutch national guideline “Breast cancer”36 contains criteria to determine eligibility 
for referral to a clinical genetic professional as shown in Table 2.
Research needs: detection of hereditary cancers
Despite aforementioned criteria for referral to clinical genetics due to suspected he-
reditary CRC or BC, recent studies have shown that both LS and HBOC remain under-
diagnosed.37,38 Attempts to improve clinician knowledge and referral patterns39 were 
not successful.40 This demonstrates the need for innovative alternatives to improve 
recognition of LS and HBOC. Some improvement was achieved by direct CRC tumor 
genetic testing for LS based on the Bethesda guidelines, which previous studies showed 
was cost-effective41,42 and did not lead to increased psychological distress in patients.43 
However, more improvements could be made to detect more families at hereditary risk 
for cancer, especially in HBOC where no such tumor genetic testing is available. 
Stage ii: Genetic testing & Counseling
Once patients are referred for evaluation at a human genetics department, they are usu-
ally seen for genetic counseling to be advised about the most appropriate course of ac-
tion (e.g. whether to start genetic testing). One of the core tenets of genetic counseling 
is non-directiveness: genetic counselors aim to guide patients to their own individual 
decisions, by helping them interpret their genetic information and weigh their different 
options in consideration of their personal situation.44 During this process, aspects to 
consider may relate to the disease in question, the nature of the proposed genetic test, 
but also characteristics specific to individual patients themselves.45
table 2: Dutch national guideline “Breast cancer” (BC) criteria for referral to a clinical genetic professional 
due to increased BC risk.36
BRCA-mutation.
First degree relative with BC <40 years.
First degree relative with bilateral or multifocal BC, at least once diagnosed <50 years.
First degree male relative with BC, regardless of age.
BC <50 years and prostate cancer <60 years on one side of the family.
Two or more first degree relatives with BC <50 years.
Three or more first or second degree relatives with BC, at least once diagnosed <50 years.
First degree relative with ovarian or tubal cancer, regardless of age.
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Knowledge without action
Patients have reported a variety of motivations to start genetic testing for hereditary 
cancer.11 On one hand, there are clear informational needs: wanting to understand their 
cancer risks, what actions can be taken, and how their family is affected. On the other 
hand, patients are also motivated by the need to feel a sense of control. This control 
could be represented by using their newfound knowledge of carrying a hereditary pre-
disposition for cancer to take preventive actions and lower their cancer risks, effectively 
increasing their life expectancy.9,10
However, in hereditary adult-onset cancer syndromes such as LS and HBOC, cancer 
prevention measures are usually not offered until the age of 25 years, while patients 
can choose to start genetic testing from 18 years onwards.45 This may leave a consider-
able time gap between these young adults’ discovery of being a mutation carrier and 
the start of cancer surveillance. These young adult mutation carriers between 18 and 
25 years may be particularly vulnerable to distress, being aware of higher cancer risks 
without the clear ability to act upon this knowledge until the age of 2546 while still in the 
midst of developing into fully independent adults.47,48
Research needs: genetic testing in young adults
Specific support needs amongst young adults in familial adenomatous polyposis (FAP) 
have already been identified, partly resulting from the aforementioned discrepancy be-
tween testing and surveillance age.49,50 However, FAP is associated with a much earlier 
onset of cancers in childhood with early prevention recommendations and therefore, 
by exception, allows genetic testing of minors. This complicates generalization to he-
reditary adult-onset cancer syndromes, where the legal adult age must be reached to 
undergo genetic testing.45 Further study of this particular age group within hereditary 
adult-onset cancer syndromes may identify those patients in special need of support.
Next generation sequencing
Until recently, genetic diagnostic technologies could only investigate one individual 
gene per DNA sequencing test.2 Therefore such conventional DNA-testing focused on 
single genes known to be associated with the disease in question, starting with the most 
likely candidate gene, such as the LS-related genes for CRC or the BRCA1/2 genes for 
BC as the most common hereditary cancer syndromes.51 However, some diseases show 
large genetic heterogeneity: for example, over 100 genes are associated with different 
forms of hereditary cancer.52 Pinpointing most likely candidate genes for individual test-
ing based on patient and family characteristics may be difficult due to overlap in cancer 
types, and sequential single gene testing is laborious, costly and time-consuming.2
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Recent years have seen the advent of next generation sequencing (NGS). These novel 
NGS technologies allow for simultaneous testing of all genes at once, at increasingly 
higher speed and lower cost.2 This may lead to a far more rapid genetic diagnosis, pre-
venting patients from undergoing more invasive diagnostic procedures and providing 
early information about prognosis and family consequences. Genes not previously asso-
ciated with or relating directly to the disease in question are also sequenced at the same 
time. There are two sides to this approach: while new disease-causing genes may be 
discovered, there is also the risk of finding mutations in genes leading to an unrelated 
disease (so-called unsolicited findings53) or variants of unclear clinical significance.54 
As of yet, the frequency and nature of such findings are unknown, but patients must 
consider this unique possibility of NGS, prior to giving informed consent.53 This remains 
an important subject of discussion, even as NGS technologies are now steadily being 
implemented into clinical diagnostics.55,56
Research needs: psychological impact of NGS
Novel NGS techniques have several advantages over conventional sequential genetic 
testing, facilitating rapid identification of a genetic cause in highly heterogenic diseases. 
But there are also issues of concern, which have led to hesitancy amongst some genetic 
professionals to implement NGS technologies into clinical diagnostics. Concerns focus 
primarily on the ethical challenges for proper informed consent due to limited knowl-
edge about the clinical impact of new disease-causing genes and unsolicited findings, 
and consequently the psychological impact on patients receiving such results.51 Evalu-
ation of early patient experiences with NGS in such a clinical diagnostic setting could 
elucidate whether psychological impact differs from conventional genetic testing and 
how to structure the informed consent and genetic counseling procedures to guide 
patients appropriately.
Stage iii: follow-up & Prevention
In hereditary cancer, knowledge is power: intensive cancer surveillance outside of 
population screening programs is usually recommended, allowing patients to ef-
fectively manage their high cancer risks. For example, LS patients are offered frequent 
CRC surveillance from age 25 years, consisting of biennial colonoscopy and removal of 
premalignant polyps.57 This lowers CRC incidence and mortality with 60%.58 Preventive 
surgery is generally not recommended, although in LS patients already diagnosed with 
CRC, the preferred surgery of choice is a subtotal (i.e. more extensive than standard 
partial) colectomy to lower the risk of a second CRC tumor.59
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Hereditary Breast/Ovarian Cancer (HBOC)
Contrary to these straightforward CRC surveillance recommendations for LS, BRCA-
mutation carriers are faced with more difficult prevention choices.60 For early BC de-
tection, female BRCA-mutation carriers are offered intensive BC surveillance61 starting 
at age 25 years with yearly MRI and clinical breast examination, with additional yearly 
mammography from age 30 years. BRCA-mutation carriers may also opt for preventive 
mastectomy (PM) as survival benefits do not differ significantly10, although PM does 
lower the risk of BC with associated treatments by 90%.10 While most BRCA-mutation 
carriers who had undergone PM considered this as a positive experience and expressed 
relief by their lowered BC risk, this was not without cost. They also experienced unex-
pected bodily sensations following surgery (feeling different) and self-consciousness of 
the look of their new body (looking different), which negatively influenced their sexuality 
and body image.62 However, surveillance also requires frequent time investment and 
patients facing the stress of these tests at regular intervals.60 These costs and benefits 
must be weighed individually by each patient to make a well-informed choice befitting 
their personal situation.
Unlike BC surveillance, gynecological screening for the elevated OC risk is ineffective63 
as there are no known premalignant stages.64 Thus BRCA-mutation carriers are recom-
mended prophylactic bilateral salpingo-ophorectomy (pBSO) between the ages of 35-40 
for BRCA1 and 40-45 for BRCA2.34,61 pBSO lowers the risk of OC by 80-85% and, if per-
formed prior to menopause, the risk of BC with 50%.10,65 Patients consider the decision 
to undergo pBSO as easier than the decision to undergo PM.60 However, similar to PM, 
reducing OC risk by pBSO comes with a price. From a medical point of view, surgically-
induced menopause increases the risks of cardiovascular disease and osteoporosis.65 
From a patient point of view, pBSO has negative effects on both physical and emotional 
levels.62 Young women feel the additional burden and increased urgency of still wanting 
to achieve certain family life goals (e.g. childbearing wishes) before the future need for 
pBSO.60,66
Several patient specific characteristics have been associated with the choice for preven-
tive surgery versus cancer surveillance such as age, personal history of BC, parity67, high 
risk perception and a history of BC in a first-degree relative.68 Possibly this decision-
making process is also influenced by advice from their physicians.69 Cancer prevention 
recommendations may differ between countries70, medical specialties, and physicians 
with varying levels of experience with genetic testing.71,72
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Research needs: follow-up of HBOC
BRCA-mutation carriers may be seen by a wide range of physicians in different levels of 
health care: first line of general practitioners, second line of regional hospitals and third 
line of university medical centers (UMC). Further research is needed to evaluate whether 
patients supported for cancer prevention in regional hospitals differ from those sup-
ported in UMCs, and how this might influence the decision-making process regarding 
cancer (especially BC) prevention. UMCs have expert teams specialized in hereditary 
cancer who may have a different focus in patient groups and advice, which might be 
most effective if matched to both patients’ and regional specialists’ needs.
thesis outline
This thesis contains the results of several studies mainly evaluating patient experiences 
in both current and novel procedures within the genetic diagnostic process. The sec-
tions of this thesis reflect the three stages of this process as described in this general 
introduction (Chapter 1). Individual chapters focus on a certain procedure within each 
stage; some evaluate current standard care to determine the need for further innova-
tion, others assess the effects of novel procedures in practice.
The first part of this thesis addresses the stage recognition & referral, in which non-
genetic health care professionals select high-risk patients to be referred to a human 
genetic department.
Chapter 2 describes efficacy and cost-effectiveness analyses of a recently proposed 
change in international guidelines for improved detection of Lynch syndrome, which 
would empower more patients and their family members to take preventive measures 
and lower their cancer mortality.
Chapter 3 outlines the study protocol to evaluate a novel procedure for patients with 
breast cancer, replacing initial face-to-face genetic counseling prior to DNA-testing 
(current practice) by telephone, written and digital information sent to patients’ homes. 
Evaluation of this so-called DNA-direct procedure is described in Chapter 4 (short-term 
follow-up) and Chapter 5 (long-term follow-up).
The second part of this thesis refers to the stage Genetic testing & Counseling, in 
which patients are seen by clinical geneticists or genetic counselors at a human genet-
ics department.
Chapter 6 illustrates patient reported outcomes of testing for hereditary cancer 
before the recommended age of surveillance (25 years), to determine whether genetic 
testing between 18 and 25 years prior to the start of surveillance measures is acceptable 
to these young adult patients.
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Chapter 7 contains results of the very first study evaluating early patient experi-
ences of gene panels based on exome sequencing (one of the novel next generation 
sequencing technologies) in a clinical diagnostic setting, using quantified psychological 
measures.
The third part of this thesis pertains to the stage follow-up & Prevention, in which 
patients with a hereditary predisposition for cancer are recommended intensive surveil-
lance or preventive surgery.
Chapter 8 outlines the characteristics and experiences of female BRCA-mutation 
carriers with follow-up care in a regional or university hospital, evaluating the regional 
collaboration between second and third lines of health care for BRCA-mutation carriers.
Chapter 9 concludes this thesis with a general discussion on patient experiences with 
innovations in the genetic diagnostic process and future perspectives.
Chapter 10 summarizes this thesis as a whole, followed by a list of associated pub-
lications and acknowledgements of those individuals who have supported the work 
collected here in various ways.

STAGE I
Recognition and referral
“The world is full of obvious things 
which nobody by any chance ever 
observes.”
(Arthur Conan Doyle)

Chapter 2
Fourfold increased detection of 
Lynch syndrome by raising age limit 
for tumour genetic testing from 50 to 
70 years is cost-effective
Sie AS
Mensenkamp AR
Adang EM
Ligtenberg MJL
Hoogerbrugge N
Ann Oncol. 2014;25(10):2001-7
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Cost-effective Lynch syndrome detection
AbStrACt
background: Recognising colorectal cancer (CRC) patients with Lynch syndrome (LS) 
can increase life expectancy of these patients and their close relatives. To improve iden-
tification of this under-diagnosed disease, experts suggested raising the age limit for 
CRC tumour genetic testing from 50 to 70 years. The present study evaluates the efficacy 
and cost-effectiveness of this strategy.
Methods: Probabilistic efficacy and cost-effectiveness analyses were performed 
comparing tumour genetic testing of CRC diagnosed at age 70 or below (experimental 
strategy) versus CRC diagnosed at age 50 or below (current practice). The proportions 
of LS patients identified and cost-effectiveness including cascade screening of relatives, 
were calculated by decision analytic models based on real life data.
results: Using the experimental strategy, 4 times more LS patients can be identified 
among CRC patients as compared to current practice. Both the costs to detect one LS 
patient (€ 9,437/carrier versus € 4,837/carrier), and the number needed to test for detect-
ing one LS patient (42 versus 19) doubled. When family cascade screening was included, 
the experimental strategy was found to be highly cost-effective according to Dutch 
standards, resulting in an overall ratio of €2,703 per extra life year gained in additionally 
tested patients.
Conclusion: Testing all CRC tumours diagnosed at or below age 70 for LS is cost-effective. 
Implementation is important as relatives from the large number of LS patients that are 
missed by current practice, can benefit from life-saving surveillance.
keywords
genetic – hereditary – colorectal cancer – Lynch syndrome – screening
key Message
Recognising colorectal cancer (CRC) patients with Lynch syndrome (LS) can increase life 
expectancy for patients and relatives. By raising the age limit for CRC tumour genetic 
testing from 50 to 70 years, 4 times as many LS patients are detected, which is cost-
effective when including family cascade screening. Implementation is important to 
reach relatives of LS patients missed by current practice.
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introDUCtion
Identification of Lynch Syndrome (LS: confirmed germline mutation) amongst patients 
with colorectal cancer (CRC) leads to effective surveillance and can prevent premature 
deaths of these patients and their relatives.58 LS is the most common hereditary form of 
CRC, accounting for 1-3% of all CRC.24 Identification of LS is based on family history and 
young age at diagnosis of CRC (below age 50) as in the Amsterdam-II and Bethesda cri-
teria (see online only supplemental S130,73). Due to small families, unawareness of family 
history and current age limits, only a proportion of the expected number of LS patients 
is identified.37 Unawareness of LS patients of their increased cancer risk and prevention 
options leads to unnecessary CRC incidence.
LS is caused by a mutation affecting one of the mismatch repair (MMR) genes: MLH1, 
MSH2, MSH6 and PMS2.22,23 LS patients have a high risk of developing CRC (25-70%), 
endometrial cancer (30-70%), and an increased risk for several other types of cancer 
(stomach, ovaries, urinary tract, brain, small bowel, hepatobiliary tract, skin).24 Over 
90% of LS-related CRC and 10-15% of sporadic CRC are characterised by microsatellite 
instability (MSI).74 MSI-testing in newly diagnosed CRC patients fulfilling MIPA criteria 
(MSI Indicated by a PAthologist42: S1) based on Bethesda guidelines, including diagnosis 
below age 50, was shown to be cost-effective (€3,801/life year gained).41
Recently a European meeting of experts specialised in LS recommended an age limit of 
70 instead of 50 years24, thereafter incorporated in ESMO guidelines.29 Updated NCCN 
guidelines advocate universal screening or selectively testing all CRC≤70 and CRC>70 
fulfilling Bethesda criteria75; both strategies equally result in a higher diagnostic yield 
in comparison to the limit of 50 years.76 However, no cost-effectiveness analyses were 
performed to justify the costs for additionally testing CRC patients diagnosed between 
ages 51-70 years.
Increasing the age limit from 50 to 70 years will greatly increase numbers to test: only 
5-6% of CRC is diagnosed below age 50 versus 50% below age 70.77 MSI-testing at higher 
age may be less effective as young age at diagnosis is a hallmark of hereditary cancer, 
and MSI-high tumours at older age more often are caused by non-hereditary MLH1 
promoter hypermethylation.74
To evaluate genetic testing of CRC diagnosed at age 70 or below (experimental strategy) 
versus age 50 or below (current practice) an economic evaluation was performed for 
newly diagnosed CRC index patients (i.e. first CRC patient tested within one family) 
including family cascade screening.
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MethoDS
Efficacy (proportion of LS patients identified amongst CRC index patients) was com-
pared between the experimental strategy (CRC≤70) versus current practice (CRC≤50). 
Only age at diagnosis for one CRC tumour was considered, excluding criteria based 
on additional tumours or family history.30,42 Cost-effectiveness analyses included both 
index patients and relatives tested by cascade screening. Effectiveness was expressed 
in life years gained and direct medical costs in Euros (€), based on the Dutch healthcare 
system, using a time horizon of average life expectancy.
Cost-effectiveness models
Three decision analytic models were developed using TreeAge version 2013. The first 
model (Figure 1) was aimed at efficacy, focusing on CRC index patients tested for MSI at 
age of diagnosis 70 or below (experimental strategy) versus 50 or below (current prac-
tice). The second model was aimed at cost-effectiveness (S2) using the same decision 
tree, but focusing on additionally tested index patients diagnosed with CRC between 51 
and 70 years. Integrated Markov chain analyses (S3a) evaluated survival and follow-up 
all CRC
patients
post-surgery
experimental strategy:
CRC ≤ 70
current practice:
CRC ≤ 50
CRC ≤ 70:
start MSI
MSI-High
IHC abnormal
MLH1
absent
test for
MLH1 promoter
hypermethylation
no MLH1
promoter
hypermethylation
patient is oered
DNA germline
mutation testing
mutation found
no mutation
conrmed MLH1 promoter hypermethylation
MSH2, MSH6,
and/or PMS2 absent
MSI-Low or negative
CRC > 70:
no MSI tested
0.50
±0.00
#
0.11
±0.01
0.69
±0.03
0.30
±0.04
0.33±0.07
#
0.31
±0.03
#
#
IHC normal
#
0.97
±0.01
start DNA germline
mutation testing
patient declines
#
patient is oered
DNA germline
mutation testing
mutation found
no mutation
0.68±0.06
#
start DNA germline
mutation testing
patient declines
#
CRC ≤ 50:
start MSI
MSI-High
IHC abnormal
patient is oered
DNA germline
mutation testing
mutation found
no mutation
MSH2, MSH6,
and/or PMS2 absent
MSI-Low or negative
CRC > 50:
no MSI tested
0.06
±0.00
#
0.12
±0.02
0.38
±0.07
0.80
±0.09
0.50±0.13
#
0.62
±0.07
#
#
IHC normal
#
0.93
±0.03
start DNA germline
mutation testing
patient declines
#
patient is oered
DNA germline
mutation testing
mutation found
no mutation
0.69±0.08
#
start DNA germline
mutation testing
patient declines
#
0.84±0.05
sporadic
sporadic
no uptake
Lynch
sporadic
sporadic
no uptake
Lynch
sporadic
no MSI
sporadic
sporadic
no uptake
Lynch
sporadic
sporadic
no uptake
Lynch
sporadic
no MSI
0.84±0.05
0.84±0.05
0.84±0.05
no MLH1
promoter
hypermethylation
conrmed MLH1 promoter hypermethylation
MLH1
absent
test for
MLH1 promoter
hypermethylation
figure 1: Patient-based decision analytic model for identifying Lynch syndrome (LS) amongst colorectal 
cancer (CRC) index patients to determine the efficacy (LS patients detected) of the experimental strategy 
testing CRC at 70 years or below (CRC≤70) versus current practice testing CRC at 50 years or below (CRC≤50). 
Numbers reflect the probability (mean±standard deviation as derived from literature, see online only S5) of 
the variable; # is the complementary probability (1-p).
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(intensive if tested in experimental strategy; standard if not tested in current practice) of 
a hypothetical cohort of CRC51-70 patients using stochastic data (means with standard 
deviations) to perform probabilistic sensitivity analyses (N=1000 Monte Carlo simula-
tions). The third model (Figure 2) focused on cost-effectiveness in relatives of CRC51-70 
patients identified as LS patients, with an integrated Markov model (S3b) for survival and 
surveillance (intensive if tested; none if not compliant or tested). First CRC in LS relatives 
non-compliant to surveillance, was assumed to be treated as LS-related. Future costs 
and effects were discounted at 4% to present values.78 Acceptable cost-effectiveness 
threshold was €80,000 per life year gained, assumed equal to quality-adjusted life years.79
Cost data sources and assumptions
Costs per care unit are shown in S4. Procedures for genetic counseling, colonoscopy, 
CRC treatment and follow-up were considered unchanged from 200541: costs were cor-
rected for the Dutch consumer price index for healthcare.80 Genetic testing costs have 
changed substantially thus were newly assessed (August 2013) locally. Average costs for 
DNA-analysis of index patients were based on pair wise testing of genes MLH1/PMS2 or 
MSH2/MSH6 (single DNA isolation processing). Average costs for DNA-analysis of rela-
tives were based on gene distribution in a local database including all index LS patients 
diagnosed between May 1996 and August 2013 (N=182: MLH1 32%, MSH2/EPCAM 34%, 
MSH6 23%, PMS2 12%). Overhead costs (35.5%) were included.78
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(detected)
compliance surveillance
no compliance surveillance
if tested:
no mutation found
no Lynch
0.39
±0.02
#
0.88
±0.05
#
family relative of
CRC51-70 patient
identi ed as
LS patient
M1
M2experimental strategy:
tested
current practice:
not tested
not tested:
mutation found
(missed carrier) no compliance surveillance
not tested:
no mutation found
no Lynch
0.39
±0.02
#
#
M3
Lynch detected:
surveillance and intensive CRC treatment
Lynch detected:
no surveillance, intensive CRC treatment
Lynch missed:
no surveillance, standard CRC treatment
figure 2: Family-based decision analytic model for identifying Lynch syndrome (LS) amongst relatives of 
patients with colorectal cancer (CRC) between 51-70 years identified as LS patients, either tested and de-
tected by the experimental strategy or not tested and missed by current practice. Numbers reflect the 
probability (mean±standard deviation as derived from literature and local database, see online only S6) of 
the variable and # the complementary probability (1-p).
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Patient data sources and assumptions
Data for patient-based models (S5) was based on a literature review, searching the 
PubMed database for MESH terms [Colorectal Neoplasms Hereditary Nonpolyposis AND 
Genetic Testing AND Aged AND Microsatellite Instability]. Search results were selected 
by year (2000-2013), publication language (English or Dutch), study design (prospective 
cohort studies of newly diagnosed CRC patients in populations similar to Dutch popula-
tions) and genetic testing including MSI (MSI-high: minimum 2 of 5 markers positive), 
IHC (four MMR genes), MLH1 promoter hypermethylation (in MLH1-deficient tumours) 
and DNA-analysis, with separable data for CRC≤70 and CRC≤50. Four studies were in-
cluded: two American81,82, one Dutch83 and one French.84 Additional data was derived 
from our previous study41 and several Dutch national databases.77,80,85
In literature, 96% of index LS patients comply with surveillance58; 100% compliance was 
assumed. Mortality rates of LS-related CRC85 were assumed zero after 15 years and equal 
for first and second CRC tumours. Intensive CRC follow-up was defined as colonoscopy 
every two years; standard as every six years.57 Yearly risks of a second CRC tumour fol-
lowing intensive versus standard CRC treatment in LS patients, were calculated using 
10 year risks for subtotal versus partial colectomy in LS.59 Age distribution of CRC 51-70 
patients was derived from literature.81-84 Markov chain analyses (S3a) were run for 30 
years, considered a realistic timeframe given aforementioned age distribution and using 
age dependent Dutch mortality rates (2012).80
family data sources and assumptions
Data for family-based models (S6) was based on a local database containing all relatives 
tested before August 2013 (N=935) of 112 index LS patients diagnosed between May 
1996 and August 2011 (S7) allowing a minimum two years for relatives to undergo DNA-
screening. Mean numbers of relatives tested (X) and identified as LS patients (Y) per 
index LS patient were calculated. Surveillance compliance amongst relatives was 88%.86 
Yearly risks of CRC for compliant and non-compliant LS patients were calculated from 
Järvinen et al.9 Risks of LS-related CRC mortality and second CRC were assumed equal to 
index patients.59 Markov chain analyses (S3b) were run for 50 years.80
reSUltS
Patient-based models
Using the experimental strategy, four times as many LS patients were identified than 
current practice. Costs and number needed to test for detecting one LS patient doubled 
(Table 1: €9,437/carrier versus €4,837/carrier and 42 versus 19). Within the age group of 
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51-70 the incremental costs were €11,541 per additional LS patient detected. Mutation 
detection rate was lower in patients diagnosed at or below 70 versus 50 years (2.4% 
versus 5.4%). In additionally tested CRC 51-70, 58.8% of MSI-high tumours was due to 
MLH1 promoter hypermethylation (not LS) versus 7.1% in CRC≤50. 
Markov chain analyses of CRC 51-70 patients showed 0.01 extra life years gained versus 
current practice at incremental costs of €212, resulting in a ratio of €25,130 per life year 
gained (Table 2; S8).
family-based model
With the experimental strategy, more CRC patients were identified as LS patient, leading 
to a proportionally increased number of relatives detected as additional LS patients. In 
our setting, every index LS patient led to genetic testing of on average 8 relatives (935 
relatives of 112 index patients) of which 39% were LS patients (S6).
Markov chain analyses of relatives showed that the experimental strategy resulted 
in -€292 lower costs and 0.32 extra life year gained versus current practice (Table 2; S9). 
Therefore the experimental strategy was dominant over current practice, which would 
miss these LS relatives, denying them CRC surveillance.
Combined patient-family results
For an average LS family, the results of eight relatives were added to results of CRC 51-70 
patients identified as LS (2.0%), resulting in an overall ratio of €2,703 per extra life year 
table 1: Efficacy (mean±standard deviation or [95% confidence interval]) of the identification of Lynch syn-
drome patients (mismatch repair gene mutation carriers) amongst patients with colorectal cancer (CRC), 
comparing the experimental strategy testing CRC at 70 years or below (CRC≤70) with current practice test-
ing CRC at 50 years or below (CRC≤50).
Efficacy (all CRC patients) Current practice:
CRC ≤ 50
Experimental strategy:
CRC ≤ 70
Difference (Δ) between 
strategies:
CRC 51-70
% tested of all CRC patients 6.0 50.0 44.0
% MSI-high of those tested 11.9 ± 2.0 10.7 ± 0.8 10.4 ± 0.8
% MLH1 promoter hypermethylation of those MSI-high 7.1 ± 3.4 46.9 ± 3.2 58.8 ± 3.6
% mutation detection rate (carriers / patients tested) 5.4 2.4 2.0
% identified as LS patient of all CRC patients 0.3 1.2 0.9
Number of CRC patients tested for MSI to detect one LS 
patient
19 42 50
Costs of genetic testing (€) per LS patient detected 4,837 9,437 11,541 [8,175 – 16,969]
CRC = colorectal cancer. MSI = microsatellite instability.
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table 2: Cost-effectiveness (mean [95% confidence interval]) considering genetic testing and follow-up 
of index patients with colorectal cancer (CRC) between 51-70 years and genetic testing and surveillance in 
relatives, comparing the experimental strategy (patients with CRC 51-70 are tested: mutation detection rate 
2%) and current practice (patients with CRC 51-70 are not tested).
Cost-effectiveness Current practice:
CRC between 51-70
are NOT tested for genetic 
susceptibility
Experimental strategy:
CRC between 51-70 ARE tested 
for genetic susceptibility
Difference (Δ) between 
strategies:
experimental - current
Patients with CRC 51-70
Costs of genetic testing, cancer treatment and 
follow-up (€) [A]
24 [17 – 35] 236 [221 – 253] 212 [202 – 222]
Effect cancer treatment and follow-up: life 
years gained [B]
0.15 [0.10 – 0.22] 0.16 [0.11 – 0.23] 0.01 [0.01 – 0.01]
Costs (€) per life year gained [A / B] 160 1468 25,130 [16,362 – 36,999]
Relative of CRC 51-70 patient identified as LS 
patient
Costs of genetic testing, surveillance and cancer 
treatment  (€) [C]
1,725 [1,330 – 2,012] 1,434 [1,122 – 1,670] -292 [-342 – -210]
Effect surveillance and cancer treatment: life 
years gained [D]
6.90 [5.29 – 8.15] 7.22 [5.51 – 8.59] 0.32 [0.21 – 0.45]
Costs (€) per life year gained [C / D] 250 199 *
Average family including CRC 51-70 patient 
and cascade screening of 8 relatives in patients 
identified as LS (2%)
Costs of genetic testing, cancer treatment, 
follow-up, surveillance (€) [A + 2%*8*C]
300 465 165
Effect cancer treatment, follow-up, surveillance: 
life years gained [B + 2%*8*D]
1.25 1.32 0.06
Costs (€) per life year gained
[(A + 2%*8*C) / (B + 2%*8*D)]
239 354 2,703
CRC = colorectal cancer.
* As demonstrated by lower costs with higher effects, the experimental strategy is dominant over current 
practice: thus accompanying (negative) cost-effectiveness ratio is not reported.
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gained (Table 2) per additionally tested CRC 51-70 patient. Smaller family sizes of four or 
six relatives resulted in €5,301 or €3,659 per extra life year gained.
DiSCUSSion
The experimental strategy for detecting Lynch syndrome is found to be cost-effective, 
as four times as many LS patients were detected for €2,703 per extra life year gained 
in additionally tested patients, including family cascade screening. This fourfold ef-
ficacy amongst index patients was achieved at only twice the cost (€9,437/carrier versus 
€4,855/carrier) and numbers needed to detect one carrier (42 versus 19), despite half of 
MSI-high CRC≤70 tumours being caused by non-hereditary MLH1 promoter hypermeth-
ylation. In additionally tested CRC51-70 patients, the experimental strategy resulted in 
more costs for negligible survival gains (€25,130 per life year gained). But higher benefits 
were found in relatives using their LS knowledge for CRC prevention, resulting in a more 
favourable ratio of €2,703 per life year gained. Although the cost-effectiveness threshold 
of €80,000 in Dutch standards uses quality-adjusted life years79 and our study used 
non-quality-adjusted life years, the experimental strategy seems good value for money. 
This recommendation could greatly improve the identification of Lynch syndrome, 
allowing more LS patients to prevent CRC mortality and simplifying the LS diagnostic 
process considerably. Half of all CRC patients would be tested immediately; only those 
with CRC>70 would require evaluation of other tumours and family history, lowering 
the burden on clinical genetic services. Such simplification may lead to high uptake at 
implementation of the new strategy.
To identify 100% of LS patients, testing all CRC patients could be considered.87 But the 
diagnostic yield of testing without any age limit is comparable to testing only CRC≤70 
and CRC>70 fulfilling Bethesda guidelines, with 35% fewer patients requiring tumour 
genetic testing and 29% fewer requiring DNA-analysis.76 Testing without age limit com-
pared to testing up to 50 years showed an incremental cost-effectiveness ratio of $37,010 
per life year gained.88 But Ladabaum et al89 demonstrated rising costs with each 10-year 
increase: testing up to 60 versus 50 years cost $33,800 per life year gained; testing up to 
70 versus 60 years cost $44,200 per life year gained; and testing all ages versus up to 70 
years cost $88,700 per life year gained. Although gynaecological screening was included 
and genetic testing costs have decreased since 2011, this shows a trend for higher ratio’s 
thus lower likelihood to be cost-effective by including CRC>70. 
In our study, the experimental strategy led to only 0.01 extra life years gained in index 
patients due to higher average age of CRC 51-70 patients than CRC≤50 with higher 
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population mortality rates. This is comparable to Ladabaum et al89: Bethesda-based 
versus no testing led to 0.18 extra life years gained. In relatives, our study showed 0.32 
extra life years were gained; lower than other conclusions that surveillance starting 
at 25 years gave 13.5 extra life years90, as average age in our study was 45 years. But it 
remains evident that although index patients may not benefit greatly from improved LS 
identification, their relatives do.
The main strength of our study is the use of stochastic data for most input variables 
(S5-S6), allowing assessment of 95% confidence intervals, showing cost-effectiveness 
even at these upper limits. Several variables were based on a previous cost-effectiveness 
study41 although different methods were used. The previous study compared two differ-
ent strategies with full patient- and family-based criteria. The current study evaluated 
only the raised age limit from 50 to 70 years in one patient with one CRC tumour, not 
considering other tumours or family history. Those with CRC≤50 overlapped in both 
guidelines therefore cost-effectiveness analyses focused on the additionally tested 
CRC51-70 index patients, comparing costs and effects if LS patients within this group 
were tested (experimental strategy) or not tested (current practice). This may explain 
higher benefits in the family-based model, where CRC surveillance in additional LS 
patients detected led to lower costs and higher effects than if they were missed. The 
previous study only considered costs and effects in those detected (€855 per life year 
gained), not weighed against those missed.41 Additional risks of a second CRC tumour59 
were incorporated, allowing more robust simulation of LS patient lifetimes and higher 
benefits than previous analyses only considering the first CRC tumour.41
Preference for MSI or IHC as first-pass LS testing is the subject of debate: sensitivity 
is equal, but IHC has the advantage of pinpointing which MMR genes to examine for 
germline mutations.29 Conversely, IHC shows higher interobserver variability depend-
ing on observer experience, leading to preferred centralisation of IHC testing within 
specialised centres.91 Thus MSI remained the gold standard for first-pass LS testing57, 
determining our testing algorithm. Including the MLH1 promoter hypermethylation 
test is important to detect non-hereditary MSI-high CRC (nearly half of CRC≤70) and 
minimise the proportion of patients undergoing expensive DNA-analysis.
The generalisability of our study results may be influenced by the assumptions made. 
Analyses were based on the Dutch healthcare system using MSI as first-pass LS testing, 
but MSI may be second to IHC elsewhere. MIPA criteria42 are used in the Netherlands to 
select CRC≤50 patients for direct tumour genetic testing, but may not reflect current 
practice in other countries. Some family-based variables were calculated using a local 
and long-term database, not considering regional variances or degree of relatedness. 
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Cascade screening may – through initial screening of first/second degree relatives – 
reach third or more degree, leading to more relatives tested per family and fewer rela-
tives identified as LS patients (in our setting 39%) than expected for close relatives 
(50%). Some LS patients amongst CRC patients may belong to the same family. Genetic 
testing costs were based on local data and may vary. However our main conclusion that 
increasing the upper age limit for MMR-deficiency testing from 50 to 70 is cost-effective 
is probably relevant for most western countries.
In conclusion, the proposed experimental strategy, testing all new CRC patients diag-
nosed at age 70 or below for Lynch syndrome, is more effective than current practice 
using an age limit of 50 years. Implementation is important as relatives from many LS 
patients missed by current practice, can benefit from life-saving surveillance.
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AbStrACt
background: Current practice for patients with breast cancer referred for genetic 
counseling, includes face-to-face consultations with a genetic counselor prior to and 
following DNA-testing. This is based on guidelines regarding Huntington’s disease in 
anticipation of high psychosocial impact of DNA-testing for mutations in BRCA1/2 genes. 
The initial consultation covers generic information regarding hereditary breast cancer 
and the (im)possibilities of DNA-testing, prior to such testing. Patients with breast 
cancer may see this information as irrelevant or unnecessary because individual genetic 
advice depends on DNA-test results. Also, verbal information is not always remembered 
well by patients. A different format for this information prior to DNA-testing is possible: 
replacing initial face-to-face genetic counseling (DNA-intake procedure) by telephone, 
written and digital information sent to patients’ homes (DNA-direct procedure).
Methods/design: In this intervention study, 150 patients with breast cancer referred 
to the department of Clinical Genetics of the Radboud University Nijmegen Medical 
Centre are given the choice between two procedures, DNA-direct (intervention group) 
or DNA-intake (usual care, control group). During a triage telephone call, patients are ex-
cluded if they have problems with Dutch text, family communication, or of psychologi-
cal or psychiatric nature. Primary outcome measures are satisfaction and psychological 
distress. Secondary outcome measures are determinants for the participant’s choice of 
procedure, waiting and processing times, and family characteristics. Data are collected 
by self-report questionnaires at baseline and following completion of genetic counsel-
ing. A minority of participants will receive an invitation for a 30 min semi-structured 
telephone interview, e.g. confirmed carriers of a BRCA1/2 mutation, and those who 
report problems with the procedure.
Discussion: This study compares current practice of an intake consultation (DNA-
intake) to a home informational package of telephone, written and digital information 
(DNA-direct) prior to DNA-testing in patients with breast cancer. The aim is to determine 
whether DNA-direct is an acceptable procedure for BRCA1/2 testing, in order to provide 
customized care to patients with breast cancer, cutting down on the period of uncer-
tainty during this diagnostic process.
trial registration: The study is registered at the Dutch Trial Registry www.trialregister.
nl (NTR3018).
keywords
hereditary – breast cancer – BRCA – genetic – counseling – DNA
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bACkGroUnD
Patients with breast cancer at high risk of an underlying hereditary predisposition face a 
time-consuming diagnostic process of several months: it might be helpful to be able to 
cut down on this long period of uncertainty and provide information applicable to their 
personal situation as early as possible. Having personal experience with breast cancer, 
these patients are likely to have enhanced personal risk estimates, thus a higher expec-
tation for protective actions such as longer or more intensive surveillance.92 Should they 
carry a pathogenic mutation in either the BRCA1 or BRCA2 gene, these patients do have a 
considerable long term risk for developing a second primary breast cancer (either ipsi- or 
contralateral) of up to 60%.31-33 Women recently diagnosed with breast cancer may want 
to take their BRCA1/2 status into consideration for their choice of surgical treatment (i.e. 
breast-conserving with radiotherapy versus ipsi/contralateral mastectomy) and, in the 
near future, chemotherapy (i.e. PARP-inhibitors).69,93-97 BRCA1/2 mutation carriers face an 
additional risk of ovarian cancer ranging from 20-60% for BRCA1 and 2-20% for BRCA2.31-33 
As screening for ovarian cancer through yearly serum CA-125 measurements and trans-
vaginal ultrasound has proven to be ineffective63,64,98, clinicians strongly recommend 
prophylactic bilateral salpingoophorectomy (pBSO) around the age of 35 to 40 years.64 
pBSO reduces the risk of ovarian cancer by 80-90%, and in unaffected premenopausal 
women simultaneously reduces breast cancer risk by 50%.65,99
Patients with breast cancer often express concern and uncertainty regarding the risk 
of breast cancer for their unaffected relatives, especially their sisters and daughters.100 
For unaffected relatives carrying a BRCA1/2 mutation, cumulative breast cancer risk at 
the age of 70 years ranges from 40-80%.31-33 At the age of 25 years, they may choose 
between an intensive breast cancer screening program consisting of yearly MRI scans, 
mammography and clinical breast examinations101,102 or undergoing prophylactic 
surgery, reducing the risk for breast cancer by 90%.10,103,104 Some carriers may still be 
at an age to be confronted with childbearing conflicts.66 These are only a few of the life-
changing decisions for both patients with breast cancer and their relatives dependent 
on the results of DNA-testing, which may or may not confirm the presence of a genetic 
predisposition for breast and ovarian cancer. A previous study in Dutch patients being 
evaluated for possible breast cancer showed that these patients experienced the period 
before the final diagnosis as the most stressful, regardless of whether they had received 
a benign or cancer diagnosis afterwards.105 This same principle likely applies to BRCA1/2 
testing. Reducing the period of uncertainty in the diagnostic process and offering vari-
ous forms of information might help substantially.
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Another attempt to speed up the diagnostic process concerning hereditary cancer was 
previously introduced in the evaluation of hereditary colon cancer in the Netherlands. 
Pathologists are now able to test tumor material of patients younger than 50 years for 
microsatellite instability (MSI) and immunohistochemical staining of gene products, 
which may reveal a high a priori risk for an underlying genetic predisposition, without 
prior consultation of a genetic counselor. If these characteristics are present, patients 
are referred for further evaluation by a genetic counselor.41,106 This so-called MIPA 
procedure (MSI-test by pathologists) is seen by patients as a valuable addition to the 
diagnostic process of hereditary colon cancer, without feeling either overwhelmed or 
underinformed, nor showing increased levels of psychosocial distress.43,107,108
Such an intervention may also be applicable to patients with breast cancer. As there 
is no equivalent of tumor material testing in hereditary breast cancer, alternatives for 
modification must be found within the current diagnostic process. Genetic testing for 
hereditary breast cancer includes genetic counseling both prior to and following DNA-
testing, based on guidelines regarding presymptomatic testing for Huntington’s disease 
(HD).109-111 This approach had been adopted for hereditary breast cancer due to concerns 
about the psychological consequences of BRCA1/2 genetic susceptibility testing.8 How-
ever, extensive prior research shows there is no significant long term psychological 
impact: after an initial increase following BRCA1/2 testing, psychosocial distress returns 
to pre-testing levels over time.112-118 Therefore, in the case of hereditary breast cancer 
where protective measures are possible, it may not be necessary to adhere to such a 
strict counseling protocol as defined for an untreatable neurodegenerative disorder 
such as HD.8 Patients with breast cancer express the most interest in answers regard-
ing their personal situation: Is my breast cancer of hereditary origin and what are my 
children’s risks?119 Answers to these questions cannot be given until the results of DNA-
testing are known. During the initial face-to-face consultation, patients are provided 
with general information regarding hereditary breast cancer, DNA-testing and possible 
consequences, prior to actual DNA-testing. Patients consider this generic information 
less relevant than the personal advice in the second consultation post DNA-testing and 
may thus experience this intake as an unnecessary delay.120 It is also widely known that 
about 40 to 80% of verbal information is immediately forgotten by patients.121 A recent 
study in Canada offered a group of Jewish women DNA-testing through written and 
telephone invitation. The majority of these women had positive experiences with this 
approach and considered it to be effective.122 Providing patients with alternative means 
to educate themselves regarding hereditary breast cancer and DNA-testing, prior to 
their decision to undergo testing, might improve patient recollection of medical infor-
mation as well as increase patient participation.
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Therefore, this study offers patients with breast cancer the choice of replacing the initial 
face-to-face consultation prior to DNA-testing (usual care DNA-intake procedure) by a 
home information package including telephone, written and digital information con-
sisting of a website and educational movie (DNA-direct procedure). DNA-testing will 
thus be performed prior to genetic counseling, contrary to current practice. At the first 
face-to-face contact, counselors will be able to disclose DNA-results and customized 
advice to patients. This eliminates extraneous information which is not applicable to the 
individual patient, and provides patients with the information they desire in a quick and 
patient-centric manner.
The aim of this intervention study is to compare this new DNA-direct procedure to 
current practice (DNA-intake procedure). The effects of the DNA-direct procedure on 
the experience and psychosocial distress on patients with breast cancer, as well as the 
speed and quality of genetic advice, will be evaluated. The hypothesis is that undergo-
ing the DNA-direct procedure does not lead to increased levels of psychosocial distress 
as compared to the usual care DNA-intake procedure, with equal levels of patient 
satisfaction plus shorter waiting and processing times. A trend similar to traditional 
BRCA1/2 testing – a short term increase in distress, falling back to pre-testing levels over 
time112-118 – is expected in the DNA-direct procedure. This would make DNA-direct an ac-
ceptable procedure for patients with breast cancer undergoing genetic testing, with the 
goal of more customized care, and a shorter period of uncertainty. Moreover, it would 
facilitate taking genetic advice into account for the treatment and follow-up of breast 
cancer.
MethoDS/DeSiGn
Design
The study examines the effect of the DNA-direct procedure on the experience and psy-
chological distress of patients with breast cancer as well as several secondary outcome 
measures, including waiting and processing times, as compared to the current DNA-
intake procedure. Two groups will be compared: the intervention group, who choose 
to undergo the DNA-direct procedure, and the control group, who will receive care as 
usual (DNA-intake procedure). Participants may choose freely between the DNA-direct 
versus DNA-intake procedures. This study is not randomized due to the wish to evalu-
ate whether there is indeed a desire for the proposed DNA-direct procedure amongst 
patients with breast cancer, and to evaluate the reasons stated for preferring one pro-
cedure over the other.
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ethical consideration
The study has been approved by the medical ethical committee of the Radboud Univer-
sity Nijmegen Medical Centre. Full medical ethical approval has been obtained in July 
2011.
Study sample
All female patients previously or currently diagnosed with breast cancer and referred 
to the department of Clinical Genetics of the Radboud University Nijmegen Medical 
Centre from August 9th 2011 are eligible for inclusion. Recruitment will continue until 
the desired total of 150 participants is reached. Patients who have problems reading 
Dutch text, problems with family communication or problems of psychological/psychi-
atric nature (including current use of related medication) will be excluded.
recruitment
Patients are sent a written letter by a trained doctor announcing a phone call, in which 
the two choices of procedure are explained (DNA-intake for a face-to-face intake consul-
tation prior to DNA-testing, versus DNA-direct for a home package of telephone, written 
and digital information) and exclusion criteria are checked. The aim of this telephone 
approach is triage: by checking for exclusion criteria such as psychological problems, 
patients who aren’t deemed suitable for DNA-direct (due to its dependency on the 
patient’s own decision making ability) are filtered out and instead invited for a regular 
intake consultation, where further psychosocial support is immediately available prior 
to DNA-testing. Genetic counseling is not offered by phone: questions of this nature 
are deferred to the personal consultations. The triage phone call has been thoroughly 
practiced (over 20 times) by the involved doctor with people both specialized and not 
specialized in clinical genetics.
All patients receive the same two questionnaires, one at inclusion (baseline) and one 
after completion of the chosen genetic counseling procedure (follow-up). Patients who 
are confirmed carriers of a BRCA1/2 mutation, patients reporting problems with the 
chosen procedure, and randomly selected (n = 10) patients will be invited for a 30 min 
semi-structured telephone interview.
BRCA1 and BRCA2 genetic testing
The coding sequences and intron/exon boundaries of BRCA1 and BRCA2 are analyzed 
by sequence analysis (primer sequences available on request). Gross deletions and 
duplications in the BRCA1 gene are detected by multiplex ligation-dependent probe 
amplification (MRC-Holland, Amsterdam, kit P002-C2). All findings are confirmed by an 
independent test.
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intervention
Patients who choose the DNA-direct procedure, receive a home informational package 
including an informational letter, a link to a website including a short educational movie 
about hereditary breast cancer and DNA-testing. Also included are two EDTA blood vi-
als with informed consent and family history forms. Patients are instructed to call their 
family doctor assistant to ask where to have their blood drawn, then return the vials 
plus signed forms in the appropriate return package. An appointment for a personal 
consultation to disclose results is set 8 weeks after DNA-testing has commenced.
All patients (whether they choose DNA-direct or DNA-intake) are seen by one of five se-
lected genetic counselors, each of whom has extensive experience in genetic counseling 
for hereditary cancer. These counselors have had multiple meetings in order to structure 
the DNA-direct consultations as follows: If no mutation is found, further screening advice 
is formulated based on familial risk scores: FHAT123, Myriad124 and Claus/van Asperen.125,126 
Further evaluation of family history and features of other hereditary cancer syndromes 
may be required. In the case of a pathogenic BRCA1 or BRCA2 mutation, this result is 
disclosed immediately, first allowing the patient to react, followed by an explanation of 
the consequences, including prevention measures and family evaluation. If considered 
necessary, a second consultation is offered for further genetic counseling. All confirmed 
BRCA1/2 carriers will be approached by a social worker to extend psychosocial support 
if needed, as in usual care.
Study outcomes
Participants are asked to fill out a questionnaire twice: at baseline and following the 
conclusion of genetic counseling and/or testing (follow-up). Some measures are used 
in both questionnaires, while others are only included in either baseline or follow-up.
Primary outcomes
Choice of procedure
Percentages of patients choosing one procedure over the other (ratio between the two 
groups) is determined to assess the desirability of the new DNA-direct procedure.
Psychological burden (baseline and follow-up)
Quality of Life
To measure global health-related quality of life (QoL), two items scored on a scale of 
1–7 were selected from the EORTC-Q30. The full EORTC-Q30 has been widely used and 
Ch
ap
te
r 3
44
Study design: BRCA-test without prior genetic counseling
validated for cancer research.127 The two global QoL items have an excellent internal 
consistency as proven by the reported Cronbach’s α of 0.91.128
General health
The 12-item version of the General Health Questionnaire (GHQ-12) is used as a measure 
of general psychological distress, using GHQ-scoring of 0,0,1,1 per item (range 0–12) with 
a threshold of ≥4 to identify ‘caseness’, recommended for patients with breast cancer. 
The GHQ-12 is the shortest version of all GHQs and recommended for research use, with 
good internal consistency (Cronbach’s α = 0.82 - 0.86).129-131
Cancer specific distress
The Impact of Event Scale (IES) measures cancer specific distress132,133 and is included in 
baseline once using genetic predisposition for cancer as the distressing event, once us-
ing breast cancer. For follow-up, only genetic predisposition is included. The IES consists 
of 15 items, each scored 0,1,3,5. A total score of 9–25 or ≥26 reflects moderate or serious 
adaptation difficulties respectively. The Dutch version of the IES has a good internal 
consistency with a Cronbach’s α of 0.87 to 0.96.133
Risk perception
Risk perception of a genetic predisposition for breast cancer, as well as breast cancer 
recurrence, is measured on a scale of 0–100.
Cancer worry scale
To measure fear of cancer recurrence, the 8-item Cancer Worry Scale (CWS) is included, 
which has previously been used in studies among cancer patients. Each item is scored 
1,2,3,4 from 1 ‘almost never’ to 4 ‘almost always’, the total score ranging from 8–32. It has 
a good internal consistency with a Cronbach’s α of 0.80.134-136
Experiences with genetic counseling (follow-up)
Decisional conflict
The difficulty of decision-making, in this study defined as whether or not to undergo 
genetic testing, is assessed using the traditional format of the Decisional Conflict Scale; 
1 item (“I expect to stick to my decision”) is left out as it is not applicable to DNA-test-
ing.137-139 15 items scored 0,1,2,3,4 from 0 ‘strongly agree’ to 4 ‘strongly disagree’ remained, 
including “I am satisfied with my decision” which is also used separately for overall satis-
faction. Scores are summed, divided by 15 and multiplied by 25, resulting in a range from 
0 to 100. Scores below 25 are considered as ‘no decisional conflict’, between 25 and 37.5 
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as ‘moderate conflict’ and exceeding 37.5 as ‘severe conflict’. The DCS has good internal 
consistency exceeding 0.78.137-139
Satisfaction with choice
Knowledge of hereditary breast cancer following versus prior to the chosen genetic 
counseling procedure, as well as the amount and quality of information received, is 
rated on a scale of 1–6. Participants answer ‘yes’, ‘no’ or ‘don’t know’ for choosing DNA-
testing and/or DNA-direct if given a second chance or asked to give advice to other 
women in a similar situation.
Satisfaction with genetic counseling
QUOTE-gene(ca) is a standard Dutch questionnaire to measure patient satisfaction with 
the service (18 items) and information (8 items) expected of a genetic counselor.140 Each 
item is scored on a Likert-scale 1–4, total scores range from 26–104. Open-ended ques-
tions evaluate positive/negative experiences during the chosen genetic counseling 
procedure.
Secondary outcomes
General information (baseline)
Demographical and breast cancer information
Data are gathered on age, education level, work status, marital and parental status, 
cancer status, medical information need (scale 1–10), use of breast cancer information 
resources and type of information previously given by their referring physician.
Empowerment (baseline)
Empowerment is the process in which patients discover and utilize their own power, 
which will be measured using the Cancer Empowerment Questionnaire (CEQ). It consists 
of 40 items, each scored on a Likert-scale of 1–5 (1 ‘strongly disagree’, 5 ‘strongly agree’). 
Four factors are identified: ‘Personal Strength’, ‘Social Support’, ‘Community’ and ‘Health 
Care’. A good internal consistency (Cronbach’s α = 0.94) was demonstrated for all four 
factors and the total Empowerment scale.141
Experiences with genetic counseling and testing (follow-up)
Choice of procedure
Participants describe reasons for choosing DNA-direct or DNA-intake.
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Family relations
Three categories of family members are defined: 1) nuclear family, being partner and/
or children; 2) family of origin, being parents, brothers and/or sisters; and 3) aunts and 
female cousins on the family side where breast cancer is prevalent, being the second 
generation relatives most likely to be affected by genetic testing of the patient. Partici-
pants report the frequency of contact with each category of relatives, as well as indicate 
the quality of their relationship on a scale of 1–10.
Family communication
For each above-mentioned relative, participants indicate whether, and if so, when 
(directly after information, just before DNA-result, after DNA-result) and how often (on 
a scale of 1–5), they had spoken to this relative about hereditary breast cancer. Also in-
cluded is the Openness to Discuss Hereditary Cancer in the Family scale (ODHCF) which 
consists of 7 items each scored 1,2,3,4 with a range 7–24: once for the nuclear family 
(α = 0.79) and once for the family of origin (α = 0.93).142
Other measures
Waiting and processing times, as well as family pedigree characteristics, are also gath-
ered.
Sample size calculation
For this intervention study, participants are not randomized into groups, but given 
their own choice. This leads to certain complications when it comes to a formal power 
calculation. First, the ratio between the two procedures is unknown: this may either be 
balanced (50% versus 50%) or unbalanced (e.g. 20% versus 80%). Second, due to not ran-
domizing, the results will have to be corrected for multiple confounders, which are not 
all known at this point. The sample size, based on aforementioned ratio between both 
groups (choice of procedure), needs to be large enough to be able to integrate these 
confounders into a regression model. Using a power of 80% and a two-tailed probability 
level for statistical significance testing of 0.05, while taking into account group ratios 
ranging from balanced (50% versus 50%) versus unbalanced (to an estimated maximum 
of 20% versus 80%), the total sample size has been set to 150 patients with breast cancer.
Statistical analyses
To compare general characteristics, baseline and follow-up results between the inter-
vention versus control group, the unpaired t-test will be used for continuous variables, 
Mann–Whitney U test for non-parametric variables and chi-square test for dichoto-
mous variables. For the comparison of baseline versus follow-up results within each 
group, the paired t-test will be used for continuous, Wilcoxon test for non-parametric 
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and McNemar’s test for dichotomous variables. Multivariate analysis will consist of a 
regression model using the follow-up results as outcome (dependent) variables, to be 
compared between the intervention versus control groups as independent variables, 
with the baseline results as covariates supplemented by variables that were found to be 
statistically significant in previous univariate analyses. The probability level for statistical 
significance testing is set at 0.05 (two-tailed). The SPSS 18.0 statistical package will be 
used to analyze the data.
DiSCUSSion
Considering today’s call for more patient participation in medical decision-making, the 
convenience of taking up information and drawing blood close to home, paired with 
customized advice from the very first consultation, might appeal to patients. Replacing 
the face-to-face intake consultation with a genetic counselor by a home informational 
package of telephone, written and digital information might speed up the diagnostic 
process of hereditary breast cancer and reduce extraneous information. For example, 
this would allow patients to go over this information at their own convenience and in 
their own homes. It could possibly reduce travel efforts to a hospital as well as time 
conflicts with breast cancer therapy.
However, there are certain downsides compared to traditional genetic testing. All 
patients with breast cancer referred to clinical genetics by their treating physician are 
eligible for the DNA-direct procedure. This means that even those patients who would 
not normally fulfill criteria for BRCA1/2 testing are now able to have their blood drawn 
for DNA-testing, regardless of those criteria. In the DNA-intake procedure, patients who 
do not fulfill the aforementioned criteria will not be offered further DNA-testing. This 
may lead to a selection bias. Our intention is to compare DNA-direct to current practice: 
adhering to these criteria is the current practice and must be reflected in the DNA-intake 
procedure.
Additionally, genetic counselors must adjust their counseling styles to the disclosure of 
the DNA-results being the first order of business, without having built up a counselor-
patient relationship beforehand. New information might come forward following result 
disclosure, leading to ad-hoc modification of screening advice. For this reason, as well as 
to avoid intercounselor variation, we have selected five genetic counselors with many 
years of experience in oncogenetic counseling to see all patients participating in this 
study (both DNA-direct and DNA-intake).
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In conclusion, the aim of our study is to determine whether DNA-direct is an accept-
able procedure for BRCA1/2 testing, in order to provide customized care to patients with 
breast cancer and remove unnecessary waiting times within the diagnostic process, 
cutting down on the long period of uncertainty that patients are currently faced with.
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AbStrACt
Currently, most breast cancer (BC) patients receive face-to-face genetic counseling 
(DNA-intake) prior to BRCA-mutation testing, with generic information regarding he-
reditary BC and BRCA-mutation testing. This prospective study evaluated a novel format: 
replacing the intake consultation with telephone, written and digital information sent 
home, and face-to-face contact following BRCA-mutation testing (DNA-direct). From 
August 2011 to February 2012, 161 of 233 eligible BC patients referred to our Human 
Genetics department chose between DNA-direct (intervention) or DNA-intake (control). 
Exclusion criteria were psychological problems (n=33), difficulty with Dutch text (n=5), 
known BRCA-family (n=3), non-BRCA-referral (n=1). 30 declined genetic counseling or 
study participation. Participants received questionnaires including satisfaction and 
psychological distress. 59% chose DNA-direct (p=0.03), of whom 90% were satisfied 
and would choose DNA-direct again (including 6/8 BRCA-mutation carriers); although 
27% hesitated to recommend DNA-direct to other patients. General distress (GHQ-12, 
p=0.001) and heredity-specific distress (IES, p=0.02) scored lower in DNA-direct than 
DNA-intake, both at baseline and follow-up two weeks after BRCA-result disclosure; all 
scores remained below clinical relevance. DNA-direct participants reported higher web-
site use (53% vs 32%, p=0.01), more referrer information about personal consequences 
(41% vs 20%, p=0.004) and lower decisional conflict (median 20 [0–88] vs 25 [0–50], 
p=0.01). Processing time in DNA-direct was reduced by one month. Mutation detection 
rate was 8% in both groups. All BRCA-mutation carriers fulfilled current testing criteria. 
In conclusion, more BC patients preferred DNA-direct over intake consultation prior to 
BRCA-mutation testing, the majority being strongly to moderately satisfied with the 
procedure followed, without increased distress.
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introDUCtion
Patients with breast cancer (BC) desire answers about their personal situation when 
considered at risk of a hereditary predisposition.119 Providing personalized information 
as early as possible and reducing the long period of uncertainty during the genetic 
diagnostic process may prove helpful. In BC patients, a pathogenic BRCA1/2-mutation 
increases the risk of a second primary BC up to 60%31-33 and may influence the choice of 
BC treatment.96 The risk of ovarian cancer is also elevated to 20-60% for BRCA1 and 2-20% 
for BRCA231-33 for which prophylactic surgery is recommended.64 BC patients are often 
concerned about the BC risk for their relatives100: unaffected BRCA1/2-mutation carriers 
have a cumulative BC risk (to age 70 years) of 40-80%.31-33 At 25 years, they are offered 
yearly BC screening or prophylactic surgery.10 Patients experience the time between BC 
suspicion and diagnosis as the most stressful, independent of a benign or malignant 
outcome.105 This likely applies to BRCA-mutation testing as well. Reducing the period of 
uncertainty and offering various forms of information might help.
Current practice in many countries involves face-to-face counseling both prior to and 
following BRCA-mutation testing, based on guidelines regarding Huntington’s disease.8 
Such a strict protocol seems unnecessary for patients with BC as extensive research 
shows no long term psychological distress after BRCA-mutation testing.12 This study 
offered BC patients the choice of replacing the initial face-to-face consultation prior 
to BRCA-mutation testing (usual care, DNA-intake procedure) by telephone, written 
and digital information with a blood drawing kit sent home (novel format, DNA-direct 
procedure). Such a combination may be preferred over a face-to-face intake consulta-
tion, since patients may forget 40-80% of verbal information in medical consultations.121 
Furthermore, BRCA-mutation testing was performed prior to genetic counseling, allow-
ing counselors to disclose BRCA-results plus personalized advice at first face-to-face 
contact, eliminating extraneous information not applicable to each individual. Previous 
experience with genetic testing prior to genetic counseling, concerning tumor material 
in colorectal cancer patients younger than 50 years, showed that patients considered 
this as valuable without feeling underinformed or highly distressed.43,106
The aim of this study is to compare the experience of BC patients (satisfaction and 
psychological distress) between the novel DNA-direct procedure and usual care (DNA-
intake). The hypothesis is that DNA-direct is preferred by BC patients undergoing BRCA-
mutation testing with equal levels of patient satisfaction and no increased psychological 
distress.
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PAtientS AnD MethoDS
The complete protocol of this study was previously published, including full psychomet-
ric details of standardized questionnaires used.143 In short, following approval by the 
local medical ethical committee in July 2011, all female patients (previously) diagnosed 
with BC and referred to our department of Human Genetics between August 2011 and 
February 2012 (n=233) were eligible (Figure 1). To evaluate whether there is a preference 
for DNA-direct, BC patients were free to choose between procedures. Patients were 
excluded if they reported psychological problems requiring professional counseling 
(n=10), medication (n=14) or advice to start treatment (n=9); if they had difficulty with 
Dutch text (n=5) or family communication (n=0), a known family BRCA-mutation (n=3) or 
were not referred for BRCA-mutation testing (n=1). 11 patients declined genetic counsel-
ing/testing. 180 patients were sent baseline (T0) self-report surveys in both procedures, 
Breast cancer patients assessed for 
eligibility (n =  233)
 
Excluded (n = 42)  
● Diculty with Dutch text (n = 5) 
● Psychological problems (n = 33) 
● Known BRCA-family (n = 3) 
● Non-BRCA referral (n = 1) 
Declined genetic genetic counseling (n = 11)
 
No response at baseline (n = 19)
 
● Chose DNA-direct (n = 9)
● Chose DNA-intake (n = 10)
 
Participants oered choice of 
procedure and responded at 
baseline (n = 161) 
Lost to follow-up (n = 8) 
● Death (n = 1) 
● No response (n = 7) 
Chose DNA-direct  
(n = 95/161, 59%) 
Follow-up analyzed 
DNA-direct (n = 87)  
BRCA-mutation test           
(n = 95/95, 100%)  
  BRCA-mutation carriers  
(n = 8/95, 8%) 
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(n = 66/161, 41%) 
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● BRCA-mutation carriers● 
BRCA-mutation test           
Lost to follow-up (n = 5) Lost to follow-up (n = 2)
● No response (n = 4)
Follow-up analyzed
DNA-intake (n = 59)
figure 1: CONSORT flowchart of patient inclusion and follow-up, procedure proportions and BRCA-results.
Chapter 4
55
BRCA-mutation testing without prior face-to-face counseling
returned by 161. Follow-up surveys were sent two weeks after BRCA-result disclosure (T1). 
A minority of patients were invited for a short semi-structured telephone interview (i.e. 
all BRCA-mutation carriers, 10 randomly selected non-BRCA-mutation carriers per group). 
Written interview notes were reviewed for common trends.
DnA-direct procedure
In the novel DNA-direct procedure, patients received telephone (triage call by a trained 
medical doctor), written and digital information (website, educational movie) at home, 
containing the same information usually covered in DNA-intake in both written and 
digital formats. A blood drawing kit was included to start BRCA-mutation testing; written 
informed consent for DNA-direct and family history forms were mandatory. Telephone or 
e-mail contact with the involved doctor were possible for questions. BRCA-results were 
disclosed in a face-to-face consultation. Further details were previously published.143
Study outcomes
Primary study outcomes were: ratio between participants choosing DNA-direct versus 
DNA-intake (T0), satisfaction (T1: regarding choice of procedure, genetic counseling, in-
formation and BRCA-mutation testing, e.g. QUOTE-gene(ca)119,140 average of 26 items on 
scale 1 ‘not at all’ to 4 ‘good’, Cronbach’s α=0.96), and psychological distress (T0/T1: gen-
eral distress (GHQ-12129 scale 0–12, α=0.84–0.89) and heredity-specific (IES132,133 scale 0–75, 
α=0.93–0.94)). Full psychometric details of these standardized measures were previously 
published.143 Secondary psychological outcomes measured at both T0 and T1 were in 
short: global quality of life (selected from EORTC-QLQ-Q30127 scale 0–100, α=0.84–0.85), 
BC worry (CWS134,135 scale 8–32, α=0.84–0.85), risk perception of hereditary BC and 2nd 
BC (visual scales 0-100). Other secondary T0 outcomes were: sociodemographics, pa-
tient and family history of breast/ovarian cancer, BC information use, decisional conflict 
(DCS137,139 scale 0–100, α=0.96), patient empowerment (CEQ141 scale 40–200, α=0.94), 
BC-specific distress (IES132,133 α=0.93). Other secondary T1 outcomes were: open-ended 
reasons for choice of procedure, processing time, mutation detection rate, family 
relations and communication (e.g. ODHCF142 two subscales 1–7, α=0.84–0.90). Further 
details of standardized measures were previously published.143
Sample size and statistical analysis
Sample size was based on the ratio between DNA-direct versus DNA-intake. A total of 
150 participants was considered necessary to account for this unknown ratio, ranging 
from balanced (50% versus 50%) versus unbalanced (to an estimated maximum of 
20% versus 80%), using a power of 80% and a two-tailed probability level for statistical 
significance testing of 0.05. Data is presented using descriptive statistics. To compare 
DNA-direct versus DNA-intake for each T0 and T1 outcome, the unpaired t-test was 
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used for continuous, Mann-Whitney U test for non-normally distributed continuous 
or ordinal and chi-square/Fisher’s Exact test for nominal/dichotomous variables. Mul-
tiple backward (Wald) logistic regression was performed to analyze 1) the influence 
of multiple T0 variables differing significantly between DNA-direct versus DNA-intake 
in univariate analyses, and 2) clinical variables concerning personal and family cancer 
history as possible predictors of the choice of DNA-direct. Significant T0 differences 
were also corrected for in multivariate analyses (multiple linear/logistic regression) of T1 
outcomes showing significant univariate differences. Repeated measurements ANOVA 
was used to test for changes over time (T1-T0) between DNA-direct versus DNA-intake 
in psychological outcomes (general distress, heredity-specific distress, quality of life, BC 
worry and risk perception of hereditary BC and 2nd BC), with statistical correction for T0 
differences as covariates. The SPSS 20.0 statistical package was used for analysis.
reSUltS
A total of 161 BC patients (Figure 1) was included. Patient characteristics are shown in 
Table 1. Most participants (66% of DNA-direct, 71% of DNA-intake) were included within 
one year following their last BC diagnosis. More patients chose the novel DNA-direct 
procedure versus DNA-intake (n=95; 59% and n=66; 41%, p=0.03).
Eight T0 patient characteristics were found to differ significantly between groups 
(marked * in Table 1). DNA-direct participants showed a higher education level (p=0.01), 
lower age of onset in their youngest BC-affected relative (p=0.03), more children living 
at home (p=0.03), more website use for BC information (p=0.01), more previous infor-
mation about personal consequences of hereditary BC (p=0.006) and about possible 
outcomes of genetic testing (p=0.03). DNA-intake participants had been previously 
informed more about genetics in general (p=0.008) and showed higher decisional con-
flict (p=0.001). In multivariate analyses, only four of these variables remained significant 
contributors to the choice of DNA-direct over DNA-intake. Participants who had previ-
ously received information about personal consequences of hereditary BC (p=0.004, OR 
3.46 [1.49–8.04]) or used websites for BC information (p=0.01, OR 2.75 [1.25–6.04]), were 
more likely to choose DNA-direct. Those who had received information about genet-
ics in general (p=0.008, OR 0.35 [0.16–0.76]) or experienced higher decisional conflict 
(p=0.007, OR 0.96 [0.93–0.99]) were more likely to choose DNA-intake. This model was 
statistically significant with χ2 (4, n=145) = 30.61 (p<0.001) explaining 26% of the vari-
ance and correctly classifying 72% of cases.
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To identify clinical predictors for the choice of DNA-direct over DNA-intake, eight per-
sonal and family cancer history variables (age at first BC diagnosis, months since last BC, 
positive family history, age at BC <40 years, ovarian cancer in patient, mother with BC, 
sister with BC and age of youngest BC-affected relative) were included in separate mul-
table 1: Baseline sociodemographic and breast cancer (BC) characteristics for all BC patients choosing ei-
ther DNA-direct (novel format) or DNA-intake (usual care).
Characteristic DNA-direct n=95:
N (%) or median [range]
or mean±SD
DNA-intake n=66:
N (%) or median [range] 
or mean±SD
P
Age at inclusion 49 [23-73] 53 [28-74] 0.10
Age at 1st BC diagnosis 47 [23-71] 49 [28-74] 0.15
Months since last BC   6 [0-247]   6 [0-195] 0.92
BRCA referral criteria
- positive family history
- age at BC <40yrs
- ovarian cancer in patient
75 (79%)
29 (31%)
  4 (4%)
53 (80%)
13 (20%)
  2 (3%)
1.00
0.15
1.00
Family characteristics
- mother with BC
- sister with BC
- age (yrs) youngest with BC
- children living at home
17 (18%)
17 (18%)
40 [23-62]
55 (58%)
13 (20%)
15 (23%)
42 [26-64]
26 (39%)
0.84
0.55
0.03 *
0.03 *
Educational level
- high
- medium
- low
39 (41%)
27 (28%)
29 (31%)
13 (20%)
25 (38%)
28 (42%)
0.01 *
Use of BC information sources
- member of patient organization
- websites
- online discussion forums
- newspaper
- TV
- physician: flyers
- physician: consultations
  6 (  6%)
50 (53%)
12 (13%)
57 (60%)
48 (51%)
63 (66%)
56 (59%)
  3 (  5%)
21 (32%)
  3 (  5%)
39 (59%)
32 (49%)
45 (68%)
28 (42%)
0.74
0.01 *
0.10
1.00
0.88
0.87
0.05
Information provided by referrer
- genetics in general
- hereditary cancer
- personal consequences
- family consequences
- procedure of genetic testing
- outcomes of genetic testing
25 (26%)
38 (40%)
39 (41%)
38 (40%)
35 (37%)
32 (34%)
31 (47%)
23 (35%)
13 (20%)
26 (39%)
17 (26%)
12 (18%)
0.008 *
0.62
0.006 *
1.00
0.17
0.03 *
Decisional conflict (DCS: 0-100) n=87: 16.2±13.9 n=58: 23.2±10.8 0.001 *
Empowerment (CEQ: 40-200) n=92: 161.7±13.1 n=63: 159.8±16.0 0.90
BC specific distress (IES: 0-75) n=92: 18.5±15.7 n=64: 22.8±17.1 0.11
* Statistically significant p<0.05: baseline differences included as covariate in multivariate follow-up T1and 
repeated measurements analyses.
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tivariate analyses. Only the age of youngest BC-affected relative remained a significant 
contributor (p=0.04, OR 4.38 [0.92–1.00]), as previously established.
follow-up
All DNA-direct participants (n=95) were tested for BRCA-mutations. 76% (50/66) of 
DNA-intake participants were tested as they were only offered BRCA-mutation testing 
if they fulfilled international guideline selection criteria61 although testing was possible 
on the patient’s persistent request. Costs of genetic testing were covered by basic 
compulsory insurance. BRCA-mutation detection rate was equal at 8% for both groups: 
8 BRCA-mutation carriers in DNA-direct and 4 in DNA-intake (one unclassified variant 
type III). Follow-up (T1) data is available of 87 DNA-direct (92%) and 59 DNA-intake (89%, 
p=0.78) participants, including 7 DNA-direct and 3 DNA-intake BRCA-mutation carriers. 
One DNA-direct BRCA-mutation carrier died before BRCA-result disclosure. One DNA-
intake BRCA-mutation carrier felt overwhelmed by her BRCA-result from rapid genetic 
testing due to upcoming BC surgery and dropped out of the study.
Satisfaction with choice of DnA-direct
The majority (89%) of DNA-direct participants would choose DNA-direct again, includ-
ing 6 BRCA-mutation carriers; one carrier retrospectively preferred DNA-intake due to 
the unexpected suspicion of an unrelated syndrome. Most (70%) DNA-direct partici-
pants, including 2 BRCA-mutation carriers, would also recommend DNA-direct to other 
BC patients; 27% (including 5 BRCA-mutation carriers) was uncertain. Three of these 
participants specified why: they would like every next participant to make their own 
individual choice.
Satisfaction with genetic counseling and information
Overall counseling services were considered sufficient (scale 1–4, median 3 [1–4]). Satis-
faction with information (scale 1–6) was good at 5 [1–6] and 97% considered the amount 
of information sufficient (14%) or good (83%), with good quality (scale 1–6, 5 [2–6]). Self-
evaluation of knowledge about hereditary BC post-counseling was good (scale 1–6, 5 
[1–6]).  Satisfaction was equal in DNA-direct versus DNA-intake.
Satisfaction with BRCA-mutation testing
53% of DNA-direct participants reported strong and 45% moderate satisfaction with 
their choice to start BRCA-mutation testing, versus 31% strong and 61% moderate 
satisfaction in DNA-intake participants (p=0.01). However, fewer DNA-direct than DNA-
intake participants would start BRCA-mutation testing again if given a second chance 
(72% versus 95%, p=0.002). In DNA-direct, 9% (versus 5% in DNA-intake) was uncertain 
and 19% (versus 0%) would not start BRCA-mutation testing again. No reasons were 
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reported. 65% of DNA-direct versus 86% of DNA-intake would advise BRCA-mutation 
testing to other BC patients (p=0.01); respectively 28% versus 13% was uncertain. Four 
participants (n=2 DNA-direct, n=2 DNA-intake) indicated that each person must make 
their own choice. Adding fulfillment of BRCA-mutation testing criteria to multivariate 
regression analyses did not show a significant contribution of this variable (p=0.70) nor 
change the statistical significance of DNA-direct.
Psychological distress
As shown in Table 2, lower scores at baseline as well as at follow-up in DNA-direct versus 
DNA-intake were found for both general distress (GHQ-12: F(1,135)=10.80, p=0.001) and 
heredity-specific distress (IES: F(1,127)=5.97, p=0.02). Neither interaction between time 
and choice of procedure nor main effect for time were found. In both groups, mean 
scores remained below thresholds for clinical relevance (GHQ-12≥4 and IES≥26).
Secondary psychological outcomes
Quality of life, BC worry, risk perception for hereditary BC and 2nd BC did not differ 
between DNA-direct versus DNA-intake or over time (Table 2).
table 2: Psychological measures (mean±SD) for all breast cancer (BC) patients choosing DNA-direct (novel 
format) or DNA-intake (usual care).
Characteristic T0 T1 T1-T0
DNA-direct:
n=95
DNA-intake:
n=66
DNA-direct:
n=87
DNA-intake: 
n=59
DNA-direct: 
n=87
DNA-intake: 
n=59
P
General distress
(GHQ-12: 0-12)
3.2 ±3.1 3.9 ±3.2 2.7 ±3.4 3.6 ±3.5 -0.5 ±3.4 -0.3 ±4.2 0.001
Heredity specific distress 
(IES: 0-75)
12.9 ±14.2 17.2 ±16.1 11.7 ±13.3 16.7 ±17.2 -1.3 ±15.1 2.0 ±16.2 0.02
Quality of Life
(QoL: 0-100)
73.7 ±18.6 72.6 ±16.5 74.2 ±17.5 73.0 ±15.7 0.7 ±17.8 1.0 ±17.5 0.35
BC worry
(CWS: 8-32)
14.7 ±3.8 15.5 ±3.9 14.7 ±3.6 15.6 ±3.8 0.2 ±3.2 -0.0 ±3.8 0.08
Risk (0-100) perception: hereditary 
BC
41.1 ±24.3 43.0 ±21.3 33.7 ±30.5 35.6 ±26.2 -6.6 ±30.8 -7.9 ±23.0 0.46
Risk (0-100) perception:
2nd BC
43.3 ±28.1 49.5 ±26.8 39.6 ±26.2 48.1 ±25.8 -4.2 ±24.6 0.4 ±27.1 0.15
* Reported P-values for T1-T0 values are associated with the main effect for choice of procedure (DNA-direct 
versus DNA-intake) in repeated measurements ANOVA, corrected for baseline differences (see Table 1) as 
covariates. No main effects for time or interaction effects between time and choice of procedure was found. 
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reasons for choice of procedure
Self-reported reasons for choosing DNA-direct were (multiple reasons per participant 
possible, not cumulative): the hope for faster BRCA-results (36%), no travel time (26%), 
received information was sufficient (20%), no extra hospital visit e.g. on top of ongo-
ing chemo/radiotherapy (18%), already had ample information (16%), ease of reading 
information at home (16%) and choice of BC therapy depending on BRCA-status (2%). 
Self-reported reasons for DNA-intake were personal contact (71%), asking questions 
(29%) and bringing family (5%).
Processing times and BRCA-mutation detection rate
Median processing time (triage call to patient BRCA-result disclosure) was lower at 70 
[23–280] days for DNA-direct versus 103 [22–303] days for DNA-intake (p=0.002). Median 
testing time (start BRCA-mutation testing to counselor receiving BRCA-result) was 34 
[7–64] days and did not differ between procedures. BRCA-mutation detection rate was 
equal at 8%; however, of those tested, 65% (n=62/95) of DNA-direct participants  and 
74% (n=37/50) of DNA-intake participants fulfilled international guideline selection cri-
teria (p=0.35). Two DNA-intake participants decided to wait (one on counselor’s advice) 
despite fulfilling criteria; another participant’s mother was the preferred relative for 
testing. The remainder did not fulfill criteria and were reassured by genetic counseling 
that BRCA-mutation testing was not necessary. If criteria were strictly enforced in DNA-
intake, the mutation detection rate of 11% would still not differ from 8% in DNA-direct 
(p=0.74). Following negative BRCA-results and genetic counseling, 2 DNA-direct and 1 
DNA-intake participants were tested for Cowden syndrome (PTEN), 1 in DNA-direct for 
familial melanoma (FAMMM). 1 DNA-intake participant did not fit BRCA-criteria, but was 
tested for hereditary stomach cancer (CDH1). Mutations in other genes than BRCA1/2 
were not detected.
family relations and communication
92% of participants spoke to their nuclear family multiple times per week, with excel-
lent relationship quality (median 9 [5–10] on scale 1–10). Family of origin showed good 
quality (8 [1–10]) with 43% speaking multiple times per week and 45% weekly to several 
times a month. Family communication (ODHCF) was excellent (median 5 [2–5] on scale 
1–5). No differences were found in DNA-direct versus DNA-intake.
interviews
One DNA-intake BRCA-mutation carrier declined, resulting in a total of 29 interviews 
(questions in Table 3): 17 DNA-direct and 12 DNA-intake participants. The main additional 
finding was that not all DNA-direct information formats had been used. Almost all (16 
of 17) DNA-direct interviewees had read the informational letter, but one preferred the 
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digital formats. Overall, these had been used less: in total, 6 visited the website and 4 
saw the movie. All interviewed participants in both groups were satisfied with informa-
tion prior to BRCA-mutation testing and the overall process.
DiSCUSSion
More patients with BC chose the new format of BRCA-mutation testing without prior 
face-to-face genetic counseling (DNA-direct) over the current standard (DNA-intake). 
Our hypothesis that psychological distress would not be increased by DNA-direct was 
proven by lower scores than DNA-intake in both general distress (GHQ-12) and heredity-
specific distress (IES) at baseline and at follow-up. This suggests patients with higher 
distress were more likely to opt for initial face-to-face contact prior to genetic testing 
and remained more distressed at follow-up. DNA-direct participants were highly satis-
fied. At this moment, we do consider the new DNA-direct procedure to be preferred by 
and appropriate for the majority of BC patients especially those without pre-existing 
psychological problems similar to DNA-direct participants in our study. Further imple-
mentation does require continued evaluation of patient experiences, considering the 
(expected) low number of BRCA-mutation carriers identified using DNA-direct in this 
study. However, current study results are promising for the overall group. Some DNA-
direct participants reacted especially positive as they were still in BC treatment. In this 
period, an extra hospital visit was considered a burden while reading information at 
home and drawing blood during chemo/radiotherapy sessions, made genetic testing 
accessible. Similarly, DNA-direct participants were more likely to have children living 
at home, possibly leading to more time constraints. Other reasons included the ease of 
(re)reading the written and digital information at their own convenience. Face-to-face 
genetic counseling by a certified genetics professional remained important also in the 
DNA-direct procedure. Our study provides evidence that receiving such counseling after 
table 3: Semi-structured questions used for the follow-up telephone interview.
What did you think of the information that was sent home / discussed during intake?
Which information (sources) about genetic testing did you use?
What would you normally do if you are worried about your health?
When and for what reason did you decide to start the genetic blood test?
What did you think of the choice: an intake consultation vs. information sent home?
How did the consultation(s) with the genetic counselor go?
Did you speak to any other professionals about the results? (e.g. social worker)
What would you advise another person in the same situation to do?
Are you satisfied with the overall process of genetic counseling and testing?
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availability of BRCA-mutation testing results is acceptable. Personalized information 
about familial cancer risks and surveillance options could thus immediately be provided 
at first face-to-face contact with a trained genetic counselor, with one month shorter 
processing time than in DNA-intake. This was achieved without preferential treatment 
by our laboratories as reflected by equal testing time.
Written materials are used by 30% of cancer patients for cancer information, the internet 
by 36% of BC patients.144 Using these patient preferred formats allowed rereading in-
formation to improve patient recall. Accurate information was ensured by directing pa-
tients to our own materials, followed by face-to-face genetic counseling at BRCA-result 
disclosure; until then telephone/e-mail contact was available for personal questions. 
DNA-direct participants were satisfied with the information sent home, although few 
made use of all different information formats offered: most had only read the written 
informational letter and all telephone/e-mail contact (n=14) concerned logistics. Offer-
ing a variety of information sources seems valuable because some preferred digital over 
written formats, others considered the availability of telephone/e-mail contact – even 
if unused – reassuring. Information redundancy across these different formats allowed 
patients to choose their own preferred format, yet still receive the same pre-test infor-
mation.
Different information formats in genetic testing have been studied before. Jewish wom-
en in Canada approached by telephone and letter for BRCA-mutation testing showed no 
negative psychological impact.145 Information about treatment-focused BRCA-mutation 
testing to BC patients in written or consultation form seemed equally effective in an 
ongoing Australian study.146 Given the choice to receive results by consultation or letter, 
most patients tested presymptomatically for BRCA or Lynch syndrome in another Dutch 
study chose disclosure by letter, without excess distress and increasing efficiency.147 
Initial genetic counseling by telephone was equal to in-person contact in a Swedish 
randomized study, showing high patient satisfaction rates.148
More DNA-direct participants reported strong (rather than moderate) satisfaction with 
their choice to start BRCA-mutation testing, compared to DNA-intake. Surprisingly, 
fewer DNA-direct than DNA-intake participants would start BRCA-mutation testing 
again. Participants may have misinterpreted the question to start BRCA-mutation test-
ing if given a second chance, as doing such testing while the majority already knew 
they were not a BRCA-mutation carrier, thus not necessarily reflecting satisfaction. Also, 
fewer DNA-direct participants would recommend BRCA-mutation testing to another BC 
patient, but those indicating why showed reluctance to influence another individual’s 
choice, rather than (non-)satisfaction.
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Non-randomization limits the generalizability of our study. We chose not to randomize 
to determine BC patient preferences and arguments for or against DNA-direct. When 
all BC patients would have preferred a face-to-face intake consultation, our conclusion 
would have been different. However, a majority of BC patients did choose DNA-direct, 
proving otherwise. This approach did lead to significant baseline differences between 
the DNA-direct and DNA-intake groups. For example, DNA-intake participants showed 
higher distress than DNA-direct. As no interaction or time effect was demonstrated, 
patients with higher distress seemed to prefer initial face-to-face contact prior to BRCA-
mutation testing and remained more distressed at follow-up compared to DNA-direct 
participants. Educational level was also lower in DNA-intake, previously established as 
an important confounder when providing BRCA-mutation testing services.149 To limit ef-
fects on study results, statistical correction for these baseline differences was performed. 
However, DNA-direct may be a best fit for those patients who match the overall profile 
of DNA-direct participants in our study: higher educated and better informed patients, 
who are more certain of genetic testing and show less distress.
Selection bias may have influenced our results: those with current psychological 
problems were excluded, as they may be prone to higher distress after BRCA-mutation 
testing. Patients did not experience difficulty with family communication as a barrier 
to DNA-direct, although counselors should remain vigilant for such problems. Another 
limitation is that effects on processing time are health system dependent and may 
provide different results elsewhere.
BRCA-mutation detection rate was equal in both groups with all detected BRCA-mu-
tation carriers fulfilling guideline criteria for BRCA-mutation testing. We conclude that 
raising efficiency by selecting eligible BC patients on referral for genetic testing by other 
medical specialists, and reducing the number of face-to-face consultations (higher costs 
compared to telephone contact) and processing time while increasing patient partici-
pation and providing to-the-point counseling, weighs up against some patients being 
tested without fulfilling guideline criteria for BRCA-mutation testing (35%). This does 
underline the importance of improving physician knowledge of appropriate referral 
criteria.38
In conclusion, more BC patients preferred replacing a face-to-face consultation with a 
trained genetic counselor prior to BRCA-mutation testing by telephone, written and digi-
tal information, the majority being strongly to moderately satisfied with the procedure 
followed, without increased distress as compared to the face-to-face intake procedure.
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AbStrACt
According to current practice most breast cancer (BC) patients receive face-to-face 
genetic counseling prior to BRCA-mutation testing (DNA-intake). We evaluated a novel 
format by prospective study: replacing the intake consultation with telephone, written 
and digital information sent home. Face-to-face counseling then followed BRCA-muta-
tion testing (DNA-direct). From August 2011 to February 2012, 161 eligible BC patients 
chose either DNA-direct (intervention: 59%) or DNA-intake (control: 41%). One year after 
BRCA-result disclosure, 108 participants (59 DNA-direct: 55%) returned long-term follow-
up questionnaires. Questionnaires included satisfaction and psychological distress. 
All participants were satisfied and 85% of DNA-direct participants would choose this 
procedure again; 10% would prefer DNA-intake and 5% were undecided. In repeated 
measurements ANOVA, general distress (GHQ-12, p=0.01) and BC-specific distress 
(IES-bc, p=0.03) were lower in DNA-direct than DNA-intake at all time measurements. 
Heredity-specific distress (IES-her) did not differ significantly between groups. Multivari-
ate regression analyses showed that choice of procedure did not significantly contribute 
to either general or heredity-specific distress. BC-specific distress did contribute to both 
general and heredity-specific distress. This suggests that higher distress scores reflected 
BC experience, rather than the type of genetic diagnostic procedure. In conclusion, the 
large majority of BC patients that used DNA-direct reported high satisfaction without in-
creased distress both in the short-term, and one year after conclusion of genetic testing.
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introDUCtion
Patients confronted with a diagnosis of breast cancer (BC) desire quick answers about 
their personal situation in light of their risk of a hereditary predisposition.119 Should a 
pathogenic BRCA1/2-mutation be found, BC patients are at an increased risk of up to 
60% of a second primary BC31-33 which may influence the choice of BC treatment.96 For 
the additional high risk for ovarian cancer (20-60% for BRCA1 and 2-20% for BRCA231-33) 
prophylactic surgery is recommended.64 Family cascade screening may identify unaf-
fected BRCA1/2-mutation carriers with an increased lifetime risk of 40-80% for BC.31-33 
BRCA1/2-mutation carriers are eligible for yearly BC screening or prophylactic surgery 
from 25 years of age.10 Current genetic counseling practice typically involves a face-to-
face counseling session with a genetic counselor prior to diagnostic BRCA-testing.150 This 
may add several weeks to the period of diagnostic uncertainty regarding BRCA1/2 gene 
status. We reasoned that a shorter trajectory of genetic information provision might be 
advantageous for BC patients with concerns about their risk of a hereditary predisposi-
tion.
To achieve this, we previously evaluated short-term patient experiences with a novel for-
mat replacing the initial face-to-face consultation prior to BRCA-mutation testing (usual 
care, DNA-intake procedure) by telephone, written and digital information with a blood 
drawing kit sent to their home address (DNA-direct procedure).143,151 In both procedures, 
BRCA-results were disclosed in face-to-face consultations by an experienced genetic 
counselor, including personalized counseling and cancer prevention recommendations 
for both patients and their families.143 Given a free choice between these procedures, 
59% (95 of 161) of eligible BC patients (p=0.03) chose the new format of BRCA-mutation 
testing without prior face-to-face genetic counseling (DNA-direct), proving an interest 
in this new procedure. Several weeks (median 5 [2–22]) after BRCA-result disclosure, 
DNA-direct participants were highly satisfied and showed lower psychological distress 
than DNA-intake, suggesting that patients with higher distress were more likely to opt 
for initial face-to-face contact prior to genetic testing and remained more distressed 
throughout the procedure.151
While these short-term results were reassuring, literature shows different trajectories 
of change in psychological adjustment after BC diagnosis: while the majority remains 
even or stabilizes one year post-diagnosis, a small group deteriorates.152 This trend was 
shown in older (>65 years) BC patients, where diminished social support was predic-
tive of deteriorating quality of life.153 BC patients may also be vulnerable due to family 
cancer history, e.g. deaths of family members diminishing their social support systems. 
Family history is often the reason for referral to genetic services154, but adding a genetic 
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diagnostic procedure could influence long-term psychological adjustment. We there-
fore sought to determine long-term effects and acceptability of the novel DNA-direct 
procedure, in order to assess whether distress is triggered at a later time.
This study thus compared long-term experiences of BC patients (satisfaction and 
psychological distress) between the novel DNA-direct procedure and usual care 
(DNA-intake), measured one year after BRCA-result disclosure. We hypothesized that 
patient satisfaction in both procedures would remain stable over time (as we observed 
previously shortly after BRCA-result disclosure), and that DNA-direct does not induce 
increased distress in short- or long-term.
MethoDS
Participants
The study protocol was previously published.143 In short, following approval by the local 
medical ethics committee, all female patients (previously) diagnosed with BC and re-
ferred to the department of Human Genetics at Radboudumc between August 2011 and 
February 2012 were eligible (Figure 1). Exclusion criteria were psychological problems 
requiring treatment, difficulty with Dutch text, or known BRCA-families. To evaluate 
whether there was a preference for DNA-direct, BC patients were free to choose be-
tween procedures.
Study procedure
Previous results were published151 based on 161 responses on baseline (T0) question-
naires. Of these, 95 (59%) chose the DNA-direct procedure over DNA-intake, and 146 
(n=87 DNA-direct) returned short-term follow-up (T1) questionnaires sent two weeks 
after BRCA-result disclosure. Mutation detection rate was equal at 8% in both groups; 
processing time was one month shorter in the DNA-direct procedure. Additional long-
term follow-up (T2) data are presented here, collected from questionnaires sent one 
year after BRCA-result disclosure to previous T1 responders; participation was voluntary.
DnA-direct procedure
In the novel DNA-direct procedure, patients received telephone (triage call by a trained 
medical doctor), written and digital information (website, educational movie) at home. 
The triage call (median 9 [5–20] minutes) served to check exclusion criteria primarily 
meant for pre-test psychosocial assessment of difficulty with Dutch text, psychological 
problems or family communication problems (Figure 1). Non-excluded patients were 
all offered the choice of DNA-direct versus DNA-intake, without genetic counseling. 
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Patients choosing DNA-direct received an informational letter and website with video 
covering basic information about BC, heredity and genetic testing, similar to a pre-test 
consultation. A blood drawing kit was included to start BRCA-mutation testing. Written 
informed consent for DNA-direct and family history forms were required before diag-
nostic testing was initiated. Telephone or e-mail contact with the physician researcher 
(AS) was available (used by 14 participants, only regarding logistics). BRCA-results were 
disclosed in a face-to-face consultation of 45 minutes (equal to the pre-test DNA-intake 
consultation) by one of five experienced genetic counselors. Further details were previ-
ously published.143,151
Breast cancer patients assessed for 
eligibility (n =  233)
 
Excluded (n = 42)
 
  
● Diculty with Dutch text (n = 5) 
  ● Psychological problems (n = 33) 
  ● Known BRCA-family (n = 3) 
  ● Non-BRCA referral (n = 1) 
Declined genetic genetic counseling (n = 11)
 
No response at baseline (n = 19)
 
  ● Chose DNA-direct (n = 9)
  ● Chose DNA-intake (n = 10)
 
Participants oered choice of 
procedure and responded at 
baseline (n = 161) 
Lost to follow-up (n = 8) 
  ● Death (n = 1) 
  
● No response (n = 7) 
Chose DNA-direct  
(n = 95/161, 59%) 
Short-term follow-up analyzed 
DNA-direct (n = 87)  
BRCA-mutation test           
(n = 95/95, 100%)  
  BRCA-mutation carriers  
    (n = 8/95, 8%) 
Chose DNA-intake 
(n = 66/161, 41%) 
 
  ● Overwhelmed (n = 1) 
   
 
 
BRCA
(n = 50/66, 76%)
   
    (n = 4/50, 8%)  
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  ● No response (n = 2) 
No 
(n = 16/66, 24%) 
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)
-mutation test           
● BRCA-mutation carriers● 
BRCA-mutation test           
Lost to follow-up (n = 5) Lost to follow-up (n = 2)
● No response (n = 4)
Short-term follow-up analyzed
DNA-intake (n = 59)
Long-term follow-up analyzed
DNA-direct (n = 59)
Long-term follow-up analyzed
DNA-intake (n = 49)
figure 1: Flowchart of patient inclusion, short term and one year follow-up, procedure proportions and 
BRCA-results.
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instrumentation
Full psychometric details of standardized measures were previously published.143 At 1 
year follow-up (T2), the primary study outcomes were: satisfaction regarding choice of 
procedure (T1/T2), general distress (T0/T1/T2: GHQ-12129 scale 0–12, Cronbach’s α in this 
study=0.84 at T0 / 0.89 at T1 / 0.88 at T2) and heredity-specific psychological distress (T0/
T1/T2: IES-her132,133 scale 0–75, α=0.93 / 0.94 / 0.95).
Secondary psychological measures were BC-specific distress (T0/T2: IES-bc132,133 α=0.93 
/ 0.92), global quality of life (T0/T1/T2: selected from EORTC-QLQ-Q30127 scale 0–100, 
α=0.85 / 0.84 / 0.91), BC worry (T0/T1/T2: CWS135 scale 8–32, α=0.84 / 0.85 / 0.82), risk 
perception of hereditary BC and 2nd BC (T0/T1/T2: visual scales 0–100). Other secondary 
T2 outcomes were: coping style (shortened TMSI16,155) categorizing responders as more 
monitoring (subscale α=0.69) i.e. actively seeking information about medical threats, 
more blunting (subscale α=0.69) i.e. seeking distraction, or neutral, as used in a previ-
ous study156; and open-ended questions regarding a) perceived causes of their BC and 
b) most important aspects for other patients to know about genetic testing (>10% 
reported).
baseline differences
In previous analyses151, significant differences in baseline (T0) sociodemographic and BC 
characteristics were found between DNA-direct and DNA-intake groups (Table 1). Most 
importantly, DNA-direct participants reported higher website use (p=0.01), more prior 
information by their referring physician about personal consequences (p=0.004), less 
prior information by their referring physician about genetics in general (p=0.008) and 
lower decisional conflict i.e. difficulty making a decision whether to start DNA-testing 
(p=0.01). Baseline differences were corrected for statistically as described below.
Data analysis
Data is presented using descriptive statistics. To compare DNA-direct versus DNA-intake 
for each T2 outcome, the unpaired t-test was used for continuous, Mann-Whitney U 
test for ordinal and chi-square/Fisher’s Exact test for nominal/dichotomous variables. 
Eight baseline differences (Table 1) were included as covariates in repeated measure-
ments ANOVA used to test for changes over the three time measurements (T0, T1, T2) 
between DNA-direct versus DNA-intake (group) in psychological outcomes (general 
distress, heredity-specific distress, BC-specific distress, quality of life, BC worry and risk 
perception of hereditary BC and 2nd BC) and multivariate regression analyses of non-
psychological outcomes showing univariate differences. Correlations between distress 
(T2: general, heredity-specific, BC-specific) and choice of procedure (DNA-direct or DNA-
intake), sociodemographic characteristics (T0: age at inclusion, educational level), BC 
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characteristics (T0: age at 1st BC diagnosis, months since last BC, BRCA referral criteria, 
family characteristics) and psychological variables (T2: quality of life, coping style, BC 
worry, risk perception for heredity and for second BC) were assessed using Pearson’s 
correlation coefficients. Characteristics with significant correlations were used as inde-
pendent variables in multiple backward linear regression analysis for the determinants 
of each psychological distress measure. The probability level for statistical significance 
testing was set at 0.05 (two-tailed). The SPSS 20.0 statistical package was used to analyze 
the data.
Genetic counselors’ experiences
Previously unreported, the five involved genetic counselors filled in a yes/no checklist 
after each individual DNA-direct consultation to determine whether they experienced: 
1) good contact with the patient, 2) unexpected patient reactions, 3) need for a follow-
table 1: Relevant baseline differences (p<0.05) in sociodemographic and breast cancer (BC) characteristics 
for all BC patients choosing DNA-direct (novel format) or DNA-intake (usual care) as evaluated in previous 
analyses.151
Characteristic DNA-direct
n=95: N (%) or
median [range]
or mean±SD
DNA-intake
n=66: N (%) or
median [range]
or mean±SD
P
Age at inclusion 49 [23-73] 53 [28-74] 0.10
Age at 1st BC diagnosis 47 [23-71] 49 [28-74] 0.15
Months since last BC   6 [0-247]   6 [0-195] 0.92
BRCA referral criteria
- positive family history
- age at BC <40yrs
- ovarian cancer in patient
75 (79%)
29 (31%)
  4 (4%)
53 (80%)
13 (20%)
  2 (3%)
1.00
0.15
1.00
Family characteristics
- mother with BC
- sister with BC
- age (yrs) youngest with BC
- children living at home
17 (18%)
17 (18%)
40 [23-62]
55 (58%)
13 (20%)
15 (23%)
42 [26-64]
26 (39%)
0.84
0.55
0.03 *
0.03 *
Educational level
- high
- medium
- low
39 (41%)
27 (28%)
29 (31%)
13 (20%)
25 (38%)
28 (42%)
0.01 *
Use of BC websites 50 (53%) 21 (32%) 0.01 *
Information provided by referring physician
- genetics in general
- personal consequences
- outcomes of genetic testing
25 (26%)
39 (41%)
32 (34%)
31 (47%)
13 (20%)
12 (18%)
0.008 *
0.006 *
0.03 *
Decisional conflict
(DCS: 0-100)
n=87: 
16.2±13.9
n=58:
23.2±10.8
0.001 *
* Statistically significant p<0.05: baseline differences included as covariate in multivariate analyses.
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up consultation, 4) need for non-standard psychosocial support, 5) the patient having 
made an informed choice to start BRCA-testing, and 6) the retrospective preference for 
a pre-test intake consultation. They were also asked for their general opinions during a 
joint DNA-direct counselor meeting.
reSUltS
A total of 108 BC patients returned one year follow-up (T2) surveys of whom 59 had 
previously chosen DNA-direct (55%), five of which were identified as BRCA-mutation 
carriers, versus 49 participants who had chosen DNA-intake of which one was a BRCA-
mutation carrier.
Satisfaction with choice of procedure
All participants in both groups were satisfied with their choice of procedure, 75% 
strongly so; none reported regret. Most DNA-direct participants (85%) would choose 
this procedure again (1 emphasized the benefit of taking action from home during BC 
diagnosis/treatment) whereas 10% now preferred DNA-intake (1 stated this seemed 
more personal) and 5% did not know (1 clarified dependency on their health at that 
time). In DNA-intake, most (80%) would choose this procedure again with 10% empha-
sizing personal contact, but 16% now preferred DNA-direct (none clarified) and 4% did 
not know (depending on explanation of the procedure).
Two-thirds (63%) of DNA-direct versus one-third (31%, p=0.001) of DNA-intake reported 
that their recommended procedure to another patient would depend on that individ-
ual person: their preferences for personal contact, information formats, comfort using 
digital media, questions and worries, capability of processing information, prior medical 
knowledge, social support. DNA-direct was specifically recommended by 24% of DNA-
direct and 10% of DNA-intake participants (1 felt the choice could also be made using 
DNA-direct, 1 would recommend DNA-intake instead if the person had many worries). 
DNA-intake was recommended by 9% of DNA-direct (1 mentioned  the ability to ask 
questions) and 57% of DNA-intake (1 emphasized their own preference for face-to-face 
contact). 5% of DNA-direct and 2% of DNA-intake participants were uncertain which 
procedure to recommend; all stated it was a personal choice.
Psychological distress
As shown in Table 2, no main effects for time (within subjects) were found for any 
psychological distress measure. In DNA-direct, lower scores were reported for general 
distress than DNA-intake (GHQ-12: p=0.01, between subjects). Notably, a near-significant 
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interaction effect between time and choice of procedure was found (p=0.051): as seen 
in Figure 2a, the difference in general distress between procedures appears greater at 
T0 and T1 than at T2. Corrected mean general distress scores for DNA-intake crossed 
the threshold for clinical relevance of GHQ-12≥4 at baseline (Figure 2a) but dropped 
below this threshold after BRCA-result disclosure; no clinically relevant distress scores 
were shown in DNA-direct. Heredity-specific distress (IES-her) did not differ significantly 
between procedures, nor showed an interaction effect. BC-specific distress in DNA-
direct did score lower than DNA-intake (IES-bc: p=0.03) without an interaction effect. All 
heredity-specific and BC-specific distress scores remained below the clinical relevance 
threshold of IES≤26.
Variables significantly correlating with general distress (GHQ-12), heredity-specific dis-
tress (IES-her) or BC-specific distress (IES-bc) are shown in Table 3. Choice of procedure 
(DNA-direct versus DNA-intake) only correlated to heredity-specific distress, but was no 
longer significant following multivariate regression analysis. Higher BC-specific distress 
was a significant contributor to both general distress (p=0.01) and heredity-specific dis-
table 2: Psychological measures for all breast cancer (BC) patients choosing DNA-direct (novel format, 
n=59) or DNA-intake (usual care, n=49) responding at follow-up one year post BRCA-result disclosure (T2). 
Estimated means±standard deviations are reported following correction for baseline differences (see Table 
1) in repeated measurements ANOVA.
Characteristic T0 T1 T2
DNA-direct
n=59
DNA-intake
n=49
DNA-direct
n=59
DNA-intake
n=49
DNA-direct
n=59
DNA-intake
n=49
P*
General distress
(GHQ-12: 0-12)
2.7±3.0 4.2±3.5 1.9±3.0 3.9±3.5 1.8±3.0 2.1±3.5 0.01 **
Heredity-specific distress
(IES-her: 0-75)
13.9±14.5 15.1±14.9 12.3±16.0 14.9±16.2 9.1±12.9 13.4±13.0 0.26
BC-specific distress
(IES-bc: 0-75)
17.0±15.7 23.7±15.8 not measured not measured 12.4±14.2 18.1±14.4 0.03
Quality of Life
(QoL: 0-100)
73.1 ±20.0 71.9±20.1 75.0±16.9 73.5±17.3 77.9±19.2 77.7±19.4 0.76
BC worry
(CWS: 8-32)
14.1±3.8 15.2±4.0 14.5±3.0 15.2±3.3 13.5±3.8 14.8±3.3 0.10
Risk (0-100) perception: 
hereditary BC
40.4±24.7 41.1±25.2 32.8±29.9 32.4±30.5 38.6±29.2 38.7±29.8 0.98
Risk (0-100) perception:
2nd BC
45.4±29.2 44.1±29.5 37.7±24.7 41.8±24.9 38.9±28.4 43.2±28.9 0.62
* Reported P-values are associated with the main effect for choice of procedure (DNA-direct versus DNA-
intake) in repeated measurements ANOVA: bold indicates statistical significance p<0.05. No main effects for 
time (within subjects) were found.
 ** Trend for interaction effect between time and choice of procedure: p=0.051. No other variables showed 
(trends for)  interaction effects.
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figure 2: Changes over time in psychological distress measures: a) general distress (GHQ-12), b) heredity-
specific distress (IES-her), and c) BC-specific distress (IES-bc). Significant group effects were found only in 
general distress (a) and BC-specific distress (c) without significant time effects in any measure.
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tress (p<0.001).  General distress was also more likely in participants with lower quality 
of life (p<0.001), while higher heredity-specific distress was associated with more BC 
worry (p=0.01) or having a sister with BC (p=0.02). More BC-specific distress was seen 
in those with higher heredity-specific distress (p<0.001), higher BC worry (p<0.001) or 
younger age at inclusion (p=0.02). 
Secondary psychological outcomes
Quality of life, BC worry, risk perception for hereditary BC and 2nd BC (Table 2) did not 
differ between DNA-direct versus DNA-intake (between subjects) or over time (within 
subjects). 
Perceived causes of breast cancer
As multiple reasons were possible per responder, percentages are not cumulative: he-
redity (30%), bad luck (30%), stress (14%) and hormonal factors e.g. oral contraception 
(14%) were reported as perceived causes of BC; 18% did not know. Only one significant 
difference was found: those in the DNA-direct group were more likely to perceive hered-
table 3: Determinants of psychological distress measures amongst all participating breast cancer (BC) pa-
tients choosing either DNA-direct (intervention) or DNA-intake (control), following correlation testing with 
choice of procedure, sociodemographics, BC characteristics and other psychological variables (significant 
correlations with p<0.05  shown).
Characteristic Pearson’s correlation 
coefficient
Multivariate regression analysis
P Beta 95% confidence interval
General distress (GHQ-12)
- Quality of Life (QoL) -0.562 <0.001 -0.544 [-0.114  –  -0.063]
- BC-specific distress (IES-bc)  0.255   0.011  0.205 [ 0.010   –   0.073]
- BC worry (CWS)  0.275 n.s. - -
- mother with BC -0.363 n.s. - -
- age youngest relative with BC -0.428 n.s. - -
- children living at home  0.196 n.s. - -
Heredity-specific distress (IES-her)
- DNA-direct vs. DNA-intake -0.192 n.s. - -
- BC-specific distress (IES-bc)  0.545 <0.001  0.386 [ 0.190   –   0.600]
- BC worry (CWS)  0.520   0.013  0.257 [ 0.239   –   1.983]
- sister with BC  0.206   0.022  0.183 [ 0.929   – 11.723]
BC-specific distress (IES-bc)
- General distress (GHQ-12)  0.255 n.s. - -
- Heredity-specific distress (IES-her)  0.545 <0.001  0.304 [ 0.135  –   0.458]
- BC worry (CWS)  0.631 <0.001  0.452 [  1.210  –  2.618]
- age at inclusion (years) -0.233   0.024 -0.165 [ -0.411  – -0.030]
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ity (e.g. “it runs in the family”) as the cause of their BC than in DNA-intake (46% vs. 10%, 
p<0.001).
important aspects of genetic testing
Responders felt (not cumulative) that other persons should know about: certainty 
and/or clarity about a hereditary predisposition (22%), consequences for family (18%), 
procedural aspects (18%), consequences of genetic testing (18%), early prevention (12%) 
and no full guarantees from test results (11%). No differences between DNA-direct and 
DNA-intake were found.
Genetic counselors’ experiences
In a total of 88 reported DNA-direct disclosure sessions, genetic counselors achieved 
good contact with patients (94%), experienced few unexpected patient reactions 
(7%), few patients needing follow-up consultations (9%) or non-standard psychosocial 
support (2%), believed most patients made an informed choice to start BRCA-testing 
(76%) and in retrospect, did not prefer a pre-test intake consultation for the majority of 
patients (85%). In general, counselors reported the benefit of to-the-point and personal-
ized counseling, saving time within the 45 minutes of a first face-to-face consultation to 
discuss personal consequences of the known BRCA-result for the patient and her family.
DiSCUSSion
The current evaluation continues our previous study, which had already shown that 
more patients with BC chose the new format of BRCA-mutation testing without prior 
face-to-face genetic counseling (DNA-direct) over the current standard of face-to-face 
counseling both prior to and following BRCA-mutation testing (DNA-intake). Follow-up 
of these patients showed that there was no increase in psychological distress at either 
short- or long-term; in fact, the DNA-direct participants scored lower on both general 
and BC-specific distress than DNA-intake. We conclude from these study results that the 
DNA-direct procedure i.e. face-to-face counseling after availability of BRCA-mutation 
testing results, is appropriate for the majority of BC patients, in particular those similar 
to DNA-direct participants in our study. Patients without pre-existing psychological 
problems may prefer to arrange BRCA-mutation testing from home due to reasons as-
sociated with their BC diagnosis and treatment, information needs and preferences, as 
well as certain family characteristics (e.g. children living at home). In retrospect genetic 
counselors did not prefer DNA-intake for most patients (85%). Counselors emphasized 
to-the-point and personalized counseling with more time to discuss personal conse-
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quences rather than general BRCA information: most patients did not require additional 
follow-up (91%).
One interesting difference at long-term follow-up should be noted: more DNA-direct 
participants reported their belief that heredity (may have) caused their BC, but this 
was not reflected in reports of risk perception for hereditary BC, which remained 
equal between groups and over time. However, one of the baseline differences found 
between groups was that amongst DNA-direct participants, BC was diagnosed in their 
family at a younger age. Although no other clinical variables were previously found to 
predict for the choice of DNA-direct151 this may suggest that these participants are more 
aware that their BC risk may still be moderately increased by familial factors, beyond 
BRCA-mutations. Risk perceptions for hereditary BC not changing over time for either 
group is also notable and in concordance with earlier literature showing that traditional 
genetic counseling and testing has no lasting effects on risk perception.12,113 Improving 
patient risk perceptions remains a challenge for genetic counseling as a whole, but is 
not enhanced nor deteriorated due to the DNA-direct procedure.
Study limitations
As described previously151, non-randomization of our study participants limits the 
generalizability of our study results. DNA-direct may therefore be most appropriate for 
those BC patients matching the overall profile of DNA-direct participants in our study: 
those who are higher educated and better informed, as well as comfortable with or 
even preferring different information formats beyond face-to-face contact. We now 
consider randomization unethical, as our study result suggest a link between distress 
and self-selection. Another study limitation is the low number of BRCA-positive results 
which may have influenced our study results, as these patients are the most likely to ex-
perience distress after disclosure.154 However, this low number is reflective of standard 
clinical genetic practice therefore does not affect generalizability of our study results.
No formal cost-effectiveness analyses have been performed, but DNA-direct reduced 
face-to-face consultation time for both genetic counselors and the surrounding re-
sources at the outpatient clinic. The DNA-intake procedure included a pre-test session 
of 45 minutes and a post-test session of 15 minutes (total 60 minutes). The DNA-direct 
procedure only included a post-test session of 45 minutes. However higher uptake 
of BRCA-testing (100% in DNA-direct versus 76% in DNA-intake) might suggest more 
patients were BRCA-tested unnecessarily in DNA-direct: BRCA-testing was only indi-
cated if one or more of familial risk scores (e.g. FHAT123, Myriad124, Claus/van Asperen126) 
exceeded certain thresholds. But familial risk selection criteria for BRCA-testing were 
not fulfilled by some patients BRCA-tested in both groups: 35% in DNA-direct versus 
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26% in DNA-intake. Mutation detection rate remained equal in both groups. This reflects 
that the choice of procedure did not result in different numbers of patients BRCA-tested, 
whereas offering DNA-direct alongside DNA-intake increased patient participation and 
reduced processing time. We consider this to be the greatest benefit of the DNA-direct 
procedure, despite cost-effectiveness not being proven, dependent on additional BRCA-
test costs.
Practice implications
Participants who chose the traditional DNA-intake procedure reported higher general 
and BC-specific distress, even one year after BRCA-result disclosure. This supports our 
earlier notion151 that distressed patients were more likely to choose face-to-face coun-
seling prior to genetic testing. However, choice of procedure did not appear to be a 
significant contributor to general and heredity-specific distress, instead both were as-
sociated with BC-specific distress. This further suggests that higher distress scores were 
based on the experience of BC, not the (chosen) genetic diagnostic procedure; and that 
those who feel more distressed and may be in need of prior psychosocial support, self-
selected to the DNA-intake procedure where such support was immediately available. 
Offering DNA-direct as an alternative to the standard DNA-intake, to match individual 
preferences for information formats prior to BRCA-mutation testing, therefore is consid-
ered acceptable in the light of our follow-up results. This adds to an ever-growing body 
of literature147,157-160 showing that these new models of cancer genetic services varying 
in combinations of face-to-face, telephone and/or digital communication, pre- and/or 
post BRCA-testing, are acceptable.5 Positive patient experiences with newer multi-gene 
panels161 have currently only been proven after pre-test counseling regarding possible 
unsolicited or unclear findings.162 Therefore we do not currently recommend DNA-direct 
for multi-gene panels.
research recommendations
Other target groups for DNA-direct may be evaluated. For example, BRCA-mutations 
account for 5-16% of all ovarian cancer cases163 and guidelines now recommend referral 
of all patients with ovarian cancer regardless of age or family history.36 Patients with 
ovarian cancer strongly supported genetic testing around the time of diagnosis164 and 
may be excellent candidates for DNA-direct in the future. Further research may also 
focus on alternative service models for the multi-gene panel setting, starting with those 
now used for conventional single-gene testing.5
Conclusions
BC patients who had chosen to forego personal genetic counseling prior to BRCA-
mutation testing, and instead receive a combination of telephone, written and digital 
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information reported high satisfaction and low distress both several weeks and one 
year after BRCA-result disclosure. Distress is triggered by the BC diagnosis, not genetic 
testing. The novel DNA-direct procedure appears acceptable for BC patients alongside 
the traditional face-to-face intake procedure.
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STAGE II
Genetic testing and counseling
“The beginning of knowledge is the 
discovery of something we do not 
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(Frank Herbert)

Chapter 6
Can we test for hereditary cancer at 
18 years when we start surveillance at 
25? Patient reported outcomes
Sie AS
Prins JB
Spruijt L
Kets CM
Hoogerbrugge N
Fam Cancer. 2013;12(4):675-82
Ch
ap
te
r 6
86
DNA-testing before 25 years
AbStrACt
background: DNA-testing for BRCA1/2 or Lynch syndrome is possible from the age of 18 
years, although surveillance usually starts at 25. Some patients regret their decision of 
testing before age 25. This retrospective study evaluates whether the testing age should 
be above 25 years to prevent adverse effects such as regret or decisional conflict, by 
determining the percentage and characteristics of patients reporting these problems.
Patients/Methods: 111 of 219 patients (51%) tested for BRCA1/2 mutations or Lynch 
syndrome between 18-25 years from July 1996 to February 2011, returned self-report 
surveys. Primary measures were regret, decisional conflict and family influence. Second-
ary measures included quality of life (QoL), coping style, impact of genetic testing, and 
risk perception.
results: Median age was 27 [21-40] years, with 86% female. 73% was tested for BRCA1/2, 
27% for Lynch syndrome. Only 3% reported regret, however 39% had moderate (32%) to 
severe (7%) decisional conflict. Regression analysis revealed that decisional conflict was 
associated with more monitoring/neutral coping style (p<0.03) or paternal/no family 
mutation (p<0.02); there were no differences in QoL, impact or risk perception. 42% 
were mutation carriers, showing equal decisional conflict to non-carriers. 68% would 
recommend testing <25 years; 77% desired surveillance <25 years if a mutation carrier.
Conclusion: Almost no patient tested for hereditary cancer between 18-25 years regret-
ted this decision. A third reported retrospective decisional conflict, especially those 
actively seeking information when faced with a threat and/or those with a paternal or 
unknown inheritance. These patients may benefit from decisional support and person-
alized information.
keywords
young adult – hereditary – cancer – BRCA – Lynch syndrome – decision making
Chapter 6
87
DNA-testing before 25 years
bACkGroUnD
Following international guidelines45, DNA-testing of the BRCA1/2 genes for hereditary 
breast cancer, or the mismatch repair (MMR) genes for hereditary colon cancer (Lynch 
syndrome) is possible from the age of 18 years. However, surveillance for BRCA1/2 or 
Lynch syndrome does not usually start until the age of 25 years (although prior to policy 
changes in 2008, surveillance for Lynch syndrome was advised from 20-25 years).57,61 
Thus, a younger carrier might be aware of their mutation status, but there is no indica-
tion to act on this knowledge (by surveillance or preventive surgery) until age 25.
In general, young adults between 18 and 25 years of age are in the midst of a vital, but 
hectic phase of life: they are expected to become fully independent adults, while still 
sensitive to family influences.47,48 When faced with hereditary cancer, especially if a 
parent is involved, they may struggle with the need to break free from their family for 
their own self-development, versus family loyalty and involvement due to cancer. Their 
own cancer risk165-167 and the experience of parental cancer in childhood or adolescence 
may lead to increased distress during genetic testing.168 Specific support needs in young 
adults and distress due to the discrepancy between the desired age of testing versus 
current practice have previously been identified in another hereditary cancer syndrome, 
familial adenomatous polyposis (FAP).49,50 As FAP is associated with a much earlier onset 
of symptoms, these studies cannot necessarily be generalized to BRCA1/2 and Lynch 
syndrome, but do indicate the need for further study of this particular age group in 
these syndromes.
The question remains whether these young adults are able to anticipate all the short 
and long term consequences of their decision. Neurophysiologic research shows that 
the brain (especially the frontal lobes responsible for planning and execution) is still in 
active development until 25 years.48,169 It is currently unclear what this means for the de-
velopment of cognitive competencies such as future orientation170, decision-making171, 
self-identity and reflection.172 However, these are important in genetic counseling as 
decisions must be based on expectations regarding possible future consequences of a 
yet unknown result.172
Young adults between 18 and 25 years of age may experience fewer benefits from 
genetic testing than older patients with a concrete goal to start prevention measures 
immediately. They may feel especially vulnerable due to the knowledge of higher cancer 
risks without clear clinical management guidelines until the age of 25.66 In our hospital, 
some of these young adults thus indicated regret of their decision to start DNA-testing 
for BRCA1/2 mutations or Lynch syndrome before the age of 25 years. Looking back, they 
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considered themselves incapable of making a decision of such importance at that time. 
This may refer to so-called decisional conflict. While regret concerns emotional remorse 
following a choice, decisional conflict is a state of uncertainty about a course of action 
due to feeling uninformed, unsupported or unclear about personal values.138,139
However, as other young adults had not reported such problems, age does not seem 
to be the only factor involved; psychological aspects such as risk perception may also 
be relevant. Some studies suggest that those with high perceived risk are more likely 
to start genetic testing.173 Risk perception is related to many factors including family 
history, stress and coping style. The uptake of genetic testing was studied in relation to 
two coping styles, monitoring (actively seeking information when faced with a threat) 
and blunting (avoidance of information). Patients with a monitoring coping style did not 
have a higher uptake of genetic testing174, but patients choosing not to undergo testing 
had higher anxiety levels than those who were tested, suggesting that coping through 
avoidance (blunting) resulted in lower uptake.173 Monitoring recipients of indeterminate 
or positive results reported increased distress.175 No differences were found in coping 
styles of patients tested for BRCA1/2 mutations or Lynch syndrome176, allowing pooled 
evaluation.
The aim of this retrospective study was to assess whether the testing age should be 
above 25 years in order to prevent adverse effects such as regret or decisional conflict, 
by determining the percentage and characteristics of patients reporting such problems 
in retrospect.
PAtientS AnD MethoDS
Participants
All patients tested for mutations in either the BRCA1/2 genes or mismatch repair (MMR) 
genes associated with Lynch syndrome between July 1st 1996 and February 14th 2011 in 
the Radboud University Nijmegen Medical Centre (RUNMC), who were younger than 
25 years of age at the time of testing (n=290), were eligible for this study. Patients were 
initially excluded if they were younger than 18 years of age when tested (n=10) or if they 
had been counseled in another medical center (n=40). Medical files of the remaining 
240 patients were reviewed for further reasons for exclusion: death (n=9), intellectual 
disability (n=5), expatriation (n=4), tumor but no gene testing (n=1), unknown address 
(n=2). A final total of 219 patients were included in the study.
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Study procedure
Patients were invited by mail to fill in an online self-report survey within two weeks. If 
needed, a reminder letter with paper survey was sent a month later. Surveys were re-
turned by 111/219 patients (51%). Despite checking addresses before mailing out surveys, 
1 was returned as unknown resident.
Measures
Decision-making
Regret
Regret of the decision to start DNA-testing before 25 years was measured by a 4-point 
Likert-scale from 1 ‘not at all’ to 4 ‘very much’. Patients indicated to start DNA-testing 
again if given a second chance now, by answering ‘yes, at the same moment’, ‘yes, but at 
a later time’ or ‘no, not at all’.
Decisional conflict
The difficulty of deciding whether or not to have genetic testing at the time of deci-
sion, was retrospectively assessed using the traditional format of the Decisional Conflict 
Scale.138,139 1 item (“I expect to stick to my decision”) was left out as it is not applicable to 
DNA-testing.137 15 items scored from 0 ‘strongly agree’ to 4 ‘strongly disagree’ remained 
with excellent internal consistency (Cronbach’s α=0.92). Scores were summed, divided 
by 15 and multiplied by 25 (scale 0–100); as defined by the test authors, scores <25 were 
considered as ‘no decisional conflict’, between 25 and 37.5 as ‘moderate conflict’ and 
≥37.5 as ‘severe conflict’. 1 DCS item “I am satisfied with my decision” (scale 0–4) was also 
used for overall satisfaction.
Family influence
Patients indicated whether the medical history of parents, sisters and brothers had in-
fluenced their decision, and specified the type of advice (‘no advice’, ‘no DNA-test’, ‘wait 
with DNA-test’, ‘immediate DNA-test’, ‘other’) received by individual relatives and friends. 
Patients also specified whose advice had the most influence on their decision, whether 
another person had been tested at the same time and whether this influenced their 
decision.
Reasons for DNA-testing
Open-ended questions assessed reasons for DNA-testing for BRCA1/2 or Lynch syndrome.
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Demographic and DNA-testing information
Demographics
Patients reported age, educational level, marital status and need for information (scale 
1–10) in the surveys. History of psychological problems was collected from medical files, 
where such problems were recorded during standard genetic consultations.
DNA-testing characteristics
Age at and indications for DNA-testing were gathered from patient medical files: 1) pre- 
symptomatic, when there was a known family mutation but the patient has no cancer; 2) 
best available, when cancer was prevalent in the patient’s family without a known muta-
tion, but affected relatives were no longer available for testing; 3) patient affected with 
cancer at a young age with no known family mutation. DNA-results were also gathered: 
1) mutation carrier; 2) definite non-carrier, known family mutation was not found in the 
patient; 3) inconclusive, no mutation was found in the patient as the first to be tested 
(but mutations in other still unknown genes may predispose to cancer).
Family history
In patient medical files information concerning family pedigrees was gathered to deter-
mine the presence of a known family mutation or cancer-affected parents, and the age 
of the youngest affected relative.
Psychological measures
Quality of Life
To measure global health-related quality of life (QoL), two items (scored 1–7, scale 2–14, 
α=0.82) were selected from the EORTC-QLQ-C30, which has been widely used and vali-
dated for cancer research.127
Coping style
The Threatening Medical Situations Inventory (TMSI16) assessed coping styles in hypo-
thetical medical situations. A shortened version using two situations was previously 
validated155,177 and chosen for length. Each situation is followed by three monitoring 
(seeking information) and three blunting (seeking distraction) statements, scored on 
a 5-point Likert-scale. Monitoring (M, α=0.61) and blunting (B, α=0.72) subscales were 
calculated by summing relevant item scores (each subscale 6–30).155, 177 No classification 
methods were found in literature. However, as mean scores came out equal in initial 
analysis, subscales were combined to determine which coping style each responder 
showed a tendency towards: if the difference between scores was ≥4, responders 
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were classified as more blunting (B>M) or monitoring (M>B). If the difference was <4, 
responders were classified as neutral, unless one score was ≥24 (extreme cases). Thresh-
olds were chosen to approximate a distribution of 25% B>M, 50% neutral and 25% M>B; 
all responders could thus be classified.
Impact of genetic testing for cancer
The Multidimensional Impact of Cancer Risk Assessment (MICRA178) focuses on specific 
psychosocial concerns following genetic testing for hereditary cancer. It consists of 19 
items scored 0,1,3,5 and divided into three subscales: Distress (6 items, scale 0–30, α=0.77), 
Uncertainty (9 items, scale 0–45, α=0.75) and Positive Experiences (4 items, reverse 
scored, scale 0–20, α=0.62).178
Risk perception
A visual scale of 0–100 was used to measure lifetime risk perception of cancer occur-
rence for breast or colon cancer.
Experiences with genetic counseling and testing
Reactions to DNA-results
Overall psychological reaction to the DNA-results was assessed by one multiple choice 
item: ‘the result did not keep me preoccupied’ (no reaction), ‘the result kept me preoc-
cupied at first, but then I moved on’ (short term), ‘I needed a long time to process the 
result’ (long term), or ‘the result is still keeping me preoccupied’ (ongoing).
Recommended age for DNA-testing
Patients specified the age at which they would recommend DNA-testing for hereditary 
cancer to other patients.
Satisfaction with genetic counseling
The QUOTE-gene(ca) questionnaire measures needs and preferences in genetic counsel-
ing for hereditary cancer.140 A modified version including 18 items for types of services 
and 8 items for types of information119 was reworded to assess whether these had been 
provided rather than desired (α=0.95). Each item is scored from 1 ‘not at all’ to 4 ‘good’. 
Items were summed and divided by 26, to rate overall satisfaction on aforementioned 
scale.
Preventive measures for hereditary cancer
Surveillance advice following DNA-results (‘none’, ‘familial’, ‘hereditary’) was collected 
from medical files and compared to patient-reported use of cancer surveillance (‘yes, 
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ongoing’, ‘yes, soon’, ‘no, too young’, ‘no, not necessary’, ‘no, do not want’). Yes/no ques-
tions evaluated satisfaction with the recommended surveillance scheme, desire to start 
surveillance before 25 years if a mutation carrier, desire to start surveillance if a non-
carrier, and whether patients adjusted their lives in any other way (e.g. childbearing) 
due to DNA-results.
Statistical analysis
Patient characteristics and measures were analyzed using descriptive statistics. Deci-
sional conflict was tested between groups: cancer syndrome (BRCA1/2 vs. Lynch), gender 
(male vs. female) and mutation status (carrier vs. non-carrier). Further comparisons of 
measures were made based on moderate-severe versus no decisional conflict. Continu-
ous variables were tested using the unpaired t-test, ordinal variables using the Mann-
Whitney U test, nominal/dichotomous values using the chi-square/Fisher’s Exact test. 
To evaluate the influence of more than one variable on decisional conflict, multiple 
backward (Wald) logistic regression was applied. The probability level for statistical 
significance testing was set at 0.05 (two-tailed). The SPSS 18.0 statistical package was 
used to analyze the data.
reSUltS
Comparing responders (n=111) to non-responders (n=108), 36% of 45 males and 55% of 
174 females returned the survey (p<0.03). No further differences (age at DNA-testing, 
current age, cancer syndrome, indication for DNA-testing, mutation status, family his-
tory, surveillance advice) were found. Median age of responders was 27 [21–40] and 86% 
were female. Three-quarters of responders (73%) were tested for BRCA1/2 mutations, 
27% for Lynch syndrome; 42% were confirmed as a mutation carrier (Table 1).
Decision-making
Regret
Most responders had no regret (97%: scored 1 on scale 1–4) and 95% would make the 
same choice, whereas 4% would start DNA-testing at a later moment and 1% would not 
at all. No differences were found based on decisional conflict (see below).
Decisional conflict
A total of 39% of responders reported either moderate (DCS 25–37.5: 32%) or severe 
(DCS≥37.5: 7%) decisional conflict. The majority of responders (98%) was satisfied with 
their choice (scored 3–4 on scale 0–4), 58% strongly so (scored 4). Patients reporting 
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table 1: General, DNA-testing and family history characteristics of all responders (n=111) tested for BRCA1/2 
or Lynch syndrome at age 18-25 years: % or median [range].
GENERAL CHARACTERISTICS
Current age 27 [21-40]
Age at DNA-testing 23 [18-25]
Years since DNA-testing 4 [0-15]
Education level
- low 11%
- medium 46%
- high 43%
Marital status
- married/registered cohabitation 28%
- unregistered relationship 55%
- single 17%
Need for information (1-10) 9 [1-10]
Recorded history of psychological problems 6%
DNA-TESTING CHARACTERISTICS
DNA-testing for
- BRCA1/2 73%
- Lynch syndrome 27%
Indication for DNA-testing
- presymptomatic (mutation in family) 76%
- index patient: best available 19%
- index patient: affected at young age 5%
DNA-test result
- mutation carrier 42%
- definitive non-carrier 36%
- inconclusive non-carrier 22%
FAMILY HISTORY CHARACTERISTICS
Presence of mutation in the family
- unknown 24%
- known on maternal side 41%
- known on paternal side 35%
Age of youngest relative with cancer 34 [18-53]
Mother affected with cancer 48%
Father affected with cancer 14%
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moderate-severe decisional conflict were less convincingly satisfied with their choice 
(p<0.001): only 17% strongly agreed, 78% agreed, and 5% was neutral, whereas 84% of 
responders without conflict strongly agreed and 16% agreed. There were no differences 
in decisional conflict based on cancer syndrome, gender or mutation status.
Family influence
The majority of responders (78%) had been influenced by the medical history of their 
parents, versus 13% by that of sisters and 1% of brothers. Nearly half of responders had 
received no advice from relatives or was supported in making their own choice (45%), 
followed by ‘immediate DNA-test’ (41%). Persons of most influence are shown in Figure 
1. In 43%, another relative was simultaneously tested, but only 15% indicated this had 
influenced their decision.
Reasons for DNA-testing
As multiple reasons were possible per responder, percentages are not cumulative: half 
(47%) included an emotional reason for DNA-testing, most importantly the need for cer-
tainty. Other reasons were family history (44%), preventive measures (24%) and (future) 
children (14%).
other
friend(s)
other relative(s)
brother(s)
sister(s)
father
m
other
partner
independent
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25%
20%
15%
10%
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0%
figure 1: Person of most influence on the decision-making process as reported by all responders (n=111) 
tested for BRCA1/2 or Lynch syndrome at age 18-25 years. Multiple choice options focused on individual first 
degree family members and partner.
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Demographic and DnA-testing information
Demographics and DNA-testing
Demographic and DNA-testing characteristics are shown in Table 1.
Family history
Family history characteristics are shown in Table 1: 76% had a known family mutation. 
Those with decisional conflict were more likely to have a lower age of the youngest 
affected relative (p<0.04), a known family mutation on the paternal side (p<0.04) or an 
affected father (p<0.05).
Psychological measures
Quality of Life (QoL)
Median overall QoL was high at 12 [5–14] (scale 2–14). No significant differences in QoL 
were found between patients with and without decisional conflict.
Coping style
Nearly a third (29%) were classified as leaning more towards monitoring coping style, 
versus 25% more blunting and 46% neutral. As shown in Figure 2, there were more 
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coping style (TMSI)
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moderate-severe decisional conictno decisional conict
figure 2: Coping style (TMSI) of young adults tested for BRCA1/2 or Lynch syndrome at age 18-25 years, in 
responders with no versus moderate-severe decisional conflict. Coping style was classified as a tendency 
towards more blunting (seeking distraction when faced with a threat), more monitoring (seeking informa-
tion) or neutral.
Ch
ap
te
r 6
96
DNA-testing before 25 years
responders leaning towards monitoring or neutral in responders with vs. without deci-
sional conflict (p<0.02).
Impact of genetic testing for hereditary cancer
Psychological impact did not differ based on decisional conflict, with overall low median 
scores of 5 [0–24] for Distress (scale 0–30), 6 [0–27] for Uncertainty (scale 0–45) and 5 
[0–20] for Positive Experiences (scale 0–20).
Risk perception
Median risk perception for breast/colon cancer was 45 [0–100] (scale 0–100) and did not 
differ based on decisional conflict.
experiences with genetic counseling and testing
Reactions to DNA-results
Most responders reported no (42%) or short term (46%) psychological reactions follow-
ing DNA-results, 6% reported long term and 6% ongoing reactions. No differences were 
found based on decisional conflict.
Satisfaction with genetic counseling
Counseling information and services were considered sufficient (median 3.3 [1.4–4.0], 
scale 1–4). There were no differences based on decisional conflict.
Recommended age for DNA-testing
2% of responders would recommend DNA-testing from birth, 4% from 16 years, 24% 
from 18 years, 20% from 20 years, 18% from an age between 21-24 years, 18% from 25 
years and 2% from 30-35. 12% of responders did not report an age as this depended on 
the person.
Prevention measures for hereditary cancer
The majority (84%) was satisfied with their surveillance scheme and 25% reported other 
life adjustments (e.g. earlier childbearing) due to their DNA-results. 88% were following 
surveillance advice correctly, 9% started surveillance earlier and 3% considered surveil-
lance unnecessary despite familial advice. Many (77%) desired surveillance measures 
before age 25 if a mutation carrier and over half (59%) desired surveillance when no 
mutation was found. No differences based on decisional conflict were found.
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Multifactorial analysis of decisional conflict
To assess the influence of multiple variables on decisional conflict, backward (Wald) 
logistic regression was performed using the four most significantly different variables 
from univariate analyses. Age of youngest affected relative and affected father were not 
significant, leaving only coping style and family mutation as variables related to deci-
sional conflict. The strongest factor was coping style: responders with more monitoring 
(OR 5.71 [1.47–22.25]) or neutral coping style (OR 5.08 [1.45–17.8]) were over 5 times more 
likely to report decisional conflict than those leaning more towards blunting (p<0.03). 
Those with a paternal family mutation (OR 4.10 [1.46–11.55]) or unknown family mutation 
(OR 3.14 [1.02–9.67]) were also more likely to report decisional conflict than those with 
a maternal family mutation (p<0.02). This model was statistically significant with χ2 (4, 
n=101) = 17 (p=0.002), explaining 22% of the variance in decisional conflict and correctly 
classifying 68% of cases.
As coping style was of strongest influence, additional univariate analyses were per-
formed comparing responders with more monitoring/neutral coping style versus 
more blunting: beyond a higher need of information in those with more monitoring/
neutral coping (p<0.02), no significant differences were found. Conversely, comparing 
responders with more blunting/neutral coping style versus more monitoring, showed a 
lower desire for surveillance as a non-carrier in those leaning more towards monitoring 
(p<0.04), but no further differences.
DiSCUSSion
It can be concluded that for the majority of young adults older than 18 years, it is not 
necessary for clinical geneticists to raise the DNA-testing age for BRCA1/2 or Lynch 
syndrome from 18 to 25 years, which is the age to start surveillance. Most responders in 
our study were satisfied with their former decision and had no regrets of DNA-testing 
at a younger age. In fact, 68% would recommend other patients to do so, with only 20% 
recommending after 25 years. However, a third did report decisional conflict, especially 
those patients who tended to actively seek information when faced with a threat (moni-
toring to neutral coping style), or with a paternal or unknown inheritance. Decisional 
conflict also lowered the rate of satisfaction with the choice made, but did not coincide 
with regret, suggesting that these are separate entities when assessed retrospectively. 
The process of genetic counseling/testing appears to have been effective in preventing 
those experiencing decisional conflict from regretting their final decision. In fact, ge-
netic counseling likely helped to select those young adults less likely to react adversely 
to DNA-results, prior to the decision to start DNA-testing.
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Young adults are known to be sensitive to social influence from family members.47,48 
Medical history of parents did influence decision-making for most young adults in 
our study. Half of the young adults felt supported by their family in making their own 
decision. Almost a quarter even specified having made their own independent choice, 
rather than pointing out another person as most influential. Genetic counselors could 
take advantage of such social support by encouraging young adults before 25 years to 
discuss DNA-testing with their adult relatives, who could provide the cognitive skills 
they have not yet fully developed.
Previous studies have shown a positive correlation between age and monitoring coping 
style174,179 thus younger patients are expected to make less use of monitoring. However, 
29% of young adult responders had a tendency towards more monitoring than blunting 
at the time of the study. Coping style may change over time depending on life events179: 
patients leaning towards blunting at the time of decision-making may lean more 
towards monitoring as a result of DNA-testing, as they become more aware of their 
health risks. It is also possible that those with a tendency for monitoring are more likely 
to start DNA-testing, while those showing more blunting delay or avoid DNA-testing 
altogether.173 In this retrospective study, it was not possible to differentiate between 
these two options.
Regardless, current tendency towards more monitoring or neutral coping style was the 
strongest factor contributing to former decisional conflict. This could be due to patients 
leaning towards monitoring finding information about both benefits and disadvantages 
of genetic testing at their age. Patients leaning towards blunting may be more likely to 
remain (deliberately) ignorant of these disadvantages. Paternal inheritance of a known 
family mutation also influenced decisional conflict. Cancers in the paternal family are 
generally underreported, possibly because males are less likely to communicate about 
family health matters.180 Patients reliant on a male relative may not know details of (he-
reditary) cancer prevalence. Similarly, when there is no known family mutation, patients 
may be less aware of their precise family history or the full consequences of a hereditary 
predisposition. Especially when such information is actively sought after (monitoring) 
but not easily available, decisional conflict may occur.
Responders were satisfied with the process of genetic counseling/testing and recom-
mended surveillance scheme, the majority showing no to short term psychological 
reactions following DNA-results and adhering to surveillance advice. Despite high sat-
isfaction and adherence, many (77%) did report a desire for surveillance to start before 
25 years if a mutation was found. Responders leaning towards monitoring showed less 
desire for surveillance as a non-carrier than those with more blunting or neutral coping 
Chapter 6
99
DNA-testing before 25 years
style. This suggests that, while the higher rate of decisional conflict might warrant ad-
ditional support for young adults leaning towards monitoring, further follow-up does 
not seem required for those who turn out to be non-carriers after testing.
Our study is limited by a possible selection bias due to low response rate (51%) and 
significantly fewer males responding (p<0.03). This is unsurprising: both males and 
younger patients are known to have lower participation rates in survey-based studies.181 
Another limitation is the retrospective nature of our study, which is sensitive to recall 
bias and perception bias such as cognitive dissonance reduction: exaggerating benefits 
of an unpleasant experience to achieve peace-of-mind thus reporting less regret.182 This 
may similarly limit our study’s ability to reflect on decisional conflict at the time of the 
actual decision to start genetic testing.137 To our knowledge, decisional conflict has not 
been studied before in this particular age group within the context of genetic testing, 
therefore it is not possible to evaluate differences due to the retrospective measure-
ment. However, as one third of our study sample reported moderate to severe decisional 
conflict contrary to a mere 3% reporting regret, possibly decisional conflict is influenced 
less by such perception bias.
Having decisional conflict did not correlate with a more adverse impact of genetic testing, 
nor were there differences in decisional conflict comparing mutation carriers vs. non-
carriers. This suggests that decisional conflict is an independent process, not influenced 
by DNA-results, which are unknown at the time of decision-making. Decisional conflict 
could then be a target for future interventions. While standardized support by a social 
worker during the decision-making process is currently provided, this support could be 
made more effective by focusing on those young adults experiencing decisional conflict 
and their specific needs. Exploring coping style and the presence of a family mutation 
may help genetic counselors to identify those young adults in need of such support.
In conclusion, our study shows that it is not necessary to change the age of DNA-testing 
for BRCA1/2 mutations or Lynch syndrome, as very few reported regret and many desired 
DNA-testing before 25 years.
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AbStrACt
introduction: The Radboud university medical center was amongst the first to imple-
ment two-step exome sequencing in clinical genetic diagnostics. This study is the first 
to evaluate patient experiences with gene panels based on exome sequencing, using 
quantified psychological variables: acceptance, psychological distress, expectations of 
heredity and unsolicited findings.
Methods: Between August 2011 and July 2012, 177 patients diagnosed with early-onset 
colorectal/kidney cancer, deafness, blindness or movement disorder consented to diag-
nostic exome sequencing offered by clinical geneticists. Baseline questionnaires were 
sent to 141 adults, returned by 111 with median age of 49 [22–79] years and positive family 
history in 81%. Follow-up included 91 responders at median 4 [2–22] weeks after results 
from known gene panels per diagnosis group; exome-wide analysis is ongoing.
results: Confirmed or possibly pathogenic mutations were found in 31% with one 
unsolicited finding (oncogenetic panel). Most patients (92%) were satisfied. There were 
no significant changes in heredity-specific distress (18% at baseline, 17% at follow-up) 
and expectations of heredity. Fewer patients expected unsolicited findings at follow-
up (29% versus 18%, p=0.01). Satisfaction and distress was equal in those with versus 
without mutations.
Conclusion: Most adults accepted and were satisfied with gene panels based on diag-
nostic exome sequencing, few reporting distress.
keywords
distress – exome – gene panels – genetic – next generation – patient experiences – 
sequencing
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introDUCtion
Next generation sequencing e.g. exome sequencing has great potential to identify 
the genetic cause of numerous diseases183 with increasing implementation in clinical 
diagnostics.2 Diseases may be suspected of heredity (e.g. positive family history or early 
onset) but show high genetic heterogeneity52,184-186: conventional sequential single-
gene testing of many candidate genes is time-consuming.2,56 Exome sequencing allows 
simultaneous testing of all genes and could lead to rapid identification of a genetic cause 
or new gene discoveries.2 An early genetic diagnosis could preclude further diagnostic 
testing and provide more information about prognosis and family consequences.186
Diagnostic exome sequencing is expected to have major impact on clinical genetic 
testing. However, counselors and patients should consider possible unclear results 
(variants possibly but not clearly pathogenic) or unsolicited findings for unrelated 
diseases, the frequency and nature of which are unknown.53 Handling these unsolicited 
findings is a main ethical concern for diagnostic implementation of exome sequenc-
ing.53 To limit possibility of unsolicited findings, the Radboud university medical center 
(Radboudumc) implemented two-step diagnostic exome sequencing within the Human 
Genetics department.56 Clinically affected patients at increased risk of an underlying 
genetic cause of their disease, were offered oral pre-test genetic counseling and written 
information leaflets by clinical geneticists. Patients were informed that exomes were 
fully sequenced, but initial analysis was targeted only at referral disease-causing gene 
panels (step 1). Identified mutations were reported back to the patient as confirmed 
or possibly pathogenic. If no mutations were identified, patients were informed and 
exome-wide analysis followed (step 2: opt-out not possible). Counseling included that 
unsolicited findings (e.g. cancer predisposition in a deafness patient) were possible 
especially in exome-wide analysis, but exact probabilities and type of findings could 
not be predicted. Such findings were discussed in a multidisciplinary advisory board 
to determine clinical relevance, before disclosure to the clinical geneticist, who then 
informed the patient.53 Patients who agreed to be informed about potential unsolicited 
findings, started exome sequencing after consent was obtained. Patients declining 
information about clinically relevant unsolicited findings were excluded from exome 
sequencing, instead offered single-gene testing.
Psychological effects of conventional genetic testing have been studied mainly in he-
reditary cancer. In colorectal cancer patients, 25% reported distress before and 13% after 
genetic counseling: mutation carriers showed higher distress than non-carriers, but 
these scores returned to baseline levels over time108; similar results were found in breast 
cancer patients.117 This study is the first to quantify patient experiences in exome se-
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quencing, using standardized psychological questionnaires. As opt-out of exome-wide 
analysis was not possible, participants in this study must consider possible unclear or 
unsolicited findings in acceptance and expectations of exome sequencing throughout 
the two-step procedure. If a similar trend to conventional genetic testing can be found, 
this may lower hesitancy amongst professionals to implement exome sequencing in 
clinical diagnostics and inform discussion regarding appropriate consent procedures.
In literature regarding conventional genetic testing in hereditary cancer, van Oostrom 
e.a.15 applied Leventhal’s common sense model of self-regulation and psychological 
adjustment, using illness perception as the basis for coping responses (monitoring 
i.e. actively seeking information, and blunting i.e. passively seeking distraction16) and 
psychological well-being. Pessimistic illness perception related to high risk perception 
(i.e. expectations), causal attribution to genetic factors and passive coping, relating to 
hereditary cancer distress.15 These may also be contributory factors to distress in exome 
sequencing and determined this study’s psychological measures.
The hypothesis of this prospective observational study is that many patients accept two-
step diagnostic exome sequencing, without increased distress or altered expectations 
after results from known disease-causing gene panels, similar to current experiences in 
conventional genetic testing.
MAteriAlS AnD MethoDS
Genetic procedure
The Radboudumc Human Genetics department implemented diagnostic exome 
sequencing for diseases with high heterogeneity and local expertise.2,55,56 Technical 
specifications on exome sequencing and variant interpretation were described previ-
ously.55,56 This study focused on adults with early-onset (<40 years) colorectal or kidney 
cancer, deafness, blindness or movement disorders.
Gene panels per diagnosis were designed by multidisciplinary expert teams and 
published previously.56 The cancer gene panel covered all known hereditary cancer syn-
dromes as association with secondary cancer types may change (e.g. urothelial bladder 
cancer in MSH2-related Lynch syndrome187): including all cancer genes was considered 
more effective. Actionable unsolicited findings within this panel were considered imme-
diately clinically relevant for patient disclosure, without consultation of an independent 
board.
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Between August 15th 2011 and July 15th 2012, 213 patients diagnosed with one of these 
four diseases were selected by clinical geneticists for an increased risk of a genetic cause 
of their disease (e.g. positive family history, early onset) and offered diagnostic exome 
sequencing after pre-test genetic counseling. Of these, 36 (17%) declined and 177 (83%) 
gave written informed consent to start exome sequencing (Figure 1).
Study procedure
This prospective observational study was required by the local medical ethical board to 
recruit only patients consenting to exome sequencing, limited by clinical lab capacity 
(maximum n=50 per group). Exclusion criteria were: death (n=4), age <18 years (n=19), 
healthy parents of an affected child (n=2), intellectual disability (n=10) or problems with 
Dutch text (n=1). 141 patients were eligible (Figure 1). Most (78%) had undergone previ-
ous single-gene testing which did not identify pathogenic mutations. Patients were 
invited by mail for an online or paper baseline questionnaire (n=34 mail reminders): 111 
(82%) baseline questionnaires were returned. Two-three weeks following gene panel 
result disclosure (step 1), follow-up questionnaires were sent (n=30 reminders): 91 (65%) 
were returned median 4 [2–22] weeks after disclosure. Exome-wide analysis (step 2) is 
ongoing and not included in this study. In two patients, exome sequencing (thus follow-
up) was halted due to a (possible) diagnosis in affected relatives.
Primary study variables included satisfaction and regret at follow-up on 4-point Likert-
scales (‘not at all’ to ‘very much’). Participants also considered the hypothetical situation 
of making their decision again: ‘exome sequencing’, ‘no exome sequencing’ or ‘do not 
know’. These questionnaires were developed in previous studies.151,156 Heredity-specific 
distress was assessed at baseline and follow-up by the Impact of Event Scale (IES132,133, 
range 0–75, Cronbach’s α in this study=0.92–0.93, threshold ≥26 for clinical relevance) 
adapted for a possible hereditary disease as the traumatic event.
Exome sequencing
oered to high-risk
patients after pre-test
counseling:
n = 213
Exome
sequencing
started:
n = 177 / 213
(83%)
Exclusion: n = 36
Death (n = 4)
Intellectual disability (n = 10)
Age < 18 years (n = 19)
Unaected parents (n = 2)
Problems with Dutch (n = 1)
Eligible:
n = 141 (100%)
Baseline:
n = 111 (79%)
Step 1
gene panel analysis:
mutation found
n = 28
Step 1
gene panel analysis:
no mutation found
n = 63
Follow-up:
n = 91 (65%)
Step 2
exome-wide
analysis
(ongoing)
(not included
in this study)
Declined
exome sequencing:
n = 36 / 213
(17%)
figure 1: Flowchart of patient inclusion and questionnaire response at baseline and follow-up amongst 
adult patients consenting to diagnostic exome sequencing.
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Secondary study variables included expectations of heredity (finding a genetic cause 
and finding the same disease in family members) measured at baseline and follow-up by 
visual numerical scales of 0–100 and verbal 5-point Likert-scales (‘very low’ to ‘very high’) 
based on breast cancer risk perception measurements.188 Perceptions of hereditary 
and non-genetic aetiologies were assessed as yes/no items to simplify data analyses. 
Expectations of unsolicited findings were also measured at baseline and follow-up 
by numerical 0-100 and verbal 5-point scales. Data on age and educational level were 
gathered from questionnaires, medical history data and gene panel results (including 
unsolicited findings) were summarized from medical files. Coping style was measured at 
baseline using the short version of Threatening Medical Situations Inventory (TMSI16,155, 
monitoring subscale α=0.66, blunting subscale α=0.52) to categorize patients as used 
in a previous study.15 Quality of life was assessed by the global health status subscale 
from the EORTC-QLQ-C30 (0–100, α=0.89–0.93127,128) and general psychological distress 
by the 12-item General Health Questionnaire (GHQ-12129, 0–12, α=0.90–0.88, threshold 
≥3130). Illness perception was measured using the Brief Illness Perception Question-
naire (B-IPQ189,190) modified for average score of only items considered applicable by 
the participant (0–10, α=0.48–0.56). The impact of genetic testing was assessed by the 
Multidimensional Impact of Cancer Risk Assessment (MICRA178) after removing 5 cancer-
specific items: renamed MIHRA for Hereditary Risk Assessment with subscales Distress 
(0–30, α=0.85), Uncertainty (0–20, α=0.58), Positive Experiences (0–20, reverse scored, 
α=0.56), Illness (0–10, α=0.16) and, if applicable, Children (0–10, α=0.63).
Decision making and reactions were assessed using questionnaires from previous 
studies.151,156 Open-ended questions assessed participants’ reaction to the offer of and 
reasons for starting exome sequencing (>10% reported). Initial expectations of exome-
results were reported retrospectively at follow-up: ‘illness is hereditary’, ‘illness is not 
hereditary’, ‘no expectations’ or ‘other’. Participants indicated emotional reactions to 
gene panel results: positive, negative and neutral. Psychological reaction was assessed 
by one multiple choice item: ‘not applicable: testing ongoing’, ‘result did not keep me 
preoccupied’ (no reaction), ‘result kept me preoccupied at first, but then I moved on’ 
(short-term), ‘I needed a long time to process the result’ (long-term), or ‘result still keeps 
me preoccupied’ (ongoing). Participants specified advice to others: ‘exome sequencing’, 
‘single-gene testing’, ‘no DNA-testing at all’ or ‘do not know’. 
Statistical analysis
Following descriptive statistics, baseline versus follow-up results were compared us-
ing the paired t-test for continuous, Wilcoxon test for ordinal and McNemar’s test for 
nominal variables. Follow-up results were compared between responders with versus 
without (confirmed or possibly pathogenic) mutations, using the independent t-test 
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for continuous, Mann-Whitney U test for ordinal, and chi-square/Fisher’s Exact test for 
nominal variables. Repeated measurements ANOVA was used to compare responders 
with versus without mutations (result) from baseline to follow-up (time). Correlations 
between expectations of heredity, expectations of unsolicited findings, heredity-specific 
distress, coping style and illness perception were assessed by Spearman’s Rank Correla-
tion (Spearman ρ). The probability level for statistical significance testing was set at 0.05 
(two-tailed). The SPSS 20.0 statistical package was used to analyze the data.
reSUltS
Demographics of baseline responders are shown in Table 1. Median age was 49 [22–79] 
years, male/female ratio was 1:1 and 81% had a positive family history; 25% were diag-
nosed with cancer, 26% deafness, 15% blindness, 34% movement disorders. Baseline 
responders (n=111, 79%) were older than non-responders (n=30) with median 49 [22–79] 
versus 42 [20–66] years (p=0.01) and more likely to have a positive family history (81% 
versus 60%, p=0.03). Males and females did not differ at baseline. Confirmed or possibly 
table 1: Sociodemographic, family and informational characteristics of all baseline responders (n=111) con-
senting to diagnostic exome sequencing.
Characteristic N (%) or median [range]
Age at inclusion (years) 49 [22-79]
Female gender 55 (50%)
Education level
- low
- medium
- high
n=109:
49 (45%)
27 (25%)
33 (30%)
Diagnosis
- colorectal or kidney cancer <40yrs
- deafness
- blindness
- movement disorders
27 (25%)
29 (26%)
17 (15%)
38 (34%)
Previous genetic testing 90 (81%)
Positive family history 90 (81%)
Affected relatives
- parent(s)
- sibling(s)
- child(ren)
- 2nd degree
- ≥3rd degree
48 (43%)
50 (45%)
16 (14%)
46 (41%)
28 (25%)
Coping style
- more blunting
- neutral
- more monitoring
29 (28%)
57 (55%)
17 (17%)
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pathogenic mutations in known gene panels were identified in 31% of 91 follow-up 
responders. Those with versus without mutations were less likely to have had previous 
genetic testing (63% versus 92%, p=0.01); no differences were found in family history. 
There was one FH-mutation (hereditary leiomyomatosis, renal cell cancer) found unre-
lated to a patient’s colorectal cancer diagnosis. This unsolicited finding was considered 
immediately clinically relevant for patient disclosure.
Satisfaction
Most responders (92%) were moderate-highly satisfied, only 3% reported regret. 89% 
would start exome sequencing again; 11% were uncertain, not being aware of alterna-
tives or depending on estimated heredity, waiting time or health benefits. No differ-
ences were found comparing those with versus without mutations. Dissatisfaction or 
regret were due to the long lag time until gene panel results were available (median 9 
[5–16] months from intake consultation to result disclosure).
heredity-specific distress
Clinically relevant heredity-specific distress (IES≥26) was reported in only 18% at base-
line, equal to 17% at follow-up (Figure 2). No differences were found comparing partici-
pants with versus without mutations at baseline and follow-up; mean scores remained 
below clinical relevance (Table 2), as did the score of the patient with an unsolicited 
finding. Heredity-specific distress was not correlated to coping style or expectations 
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figure 2: Psychological distress, expectations and perception of illness causes in adult patients consenting 
to diagnostic exome sequencing, at baseline (n=111) versus follow-up (n=91).
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of hereditary results or of unsolicited findings, but showed significant correlations to 
overall illness perception at baseline (ρ=0.29, p=0.01) and follow-up (ρ=0.22, p=0.04); 
specifically subscales concern (ρ=0.48, p<0.001), emotional response (ρ=0.38, p<0.001) 
and identity (ρ=0.24, p=0.02).
expectations of heredity
Expectations of finding a genetic cause and of finding the same disease in family 
members did not differ comparing baseline with follow-up (Figure 2). Those with versus 
without mutations scored higher for both expectations at baseline and follow-up (Table 
2, p=0.01). These expectations did not correlate to heredity-specific distress, coping style 
or illness perception. Causal perceptions did not differ (Figure 2).
expectations of unsolicited findings
Expectations of unsolicited findings were lower at follow-up than baseline regardless 
of results (p=0.01, Figure 2, Table 2). Those with mutations did score consistently higher 
than those without (p=0.01, Table 2). There were no correlations between these expecta-
tions and heredity-specific distress, coping style or illness perception.
Psychological measures over time
General distress (GHQ-12) was equal at baseline and follow-up regardless of results (Fig-
ure 2, Table 2). Quality of life (QoL) was lower at follow-up versus baseline in those with 
mutations, but equal in those without mutations (Table 2). Overall illness perception was 
equal at baseline and follow-up but those with mutations experienced specifically more 
consequences (p=0.02) and longer duration (p=0.05) of their illness (Table 2). Impact of 
genetic testing (MIHRA: Table 3) was low.
Decision-making and reactions
Most responders (78%) reacted positively to the offer of exome sequencing. Reasons 
for exome sequencing were (multiple reasons possible, not cumulative): determine if 
heredity caused their disease (57%), children/family (42%), scientific progress (20%), 
possible prevention/treatment (16%) and no genetic cause found previously (14%). At 
follow-up, 40% reported initial expectations of exome-results to show their illness was 
hereditary, 32% had no expectations and 12% did not expect hereditary illness (16% 
other: e.g. more clarity in general). Those with versus without mutations were more 
likely to report retrospective expectations of hereditary illness (57% versus 32%, p=0.04). 
Few participants reported adverse reactions to gene panel results (Table 3). Most (78%) 
would recommend exome sequencing to others; only 2% recommended single-gene 
testing; 20% was uncertain, depending on the person or illness. No differences were 
found based on gene panel results.
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DiSCUSSion
The large majority of adult patients at high risk for hereditary disease, accepted two-
step exome sequencing in a clinical diagnostic setting and were satisfied, reporting low 
distress following results from known disease-causing gene panels (step 1). Expectations 
of heredity did not change significantly, despite trends for lower expectations of finding 
a genetic cause and heredity causing their illness with more belief in random causality 
after gene panel results. However, before these results, patients with confirmed or pos-
sibly pathogenic mutations already had higher expectations of heredity and were less 
likely to have undergone previous genetic testing. They might have viewed their clinical 
and/or family history as more suggestive for hereditary disease, not having previously 
received negative results. Satisfaction or distress was equal to those without mutations. 
Relations between coping style and distress from literature15 were not confirmed by our 
study. Heredity-specific distress instead correlated to illness perception, but not muta-
tion status. Expectations of unsolicited findings were lower after gene panel results, 
although higher in those with versus without mutations; but in current results, unso-
licited findings are less likely. We conclude that this novel two-step exome sequencing 
is acceptable to adult patients with normal intelligence, regardless of mutations found 
within known disease-causing gene panels. This sets the stage for continued evaluation 
of patient experiences following exome-wide analysis. Gene panels resulted in only one 
unsolicited finding without distress or dissatisfaction. Negative gene panel results low-
table 3: Reactions and impact of diagnostic exome sequencing results in all follow-up responders (n=91) 
after known disease-related gene panels based on exome sequencing.
Characteristic N (%) or mean±SD
Impact of genetic testing (MIHRA)
- subscore: Distress (0-30)
- subscore: Uncertainty (0-20)
- subscore: Positive experiences (0-20)
- subscore: Illness (0-10)
- subscore, if applicable: Children (0-10)
n=86:   5.2±6.0
n=88:   3.0±3.5
n=85: 10.7±4.9
n=86:   3.3±2.4
n=66:   5.5±3.3
Emotional reactions to gene panel results 
- positive (relieved, happy)
- negative (sad, angry)
- neutral (surprised, calm)
(non-cumulative)
13 (14%)
10 (11%)
63 (69%)
Psychological reactions to gene panel results
- not applicable: testing ongoing
- no reaction
- short term reaction
- long term reaction
- ongoing reaction
56 (62%)
15 (16%)
16 (18%)
  0 (  0%)
  4 (  4%)
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ered expectations of unsolicited findings, but also initiated exome-wide analysis which 
may uncover unsolicited findings farther removed from the referral disease.
Genetics is a fast-evolving field with many innovations within the genetic diagnostic 
process in which patient experiences have been studied before. For example, tumor 
genetic testing in colorectal cancer patients <50 years prior to genetic counseling was 
seen as valuable by patients without higher distress.43 Breast cancer patients who were 
offered BRCA-mutation testing before genetic counseling, replacing the intake consulta-
tion with telephone, written and digital information, reported high satisfaction without 
increased distress.151 Our current study supports that offering novel genome-wide 
tests may be acceptable to patients after pre-test counseling, despite concerns about 
adverse psychological effects. This is an important consideration for future clinical 
implementation of new genetic technologies. The study’s main strength is the novel 
use of standardized psychological questionnaires to quantify early patient experiences 
with gene panels based on diagnostic exome sequencing. Patients reporting distress 
may require psychological follow-up, already incorporated in standard clinical genetic 
services through availability of specialized social workers or psychologists. As we con-
clude that the proportion of distressed patients is similar to numbers previously seen in 
conventional genetic testing108, such standard care seems sufficient.
Although results of exome-wide analysis are yet to follow, our study thus far supports 
diagnostic exome sequencing as a two-step procedure, where initial analysis targets pre-
defined gene panels, with the ability to expand beyond known genes, facilitating new 
gene discoveries. Our department chose exome sequencing with initial targeted data 
analysis of disease-specific gene panels, rather than disease-specific sequencing arrays. 
This allowed frequent updating of these panels, as all data were already sequenced thus 
ready for reanalysis, without new blood drawing.2 Recently, our department allowed 
patients to opt out after gene panel analysis, offering the benefits of this new technique 
without the exome-wide risk of unsolicited findings.
A limitation of our study is including only patients who accepted diagnostic exome 
sequencing, as required by the local medical ethical board. Positive views were reported 
by those patients who opted in and may not be universally held, as 17% declined. It 
would be interesting to learn from this minority of patients, considering the current 
informed consent without opt-out for clinically relevant unsolicited findings. Most 
patients accepted exome sequencing including this risk, but some may have declined 
not wanting to know about (specific) unsolicited findings. Adjustments to the informed 
consent might be worth considering; this is up for debate within our department as well 
as in current literature.53
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Our study results may be influenced by responders versus non-responders being 
older and more likely to have a positive family history. Patients with blindness (perhaps 
prohibiting patients from reading and filling in questionnaires) were underrepresented, 
making it impossible to compare diagnosis groups. However, the question “is there a 
genetic cause for my disease?” with implications for prognosis and family remains an 
overarching theme. The lack of impact on distress following results from gene panels 
based on diagnostic exome sequencing, may lower hesitations felt by genetic profes-
sionals in offering patients this new technique, allowing them to benefit from a higher 
diagnostic yield versus conventional single-gene testing, without concern for adverse 
psychological effects. As new genetic technologies continue to develop, likely starting 
with whole-genome sequencing, this provides support for clinical implementation of 
future innovations.
In conclusion, two-step exome sequencing in a clinical diagnostic setting is accepted 
by most adult patients, who report high satisfaction and low distress after results from 
predefined gene panels based on exome sequencing.
ConfliCt of intereSt
All authors declare no conflict of interest.
Acknowledgements
The authors would like to acknowledge B.W.M. van Bon, M.H.F. Bongers, H.G. Brunner, 
C.J.A.M. van der Burgt, M.C.J. Jongmans, M.J.E. Kempers, C.M. Kets, T. Kleefstra, R.J. Koers, 
D.A. Koolen, C.W. Ockeloen, M.I. Schouten, L. Spruijt and S. Vermeer for genetic counsel-
ing of patients; E.H. Hoefsloot, E.J. Kamsteeg, M.J.L. Ligtenberg, A.R. Mensenkamp, M.R. 
Nelen, K. Neveling, H. Scheffer and H.G. Yntema for their involvement in diagnostic 
exome sequencing; P. Manders for statistical expertise; and all the participants for their 
cooperation. The study is funded by the Radboud university medical center.

STAGE III
Follow-up and prevention
“We may never understand illnesses such 
as cancer. In fact, we may never cure it.
But an ounce of prevention is worth 
more than a million pounds of cure.”
(David Agus)
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AbStrACt (enGliSh)
regional and university hospitals fulfill different needs in follow-up of BRCA-
mutation carriers
objective: Are there differences between BRCA-mutation carriers treated for preven-
tion of breast cancer (BC) in a regional or university hospital?
Design: Retrospective observational study.
Method: Questionnaires were sent to 402 females between 25–60 years diagnosed 
with a BRCA-mutation in the Radboudumc (university medical center, UMC) between 
2006–2012, then supported for surveillance in a regional hospital (RH follow-up) or the 
Radboudumc (UMC follow-up). Primary outcome measure was decisional conflict (DCS) 
i.e. doubt regarding BC prevention (preventive mastectomy (PM) or surveillance). Also, 
105 oncologic specialists from 11 regional hospitals cooperating with the Radboudumc 
received questionnaires about the role of the UMC expert team regarding BRCA-care.
results: 192 patients (48%) responded, of whom 80 (42%) were in RH follow-up and 112 
(58%) in UMC follow-up. BRCA-mutation carriers in UMC follow-up reported more deci-
sional conflict (median 17 [0–77] RH versus 25 [0–82] UMC, p=0.02) and information need 
(17% versus 35%, p=0.003); fewer chose PM (64% versus 40%, p=0.003). BRCA-mutation 
carriers in RH follow-up were more likely diagnosed with BC (39% RH versus 11% UMC, 
p<0.001). Among 47 regional specialists (response 45%), 47% had no experience con-
sulting the UMC expert team; 70% preferred one-time UMC consultations for patients 
to discuss consequences for family relatives (89%) and prevention recommendations 
(83%).
Conclusion: BRCA-mutation carriers in RH versus UMC follow-up were different: women 
with BC more likely went or returned to regional hospitals, whereas women supported 
by the UMC expert team had more decisional conflict and/or information need and/or 
were presymptomatic.
Keywords
BRCA – hereditary – breast cancer – follow-up  –  risk management – surveillance – 
preventive surgery 
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SAMenvAttinG
Doel: Zijn er verschillen tussen BRCA-mutatiedraagsters die voor preventie van mam-
macarcinoom (MC) begeleid worden in een regionaal ziekenhuis of UMC?
opzet: Retrospectieve observationele studie.
Methode: Er werden vragenlijsten verstuurd naar 402 vrouwen tussen 25–60 jaar bij wie 
een BRCA-mutatie vastgesteld is in het Radboudumc (UMC) tussen 2006–2012, waarna 
zij voor surveillance begeleid werden in een regionaal ziekenhuis (RZ follow-up) of het 
Radboudumc (UMC follow-up). Primaire uitkomstmaat was decisional conflict (DCS) 
oftewel twijfel rondom MC preventie (preventieve mastectomie (PM) of surveillance). 
Daarnaast ontvingen 105 specialisten van 11 regionale ziekenhuizen die samenwerken 
met het Radboudumc vragenlijsten over de rol van het UMC expertiseteam met betrek-
king tot BRCA-zorg.
resultaten: 192 BRCA-mutatiedraagsters (48%) respondeerden, waarvan 80 (42%) in RZ 
follow-up waren en 112 (58%) in UMC follow-up. BRCA-mutatiedraagsters in UMC follow-
up rapporteerden meer decisional conflict (mediaan 17 [0–77] RZ versus 25 [0–82] UMC, 
p=0,02) en informatiebehoefte (17% versus 35%, p=0,003), waarbij zij minder vaak kozen 
voor een PM (64% versus 40%, p=0,003). BRCA-mutatiedraagsters in RZ follow-up waren 
vaker gediagnosticeerd met MC (39% RZ versus 11% UMC, p<0,001). Van 47 regionale 
specialisten (respons 45%) had 47% geen ervaring met overleg met het UMC expertise-
team; 70% gaf de voorkeur aan eenmalige UMC adviesgesprekken voor patiënten om 
gevolgen voor familieleden (89%) en preventieadviezen (83%) te bespreken.
Conclusie: BRCA-mutatiedraagsters die begeleid werden in een RZ tegenover UMC 
verschilden van elkaar:  vrouwen met een MC gingen vaker (terug) naar de regio, terwijl 
vrouwen onder specialistische UMC begeleiding meer decisional conflict en/of informa-
tiebehoefte hadden en/of presymptomatisch waren.
Sleutelwoorden
BRCA – erfelijk – mammacarcinoom – follow-up  –  risico management – surveillance – 
preventieve operatie
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inleiDinG
BRCA1/2-mutaties worden verantwoordelijk geacht voor ongeveer 5-10% van de mam-
macarcinomen (MC) en ovariumcarcinomen (OvC).31-33 Gezonde BRCA-mutatiedraagsters 
hebben een verhoogd levenslang risico op MC van 60-80% en op OvC van 30-60% bij 
BRCA1 en 5-20% bij BRCA2.31-33 Vanwege het verhoogde risico op mammacarcinoom 
wordt vanaf 25 jaar jaarlijks surveillance geadviseerd bestaande uit klinisch borston-
derzoek en een MRI-scan met vanaf 30 jaar daarbij een mammografie.61 BRCA-mutatie-
draagsters ervaren mogelijk stress bij deze regelmatige controles in het ziekenhuis.60 
Zij kunnen kiezen voor een preventieve mastectomie (PM), wat het MC risico verlaagt 
tot minder dan 5%154 maar fysieke en psychosociale gevolgen heeft op bijvoorbeeld 
lichaamsbeeldvorming en seksualiteit.62 BRCA-mutatiedraagsters bij wie een MC wordt 
gediagnosticeerd kunnen kiezen (indien technisch mogelijk) voor een mammaspa-
rende operatie of mastectomie (unilateraal of bilateraal (contralateraal preventief )).61 Na 
unilaterale behandeling is er een verhoogd risico op contralateraal mammacarcinoom 
tot 60%.35 Gynaecologische surveillance (vaginale echoscopie en tumormerkstof CA125) 
voor OvC bleek niet effectief63, hetgeen geleid heeft tot het advies van een risicoredu-
cerende salpingooöphorectomie (RRSO): voor BRCA1-mutatiedraagsters tussen 35 en 40 
jaar en voor BRCA2-mutatiedraagsters tussen 40 en 45 jaar.61 Dit verlaagt het OvC risico 
met 69-100% met een klein restrisico op een primair peritoneaal carcinoom (waarvoor 
eveneens geen effectieve surveillance).154
De overlevingswinst van PM vergeleken met mammasurveillance is gering.10 Het is aan 
BRCA-mutatiedraagsters zelf om, met de begeleidend specialist, voor- en nadelen af te 
wegen en een individuele keuze te maken. Ditzelfde geldt voor de timing van RRSO in 
relatie tot eventuele kinderwens. Vooral de keuze voor PM hangt samen met bepaalde 
patiëntkenmerken: jongere leeftijd, voorgeschiedenis van MC, kinderen, familieanam-
nese m.n. zus of moeder met MC.67,191 BRCA-mutatiedraagsters kunnen twijfels hebben 
bij de besluitvorming rondom preventie (decisional conflict138), waarbij psychologische 
factoren zoals verwerkingsstrategie (omgaan met bedreigende informatie), stress en 
risicoperceptie mogelijk meespelen.15 Ook worden preventiekeuzes beïnvloed door 
adviezen van artsen.69 Adviezen verschillen tussen landen70, medisch specialismen en 
artsen met meer of minder ervaring met genetisch testen.71,72
De zorg voor BRCA-mutatiedraagsters vindt plaats in de tweede- en derdelijns zorg. 
Genetische counseling en BRCA-testen vinden plaats bij UMC-gebonden afdelingen Ge-
netica. Klinisch genetische spreekuren worden ook op locatie in regionale ziekenhuizen 
gehouden192, veelal voor vrouwen met MC die als eerste in de familie getest worden. 
Presymptomatische vrouwen uit bekende BRCA-families worden vooral gezien en 
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getest in het UMC. UMC’s beschikken over multidisciplinaire BRCA-expertise teams, die 
BRCA-mutatiedraagsters adviesgesprekken aanbieden bij de gynaecoloog en internist 
of chirurg. Hierna volgt follow-up voor surveillance of preventieve operaties. Hiervoor 
worden BRCA-mutatiedraagsters verder begeleid in een regionaal ziekenhuis (mogelijk 
voorafgegaan door een eenmalige UMC consult) of het UMC (Figuur 1). De vraag is of de 
huidige BRCA-zorg verschilt tussen regionale ziekenhuizen en UMC’s wat de continuïteit 
van deze zorg zou kunnen belemmeren, en hoe de samenwerking geoptimaliseerd kan 
worden.
Het doel van deze studie is om BRCA-mutatiedraagsters begeleid in regionale zieken-
huizen te vergelijken met vrouwen begeleid in het UMC door de evaluatie van hun 
besluitvorming en keuzes rondom MC preventie. Ook worden regionale specialisten 
benaderd over de samenwerking met het UMC rondom BRCA-zorg.
MethoDen
BRCA-mutatiedraagsters
Studiepopulatie
Vrouwen van 25 tot 60 jaar bij wie een BRCA-mutatie is vastgesteld tussen 2006–2012 bij 
de afdeling Genetica van het Radboudumc (UMC), kregen in februari 2014 een eenma-
Vaststelling BRCA-mutatie
(UMC 3e lijn: klinisch genetische spreekuren
zowel op locatie in regionale ziekenhuizen als in UMC’s)
regionale ziekenhuis
(RZ) follow-up
Consult bij multidisciplinair
UMC expertiseteam (3e lijn)
Na eenmalig consult:
terugverwijzing
regionale ziekenhuis
(2e lijn)
Blijft bij
UMC
voor follow-up
(3e lijn)
UMC
follow-up
Directe
terugverwijzing
regionale ziekenhuis
(2e lijn)
figuur 1: Zorgpaden na vaststelling van een BRCA-mutatie.
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lige vragenlijst en werden gecategoriseerd in: regionale ziekenhuis (RZ) follow-up en 
UMC follow-up (Figuur 1).
Primaire uitkomstmaat
Decisional conflict (DCS138) rondom MC preventie.
Secundaire uitkomstmaten
Algemene (o.a. leeftijd, opleidingsniveau, verwerkingsstrategie (TMSI155,156)) en klinische 
kenmerken (m.n. bekende of nieuw ontdekte BRCA-familie, diagnose MC, wel/geen PM), 
inschatting BRCA-expertise (meerwaarde UMC) en besluitvorming (invloeden, shared 
decision making, spijt van keuzes (DRS193)). Psychologische maten waren MC-specifieke 
stress (IES/SVL133), impact van genetisch testen (MICRA178), lichaamsbeeld, seksueel 
functioneren/plezier (uit EORTC-QRQ-BR23194) en MC risico perceptie voor en na PM. 
Verbeterpunten voor samenwerking tussen regionale ziekenhuizen en UMC’s werden 
geïnventariseerd als open vraag.
regionale oncologische specialisten
Studiepopulatie
De afdeling Genetica van het Radboudumc heeft samenwerkingsverbanden met 11 
regionale ziekenhuizen in zuidoost Nederland voor spreekuren op locatie. Medisch 
oncologen, chirurgen en gynaecologen van deze ziekenhuizen ontvingen per post een 
vragenlijst.
Uitkomstmaten
Ervaring met overleg UMC expertiseteam; voorkeur voor directe terugverwijzing, een-
malig consult of overname van de zorg van de BRCA-mutatiedraagsters; welke onderwer-
pen moet het UMC expertiseteam met BRCA-mutatiedraagsters bespreken; gewenste 
ondersteuningsmiddelen; MC/OvC preventie adviezen voor BRCA-mutatiedraagsters, 
met of zonder diagnose MC.
Statistische analyses
Resultaten van vragenlijsten van BRCA-mutatiedraagsters en regionale specialisten 
werden als beschrijvende statistieken gerapporteerd. Patiëntkenmerken werden ver-
geleken tussen responders versus niet-responders, responders in RZ follow-up (met of 
zonder eenmalig UMC consult: geen relevante verschillen) versus UMC follow-up, en 
responders mét versus zonder MC diagnose, met onafhankelijke t-toets voor continue, 
Mann-Whitney U toets voor ordinale en chi-kwadraat toets voor nominale variabelen. 
Multivariate logistische regressie analyse van RZ versus UMC follow-up werd uitgevoerd 
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met decisional conflict, verwerkingsstrategie en diagnose MC. Het significantie toet-
singsniveau was 0,05 (tweezijdig) en data werden geanalyseerd met SPSS 20.0.
reSUltAten
BRCA-mutatiedraagsters
De vragenlijst werd ingevuld door 192 van 402 (48%) BRCA-mutatiedraagsters (Tabel 1). 
Responders verschilden niet van non-responders wat betreft BRCA1 versus BRCA2, eerst 
geteste familielid versus bekende BRCA-familie, leeftijd en jaren sinds BRCA-uitslag.
Decisional conflict rondom MC preventie
BRCA-mutatiedraagsters in UMC follow-up hadden meer moeite met besluitvorming 
rondom MC preventie (decisional conflict: p=0,02; Tabel 2, Figuur 2) en meer spijt 
van hun keuze (p=0,01), waarbij zij minder vaak PM hadden ondergaan dan BRCA-
mutatiedraagsters in RZ follow-up (p=0,003; Figuur 2). Dit verschil gold voor BRCA-
mutatiedraagsters zonder MC (p=0,003) maar niet voor BRCA-mutatiedraagsters mét MC 
(p=0,34). BRCA-mutatiedraagsters in UMC follow-up waren ook vaker beïnvloed door 
0
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20
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40
50
60
70
80
Preventieve
mastectomie
Mammacarcinoom 
in voorgeschiedenis
Informatiezoekende
verwerkingsstrategie
UMC follow-up
(n=112)
RZ follow-up
(n=49)
p=0,003p<0,001 p=0,003
90
Decisional conict
(DCS: score)
p=0,02
(%)(%) (%)
figuur 2: Verschillen tussen BRCA-mutatiedraagsters (n=191) op basis van locatie van begeleiding voor 
mammacarcinoom (MC) preventie: 1) UMC follow-up (n=112, 58%); 2) regionale ziekenhuis (RZ) follow-up 
(n=80, 42%); wat betreft % preventieve mastectomie uitgevoerd, % mammacarcinoom in voorgeschiede-
nis, % neiging tot een informatiezoekende verwerkingsstrategie en mediaan [range] van decisional conflict 
(DCS) score. 
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advies van UMC specialisten (p<0,001) en advies mammasurveillance (p<0,001). Shared 
decision making verschilde niet (Tabel 2). Enkelen noemden verwarrende verschillen in 
voorlichting tussen specialisten: 5% noemde dringend adviseren versus juist afhouden 
van preventief opereren, 3% noemde verschillen in surveillance of operatief beleid.
Algemene kenmerken
BRCA-mutatiedraagsters in UMC follow-up waren wat betreft verwerkingsstrategie 
vaker informatiezoekend oftewel hadden meer informatiebehoefte (p=0,003; Tabel 1, Fi-
guur 2) en gaven vaker meerwaarde aan het UMC voor BRCA-expertise (kennis p<0,001; 
uitleg p<0,001) dan BRCA-mutatiedraagsters in RZ follow-up. BRCA-mutatiedraagsters 
in RZ follow-up waren vaker gediagnosticeerd met MC dan BRCA-mutatiedraagsters in 
UMC follow-up (p<0,001; Figuur 2). 
Voorgeschiedenis MC
BRCA-mutatiedraagsters met MC waren ouder bij BRCA-uitslag (p<0,001), vaker laag op-
geleid (p=0,001) en gaven minder meerwaarde aan het UMC voor BRCA-kennis (p<0,001) 
en uitleg (p<0,001) dan BRCA-mutatiedraagsters zonder MC (Tabel 1).
Keuze OvC preventie
In RZ follow-up hadden meer BRCA-mutatiedraagsters de maximale adviesleeftijd 
bereikt voor RRSO (74% versus 55%, p=0,007) met minder spijt van hun keuze voor 
OvC preventie (5 [0–60] versus 20 [0–50], p=0,001) dan BRCA-mutatiedraagsters in UMC 
follow-up. Het verschil in RRSO tussen RZ (77%) en UMC follow-up (65%) bleek niet signi-
ficant (p=0,08). BRCA-mutatiedraagsters met MC hadden vaker de maximale adviesleef-
tijd voor RRSO bereikt (80% versus 56%, p=0,002) en RRSO ondergaan (86% versus 63%, 
p=0,004) met minder spijt van hun preventiekeuze (5 [0–60] versus 20 [0–50], p=0,02) 
dan BRCA-mutatiedraagsters zonder MC. Bij evaluatie van toekomstige plannen voor 
deze leeftijdsafhankelijke RRSO hadden bijna alle BRCA-mutatiedraagsters de intentie 
om uiteindelijk RRSO te ondergaan (95%).
Psychologische aspecten
BRCA-mutatiedraagsters rapporteerden gemiddeld weinig psychische problemen (Ta-
bel 3). Follow-up locatie gaf geen verschil. Wel scoorden BRCA-mutatiedraagsters met 
MC anders dan degenen zonder MC (tabel 3): hogere stress (p=0,05) en onzekerheid 
(p=0,02), lager lichaamsbeeld (p=0,003), meer problemen met seksueel functioneren 
(p=0,01) en plezier (p=0,02) en hogere risicoperceptie MC na PM (p<0,001).
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Samenwerking BRCA-zorg
De helft (52%) van de BRCA-mutatiedraagsters had geen mening over de samenwerking 
tussen regionale ziekenhuizen en het UMC; 8% merkte hier niets van. Als verbeterpun-
ten noemde 9% onderlinge communicatie, 7% overeenstemming van beleid, 5% meer 
BRCA-kennis in de regio en 4% meer BRCA-zorg naar de regio.
Multivariate analyse
Zowel decisional conflict (OR 0.97 [0.95–0.99]) als meer informatiezoekende verwer-
kingsstrategie (OR 0.26 [0.10–0.73]) en diagnose MC (OR 6.99 [3.03–16.15]) leverden 
onafhankelijke bijdragen aan RZ follow-up.
regionale oncologische specialisten
Van de 105 regionale oncologische specialisten respondeerden er 47 (45%): onder me-
disch oncologen was er 42% respons, chirurgen 29% en gynaecologen 68%.
Rol van het UMC
Van de responders was 32% tevreden over overleg met het UMC expertiseteam en 21% 
had verbeterpunten (sneller overleg, geen overname van zorg); 47% had geen ervaring 
met dergelijk overleg. De meerderheid (70%) gaf voorkeur aan een eenmalig UMC con-
sult voor patiënten om gevolgen voor familieleden (89%) en preventieadviezen (83%) te 
bespreken. Vooral passieve ondersteuningsmiddelen bijv. website (66%) of zakkaartjes 
met verwijscriteria (60%) werden gewaardeerd.
Preventieadviezen
Voor mammasurveillance (Tabel 4) adviseerde 12% van internisten en chirurgen conform 
de landelijke richtlijn, 31% gaf geen eigen advies maar volgde het UMC expertiseteam 
en 54% gaf een advies dat afweek (soort controles, leeftijden, frequentie) van de richtlijn. 
Bij diagnose MC adviseerde 26% bilaterale mastectomie, bij BRCA-mutatiedraagsters 
zonder MC adviseerde 11% PM. Voor OvC preventie adviseerde 81% van gynaecologen 
alleen RRSO, 19% adviseerde daarnaast gynaecologische surveillance voorafgaand aan 
RRSO.
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beSChoUwinG
Er blijken verschillen tussen BRCA-mutatiedraagsters die begeleid worden in regionale 
ziekenhuizen of het UMC. BRCA-mutatiedraagsters in de regio waren vaker gediagnos-
ticeerd met MC; BRCA-mutatiedraagsters in UMC follow-up hadden meer decisional 
conflict en/of informatiebehoefte rondom MC preventie en/of waren vaker presympto-
matisch. Hierbij kozen zij minder vaak voor preventieve mastectomie. Dit suggereert dat 
deze vrouwen een specifieke subgroep onder BRCA-mutatiedraagsters betreft met meer 
behoefte aan academische begeleiding.
In ander onderzoek kozen BRCA-mutatiedraagsters met MC driemaal vaker PM dan 
degenen zonder MC67, maar in onze studie was dit niet verschillend. Er is geen eerdere 
tabel 4: Advisering mamma/ovariumcarcinoom preventie (N(%)) van oncologische specialisten uit regio-
nale ziekenhuizen (n=47) voor BRCA-mutatiedraagsters.
Kenmerk Totaal
(n=47)
Internisten
(n=14: 30%)
Chirurgen
(n=12: 25%)
Gynaecologen
(n=21: 45%)
Advies voor schema mammacarcinoom (MC) surveillance
- advies geheel conform landelijke IKNL richtlijn   3 (  7%) 0 (  0%) 3 (25%) 0 (  0%)
- volgt advies expertiseteam 11 (23%) 6 (43%) 2 (17%) 3 (14%)
- laat advies rondom MC preventie over aan andere specialist   9 (19%) 1 (  7%) 0 (  0%) 8 (38%)
- afwijkende leeftijd of frequentie 11 (23%) 5 (36%) 4 (33%) 2 (10%)
- afwijkende soort controles 13 (28%) 2 (14%) 3 (25%) 8 (38%)
Advies bij BRCA-mutatiedraagster met recent MC
- mammasparend   0 (  0%) 0 (  0%) 0 (  0%)   0 (  0%)
- unilaterale mastectomie   2 (  4%) 1 (  7%) 1 (  8%)   0 (  0%)
- bilaterale mastectomie 12 (26%) 4 (36%) 3 (25%)   4 (19%)
- geen specifiek advies of alle opties 33 (70%) 8 (57%) 8 (67%) 17 (81%)
Advies gezonde BRCA-mutatiedraagster rondom MC preventie
- mammasurveillance   2 (  4%)   1 (  7%) 1 (  8%)   0 (  0%)
- preventieve mastectomie (PM)   5 (11%)   1 (  7%) 2 (17%)   2 (10%)
 - geen specifiek advies of beide opties 40 (85%) 12 (86%) 9 (75%) 19 (91%)
Advies gezonde BRCA-mutatiedraagster rondom ovariumcarcinoom 
(OvC) preventie
- jaarlijkse OvC surveillance   2 (  4%) 2 (14%) 0 (  0%)   0 (  0%)
- preventieve bilaterale salpingoöphorectomie (RRSO) 26 (55%) 4 (29%) 5 (42%) 17 (81%)
- geen specifiek advies of beide opties 19 (41%) 8 (57%) 7 (58%)   4 (19%)
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vergelijking gemaakt tussen UMC en regionale ziekenhuizen, maar in onze groep BRCA-
mutatiedraagsters kozen juist vrouwen zonder MC vaker voor PM in de regio dan in 
het UMC. Dit lijkt vooral te maken hebben met het verschil in decisional conflict. Een 
preventieve operatie is onomkeerbaar: vrouwen in decisional conflict zullen een in-
greep vaker uitstellen en ter overbrugging kiezen voor mammasurveillance.60 Dit kan 
te maken hebben met verwerkingsstrategie: meer decisional conflict speelde reeds 
onder jong volwassenen getest voor BRCA-mutaties met behoefte aan veel informatie.156 
Mogelijk zien zij vaker zowel voor- als nadelen, leidend tot decisional conflict; andersom 
kan decisional conflict leiden tot zoeken naar meer informatie om hiermee dit conflict 
op te heffen.
UMC’s en regionale ziekenhuizen vervullen verschillende behoeften van patiënten 
en hebben ieder een eigen functie binnen de BRCA-zorg: de regionale ziekenhuizen 
begeleiden vooral vrouwen die reeds bekend zijn met een diagnose MC, terwijl UMC’s 
begeleiding bieden aan vrouwen die presymptomatisch zijn, of meer twijfel of infor-
matiebehoefte hebben. Dit komt overeen met de wens van de regionale specialisten: 
de meerderheid wenst een eenmalig adviesgesprek tussen BRCA-mutatiedraagsters 
en het UMC expertiseteam om gevolgen voor de patiënt en haar familieleden (veelal 
presymptomatisch) en preventieadviezen te bespreken. Regionale samenwerking is 
heel belangrijk om te zorgen dat de individuele BRCA-mutatiedraagster op de juiste 
plaats optimale zorg krijgt, waarbij aandacht besteed wordt aan eenduidige advisering 
over surveillance volgens de landelijke richtlijnen.
Een sterk punt van dit onderzoek is het gebruik van gevalideerde vragenlijsten. De 
retrospectieve opzet is echter gevoelig voor recall bias (zaken anders herinneren dan de 
werkelijkheid) en cognitieve dissonantie (onbewust herzien van meningen om ze meer 
in overeenstemming met elkaar te brengen en daarmee spanning te reduceren).182 Voor 
BRCA-mutatiedraagsters is het lastig om verschillende adviezen te rapporteren: 40-80% 
van informatie in een medisch consult wordt direct vergeten.121 Mogelijk is de respons 
onder BRCA-mutatiedraagsters laag (48%) vanwege het versturen van de vragenlijsten 
vlak na een landelijke vragenlijst studie in dezelfde patiëntengroep (HEBON: landelijke 
onderzoeksgroep naar erfelijke borst- en eierstokkanker). De groep regionale specia-
listen is klein en beperkt tot de ziekenhuizen in samenwerking met het Radboudumc.
Conclusie
Regionale ziekenhuizen en UMC’s hebben ieder een eigen rol binnen de BRCA-zorg. 
BRCA-mutatiedraagsters in beide types ziekenhuizen verschilden van elkaar: vrouwen 
met MC gaan meestal (terug) naar de regio, terwijl vrouwen onder UMC begeleiding 
meer decisional conflict en/of informatiebehoefte hebben en/of presymptomatisch 
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zijn. Regionale specialisten hebben voorkeur voor eenmalige UMC adviesgesprekken 
voor patiënten om gevolgen voor familieleden en preventieadviezen te bespreken. 
Regionale samenwerking is heel belangrijk om te zorgen dat de individuele BRCA-
mutatiedraagster op de juiste plaats de optimale zorg krijgt.
belAnGenConfliCt en finAnCiële onDerSteUninG
Geen.
leerPUnten
wat is bekend?
• Vaststelling van een BRCA-mutatie vindt plaats bij afdelingen Genetica van uni-
versitair medisch centra (UMC’s), waarbij klinisch genetische spreekuren zowel in 
regionale ziekenhuizen als in UMC’s gehouden worden.
• BRCA-mutatiedraagsters kunnen voor follow-up (intensieve surveillance of preven-
tieve operaties) begeleid worden door het multidisciplinair UMC expertiseteam of 
door specialisten in de eigen regio, met of zonder een eenmalig consult bij het UMC 
expertiseteam.
• Keuzes van BRCA-mutatiedraagsters ten aanzien van kanker preventie worden mede 
bepaald door patiëntkenmerken: mogelijk verschillen BRCA-mutatiedraagsters die 
begeleid worden in een UMC van degenen die begeleid worden in een regionaal 
ziekenhuis.
wat is nieuw?
• BRCA-mutatiedraagsters reeds gediagnosticeerd met mammacarcinoom gingen 
voor verdere begeleiding vaker (terug) naar een regionaal ziekenhuis, terwijl vrou-
wen onder specialistische UMC begeleiding meer decisional conflict en/of meer 
informatiebehoefte hadden en/of presymptomatisch waren.
• De helft van de regionaal werkende oncologisch specialisten had nog geen ervaring 
met overleg met het UMC expertiseteam; de meerderheid gaf voorkeur aan een-
malige UMC adviesgesprekken voor de BRCA-mutatiedraagsters met aandacht voor 
familieleden en preventieadviezen.
• Regionale ziekenhuizen en UMC’s vervullen verschillende patiëntbehoeften en heb-
ben hiermee ieder een eigen functie binnen de BRCA-zorg: regionale samenwerking 
is heel belangrijk om te zorgen dat de individuele BRCA-mutatiedraagster op de 
juiste plaats de optimale zorg krijgt.
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“We keep moving forward, opening new 
doors and doing new things,
because we’re curious and curiosity keeps 
leading us down new paths.”
(Walt Disney)

Chapter 9
135
General discussion
GenerAl DiSCUSSion
Primary prevention is heralded as the most effective way to fight cancer: between one 
third and half of all cancers could be prevented based on our current knowledge of risk 
factors.195 Despite these expected benefits, primary prevention remains insufficiently 
integrated into clinical practice and more attention is called to modifiable cancer risk 
factors include smoking, alcohol, diet, physical activity.195 Beyond these common risk 
factors, a minority of people is at highly increased lifetime risk for certain cancers, based 
on a variety of genetic predispositions.21 These patients can take preventive actions such 
as early surveillance or prophylactic surgery to effectively lower their risks of cancer 
incidence and mortality.9,10 Therefore genetics also provide excellent opportunities for 
this highly sought-after primary prevention.195 But these preventive actions are only 
possible if patients are, in fact, aware of carrying these risk factors and if they know 
which actions are appropriate in their individual situation.
As described in the General Introduction (Chapter 1), the cancer genetic diagnostic pro-
cess can be split into three stages with each their own research needs. Previous litera-
ture has shown that hereditary cancer syndromes remain under-recognized37,38 (Stage 
i: recognition & referral) while technical possibilities2 as well as societal demands5,196 
for genetic testing are ever growing (Stage ii: Genetic testing & Counseling), but ap-
propriate guidance and follow-up of hereditary cancer are not always clear197,198 (Stage 
iii: follow-up & Prevention). To improve patient awareness of hereditary cancer and 
proper prevention, changes may be necessary in all three stages to aid the integration of 
primary prevention based on genetic factors into oncologic care. New models of genetic 
services are currently being developed and evaluated throughout the world, challeng-
ing the long-standing tradition of two-visit face-to-face models.5
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The implementation of health care innovations is often met with certain apprehension. 
Donald Berwick stated in 20037: “In health care, innovation is hard, but dissemination is 
even harder.” Perceptions of each innovation predict the majority of the rate of spread: 
what people think of the innovation will determine whether or not they will adopt this 
change. Important perceptions include:
1. benefits versus risks: how does it help them compared to the known status quo?
2. compatibility with individual values and needs: does it fit within their current context?
3. complexity: how hard is it to implement? (i.e. the simpler, the better)
4. trialability: is there a way to test it on a small scale first? (i.e. pilot testing)
5. observability: how easy is it to observe others who try the innovation first?
Changes spread faster when these five perceptions are beneficial. These perceptions are 
related: for example, reduction of uncertainty in weighing benefits versus risks is made 
easier if the individual can observe benefits experienced by early adopters in a pilot 
test prior to full-scale implementation. Therefore it is important to evaluate these early 
adopter experiences and make them known to the greater majority, for these to follow 
in their footsteps.7 Previous chapters have described several studies that evaluated real-
life experiences with innovations within the cancer genetic diagnostic process, to inform 
perceptions held by the larger majority (including other health care professionals) in 
order to support acceptance and implementation into common clinical practice. This 
chapter will summarize the principal findings for each stage within the cancer genetic 
diagnostic process and discuss both their clinical implications and future prospects.
Stage i: recognition & referral
Improved recognition of hereditary cancer can be achieved by two main 
strategies: improving genetic testing selection criteria and improving ac-
cess to cancer genetic services (Chapters 2 through 5).
Providing scientific evidence e.g. cost-effectiveness analyses to support 
changes in selection criteria for genetic testing is useful to encourage 
further clinical implementation (Chapter 2).
New genetic service models are necessary and often acceptable, especially 
to affected patients where psychological distress is based on the experience 
of their cancer diagnosis, not the additional genetic diagnostic procedure 
(Chapters 3, 4 and 5).
Despite growing public awareness of genetic aspects to cancer5,196, two of the most 
common forms of hereditary cancer, Lynch syndrome for colorectal and endometrial 
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cancer (CRC and EC) and BRCA-mutations for breast and ovarian cancer (BC and OC)21 
remain under-recognized even today.37,38 Not identifying families at high risk for cancer 
prohibits these individuals from taking actions to lower their cancer incidence and 
mortality9,10: these are missed chances for primary cancer prevention.
Several strategies are possible to improve detection of hereditary cancer. On one hand, 
selection criteria for referral to genetic diagnostics should be continuously refined, 
such as the age limit for CRC tumor genetic testing recently being raised from 50 to 70 
years.24,29,75 Chapter 2 showed that this novel strategy was indeed cost-effective and 
would lead to a fourfold detection of Lynch syndrome compared to current practice. 
Refinement of selection criteria can therefore have great benefits. Furthermore, pro-
viding scientific evidence on clinical efficacy and cost-effectiveness may support the 
implementation of these guideline changes among various stakeholders, including 
policy makers.199
However, literature showed there to be insufficient knowledge of familial cancer risk 
assessment amongst non-genetic professionals37: efforts to provide improved selec-
tion criteria are for naught when not put into practice by clinicians selecting patients. 
Education of clinicians alone does not improve the referral rate of high risk patients40: 
therefore, easy-to-use online referral tests based on national guidelines36,57 were made 
available at www.radboudumc.nl/hereditarycancer.200 These tests guide appropriate 
family history collection, based on the consideration “the simpler, the better”7: clinicians 
no longer need to consult complex criteria manually but receive an automatic recom-
mendation for referral to clinical genetics, early surveillance or neither. Non-medical 
staff used the referral test for correct advice in 84% of patient cases200 while physicians 
without the test achieved only 65%.37 This has led to widespread use in daily practice by 
general practitioners and oncology practices and may augment further genetic training 
of clinicians.201
Another strategy is to improve patient access to clinical genetic services for further 
counseling and germline testing, especially considering growing public awareness and 
demands196, leading to the development of new models of service delivery.5 One such 
novel procedure was described in Chapter 3 through 5 for BRCA-mutation testing in BC 
patients, replacing the pre-test intake consultation by an informational package sent to 
patients’ homes and only providing post-test face-to-face counseling. This allowed BC 
patients who preferred these alternative information formats and/or felt burdened by 
additional hospital visits to initiate genetic testing close to home. Similar new models 
are being evaluated elsewhere, including the use of pre-visit tailored websites157, the 
choice after an intake consultation to learn test results by letter instead of face-to-face 
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counseling147 and certain risk groups being offered BRCA-testing by pre-test telephone 
contact, with post-test counseling only following a positive BRCA-result (otherwise 
reported by letter158). All these studies showed high satisfaction without long-term 
distress: if psychological distress is present, this seems to be based primarily on the 
experience of cancer rather than the additional genetic diagnostic procedure (Chapters 
4-5). This demonstrates that patients are well able to withstand these necessary changes 
in cancer genetic services models.5
However, a further attitude shift among the greater majority of genetic professionals 
towards “P5 medicine”202,203 is necessary: predictive, personalized, preventive, par-
ticipatory and psychocognitive. We would argue that this also involves prioritizing the 
individual needs and preferences of patients over the traditional model of personal 
pre- and post-test genetic counseling. Trepanier e.a.5 previously identified perception 
of reduced quality of cancer genetics services as one of the main barriers to using non-
traditional models, especially post-test counseling (85%). But high patient satisfaction 
and low distress were reported in aforementioned studies where pre-test information 
is provided by alternative (not face-to-face) means, seeming to suggest that no such 
quality reduction occurs from the perspective of the central stakeholder: the patients.
Such attitude shifts have happened successfully before: adjusting the Huntington-based 
model of two to only one pre-test consultation in cancer genetics, following reassuring 
patient experiences and expected increases in test requests.8 But there seems to be 
some resistance to further shifts now, despite recognition of the need for more acces-
sible genetic services.5 It is interesting to note that genetic counseling is based on a long 
standing foundation of non-directiveness and shared decision making when it comes 
to the decision whether to undergo genetic testing.204 But when attempts are made to 
hold the same ethical standards to the decision how to undergo genetic testing, these 
are met with far more hesitation. Instead, this basis of preserving patient autonomy 
should be ripe for more personalization of cancer genetic services, inviting more patient 
participation as called for in modern medicine.4 Future studies should evaluate more 
possible service models that are aimed at individual preferences for information, explor-
ing different avenues for fulfilling the need for and shift towards P5 medicine in cancer 
genetics202 whilst upholding the quality of genetic counseling.5
Stage ii: Genetic testing & Counseling
Standardized psychosocial support by social workers or psychologists for 
generalized patient groups is excessive: such support is more effective if 
focused on specific subgroups in need (Chapter 6).
Chapter 9
139
General discussion
Offering new genetic technologies in a clinical diagnostic setting is accept-
able if accompanied by proper genetic counseling and informed consent 
procedures which are open to changes based on further experiences 
(Chapter 7).
Being faced with the possibility of increased risks for cancer can have a psychosocial 
impact, even without clinically relevant distress.13 Attempts to evaluate these intricate 
psychodynamics within genetic counseling have long been made3 but only in recent 
years have these aspects been summarized into six main psychosocial issues: coping 
with cancer risk, practical issues, family-related problems, children-related problems, 
living with cancer and emotional reactions.13 While standard genetic counseling is suffi-
cient for the majority of patients, a quarter of patients experiences serious psychological 
distress13: certain patients are known to be at higher risk of such distress.18 Additional 
decisional support is made mandatory for certain risk groups prior to the start of ge-
netic testing: for example, young adults between 18 and 25 years who may learn of their 
genetic status years before surveillance starts.46 However, Chapter 6 showed that the 
great majority of these young adults did not regret their decision to be tested and such 
generalized support is excessive. But there was a subgroup of young adults who expe-
rienced decisional conflict: rather than spreading out these precious resources across 
an entire group, psychosocial support would be most effective if focused on those in 
need. Recently developed screening questionnaires may be useful in helping clinical 
geneticists and genetic counselors identify those specific patients.205
At the same time, the focus of psychosocial support could also shift from the pre-test to 
the post-test setting following identification of mutation carriers. Among cancer patients, 
adolescent and young adult patients already diagnosed with cancer between the ages 
of 15 and 39 are increasingly recognized as a unique group requiring special services. 
The Radboudumc has developed an adolescent and young adult (AYA) expertise center 
to provide this particular subgroup with integrated medical-technical and psychosocial 
care.206 But unaffected young adults at genetic risk for cancer may still feel out of place 
in these systems, not having experienced an actual cancer diagnosis themselves.207 This 
“previvor” experience i.e. having a hereditary predisposition for cancer but not yet hav-
ing had the disease208 can be generalized to all age groups, but young adults deal with 
additional concerns in their development as independent adults (e.g. moving out, new 
careers, starting a family).46,47,66,172,207,209 In future studies, the expertise of both oncologic 
specialists caring for young adult cancer patient/survivors as well as genetic counselors 
providing guidance to families at high risk for cancer should be joined together in a 
new type of young adult previvor services. Not only would this address this age group’s 
unique set of support needs and preferences, but it would also help to cross bridges 
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between genetics and medical oncology, aiding in the integration of primary cancer 
prevention.
Another situation where psychological distress could occur, are uncertain54 or unexpect-
ed results.210 The increasing availability of genome-wide technologies2 also leads to the 
increasing possibility of such results leading to many discussions about the acceptability 
of integrating these technologies into clinical diagnostic settings.53 However, looking at 
certain precedents, this is a natural progression of advancing genetic technologies with 
chromosomal microarray leading the way.211 A similar trend of initial hesitation was seen 
in these technologies which could more precisely identify chromosomal abnormalities, 
resulting in a significantly higher diagnostic yield compared to traditional karyotyping 
but still seen as “experimental” at first.212 Nowadays, chromosomal microarrays are rec-
ommended as first-line diagnostic test in patients with developmental delay, intellectual 
disability, autism spectrum disorders and multiple congenital anomalies.213 The majority 
of abnormal microarray results have had clinical consequences, which were expected to 
help further improve patients’ medical management and health.214
Similarly, two-step exome sequencing was shown to outperform traditional single-
gene sequencing in a diagnostic setting.56 Additional to this clinical utility, Chapter 7 
described a study of patient experiences with gene panels based on exome sequencing 
(step 1) in clinical diagnostics, with high acceptance and low distress. Although evalua-
tion following full exome-wide analyses (step 2) is yet to follow, the current study results 
provide an optimistic expectation of exome-wide results being received well by pa-
tients. Other recent studies regarding clinical implementation of NGS showed a variety 
in patient preferences to receive unsolicited findings215 but emphasize the wish for an 
opt-out for (certain) unsolicited findings.162,215,216 Various models have already been sug-
gested but not yet evaluated in practice.162 Unsolicited findings can be categorized into: 
1) life-saving/immediate clinical utility, 2) potential/moderate clinical utility, 3) repro-
ductive significance and 4) personal/recreational significance.217 A qualified disclosure 
policy was proposed where the first category was standard and mandatory, whereas the 
other three categories could be opted into by patients as additional packages.217 This 
approach could strike the right balance between patient autonomy and physician duty 
to report, thus may be the future of NGS informed consent procedures. These various 
studies show that new genetic technologies are acceptable if accompanied by proper 
genetic counseling and informed consent procedures, which are open to adjustments 
based on new experiences in practice.
Considering these positive past and current experiences, taking sequencing to the next 
level of whole-genome2 seems both achievable and acceptable. But beyond ethical 
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and psychosocial concerns, there is currently an inflexible divide between research and 
clinical care limiting both.218 Aggregation of large-scale sequencing data is necessary to 
provide conclusive results in either setting and this data is best used pooled together 
for shared use. Although there are concerns such as the therapeutic misconception 
(patients’ mistaken belief that research will benefit them directly), this may help many 
more patients and families to end otherwise long diagnostic odysseys.218 Future studies 
are needed to identify effective strategies for bridging this gap between research and 
clinical care, which are carefully balanced not to add therapeutic misconceptions218 or 
problems with financial coverage as previously seen with the clinical implementation of 
chromosomal microarray technologies.213
Stage iii: follow-up & Prevention
Regional and university hospitals fulfill different patient needs in the clini-
cal follow-up of BRCA-mutation carriers for cancer prevention: regional col-
laboration is essential to ensure that the individual BRCA-mutation carrier 
receives optimal care at the appropriate location (Chapter 8).
The main benefit of identifying individuals with a hereditary cancer syndrome, is the 
ability to take preventive action and lower cancer incidence and mortality9,10 especially 
in unaffected carriers. BRCA-mutations and Lynch syndrome (LS) are the two most well-
known forms of hereditary cancer21 but only explain a small proportion (estimated 
5-10%) of all cancer cases195 therefore non-genetic professionals are not likely to come 
across a great number of these patients. Specific knowledge of these hereditary cancer 
syndromes is important to support these patients, for which continued medical educa-
tion in cancer genetics was shown to be vital.72 In our study described in Chapter 8, 
BRCA-mutation carriers previously diagnosed with BC were more likely to go or return to 
regional hospitals. Conversely, those women who chose to be supported in a university 
hospital had higher decisional conflict and/or information need and/or were more likely 
presymptomatic. 
This shows that patient characteristics differ between the two follow-up locations: 
regional and university hospitals therefore fulfill different patient needs in clinical 
follow-up of BRCA-mutation carriers. Care for those patients who do not experience 
high decisional conflict and/or information need and/or already have a cancer history, 
could shift more towards regional hospitals i.e. second line of health care. Care for those 
patients expressing a need for specialized support (e.g. decisional conflict) should 
remain in university hospitals (third line) with special expertise in hereditary cancer. 
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Regional collaboration between these hospitals is therefore essential to ensure that the 
individual BRCA-mutation carrier receives optimal care at the appropriate location.
Therefore, while all BRCA-mutation carriers should be provided with consistent cancer 
prevention information in all lines of health care, they should not be considered a 
uniform group for “one size fits all” policies. These patients have individual preferences 
not just for the type of health care received, but also the location thereof. Especially 
with increased public awareness196 and the gradual shift of clinical genetic services 
towards regional hospitals192, university hospitals with specific hereditary cancer ex-
pertise should thus focus on continued medical education of regional specialists72 and 
providing more support tools not just for referral201 but also for clinical follow-up once a 
hereditary predisposition has been identified. This ensures quality BRCA-care across all 
lines of health care, allowing patients their free choice of preferred and most appropri-
ate follow-up location.
Methodological reflections
Strengths
The Radboudumc is a frontrunner when it comes to innovative genetic health care, such 
as being among the first to implement two-step exome sequencing in a clinical diagnos-
tic setting.56 The studies described in this thesis are unique as they took advantage of 
being in the midst of this fast-developing field and first-in-line institution, using these 
opportunities to help develop and evaluate such innovations in this real life setting. This 
provided more realistic outcomes than previous discussions and studies found in litera-
ture based on hypothetical or research settings, or based on the views of professionals 
rather than patients as the central stakeholders.51,183,219-227
Resulting from the previous lack of practical experience, clinical recommendations and 
policies were often based on such expert opinions and assumptions. However, these 
may not always reflect reality. For example, another recent study demonstrated dis-
cordant perspectives of different stakeholders on reporting unsolicited findings: while 
clinicians focused on the clinical relevance as the determining factor for whether or not 
to report, the lay groups emphasized autonomy and patients’ right to choose which 
results to receive, accepting consequences of possible anxiety or uncertainty.228 The 
purpose of the studies described in this thesis was to evaluate realistic settings directly 
to test these clinician assumptions and create a scientific basis for further policy-making, 
either through patient experiences or models based on real-life data.
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When patient experiences regarding subjects within this thesis had previously been 
studied, these studies were often qualitative of nature.46,47,66,172,207,209,215,228 This was 
suited for exploring certain recurrent themes for informing further research. This thesis 
focused on the use of quantitative measures, to allow more precise measurement of 
change over time (Chapters 3-5 and 7), testing for differences between groups (Chap-
ters 3-6 and 8) or to determine specific subgroups to focus support on (Chapters 6 
and 8). Neither research methodologies is superior or inferior to the other; rather the 
quantitative studies described in this thesis were often based on and then considered 
complements to the previous qualitative studies found, both shedding further light on 
these research subjects from different angles.
Limitations
The studies described in this thesis have several limitations in common. Some studies 
of patient experiences were retrospective (Chapters 6 and 8) and therefore sensitive to 
recall bias and cognitive dissonance. Furthermore, although correlations were found, it 
was not always possible to measure prospectively to determine the direction of causal 
relations: one example is the correlation between decisional conflict and monitoring 
coping style, which were suggested in both Chapters 6 and 8. Assessing these mea-
sures in prospective studies may further elucidate the precise relation between the two 
psychological aspects in the context of genetic testing.
Other limitations of some studies were non-randomization (Chapters 3-5) or being able 
only to evaluate acceptors of a certain genetic procedure (Chapters 6 and 7), which lim-
ited generalizability of these study results. Regarding the non-randomization of DNA-
direct, this was a conscious choice as the main study outcome was patient preference 
for the novel DNA-direct procedure instead of the traditional DNA-intake procedure: 
without any interest among patients, the effort of implementing such a new procedure 
would be for naught. Regarding the evaluation of only acceptors, this was limited by 
the ethical allowances of our research studies as we were restricted from approaching 
those who had declined genetic testing, although it would also be valuable to know 
their motivations for this choice.
Finally, some studies were limited by small study samples, for example due to restriction 
in lab capacity (Chapter 7), although significant results were found even with these 
limited numbers.
implications for Clinical Practice
The main goal of cancer genetic services is to identify those individuals at increased risk 
for cancer. Current literature suggests that we are still missing many families at risk.37,38 
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New strategies discussed in this thesis were proven to be effective: the next step is to 
implement these strategies into clinical practice.
First, the detection of hereditary cancers is highly dependent on the criteria used to 
identify these syndromes. Basic hallmarks of hereditary cancer are young age and posi-
tive family history, but exact referral criteria are subject to change depending on new 
insights. However, this may also broaden the group of eligible patients, accompanied by 
higher costs: clinicians and financial stakeholders may therefore be hesitant to imple-
ment these changes unless these costs are proven to be balanced by greater benefits. 
Cost-effectiveness analyses such as described in Chapter 2 are necessary to provide 
this scientific evidence to reduce uncertainty regarding the economical consequences 
and thereby support the clinical implementation of these changes7 i.e. all patients diag-
nosed with CRC at age 70 or younger should undergo tumor genetic testing for Lynch 
syndrome.
Another aspect to consider is patient access to cancer genetic services. Considering 
higher demands for these services and an increased call for patient participation in 
health care, other models beyond the traditional two-visit format should be explored.5 
Our study on the novel DNA-direct procedure described in Chapters 3-5 adds to the 
ever-growing body of literature147,157,158 showing that patients find these new models 
of cancer genetic services acceptable, despite concerns about the lower priority on 
face-to-face counseling. Models involving post-test genetic counseling may increase 
patient access to genetic testing, as pre-test information could be provided in alterna-
tive and possibly preferred formats. Patients could even arrange genetic testing without 
additional hospital visits, which is especially important as genetic tests are often con-
centrated within expert but geographically sparse clinical genetic centers. Detecting 
hereditary cancer is only possible if patients are given the opportunity to make use of 
these tests: clinicians should explore new models bringing these tests and these patients 
closer together, while upholding the high quality of genetic counseling. The DNA-direct 
procedure evaluated here is one such model considered acceptable for clinical practice.
Similarly, additional psychosocial support prior to genetic testing may be necessary in 
certain patients, but current practice made such support mandatory as a “one size fits all” 
approach to a generalized group of patients. One such group consists of young adults 
between 18 and 25 years as described in Chapter 6. Instead such support should focus 
only on those patients portraying specific vulnerability or decisional conflict regarding 
their choice whether or not to start genetic testing. Social workers and psychologists are 
a sparse resource in cancer genetic service centers: this allows them to be more effective. 
Clinical geneticists and genetic counselors should explore certain aspects correlating 
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to decisional conflict – such as coping style and the presence of family mutations – to 
identify those specific patients in need of decisional support and personalized informa-
tion as a filter step prior to referral for additional psychosocial support. Counselors may 
also consider using standard screening questionnaires205 as a tool to help them select 
these patients. 
The road towards genetic testing is undergoing aforementioned changes, but innovative 
genetic technologies such as next generation sequencing are also breaking into clinical 
diagnostics.2 Current evaluations of early patient experiences with two-step exome se-
quencing described in Chapter 7 show that genetic professionals should not hesitate to 
offer this technology in clinical diagnostic settings, provided it is framed within proper 
genetic counseling and informed consent procedures. Further experiences with these 
novel techniques are necessary to increase its clinical benefits: fine-tuning the exist-
ing gene panels, expansion to other heterogenic diseases, as well as allowing for more 
personalized informed consent with patient opt-out possibilities. Continued evaluation 
of worldwide experiences with NGS, be it on a whole exome or even genome level, must 
also continue to inform such genetic testing and counseling policies, especially as more 
becomes known about the nature and frequency of the much-discussed unsolicited (or 
incidental) findings.162
Finally, once a hereditary cancer syndrome has been identified, patients are usually rec-
ommended long-term clinical follow-up. Though university hospitals are often expertise 
centers for hereditary cancer syndromes, patients may prefer regional hospitals for the 
location of their follow-up consultations as shown in BRCA-mutation carriers (Chapter 8) 
especially in the case of a previous cancer diagnosis. Patients in decisional conflict about 
their cancer prevention management options may be more likely to opt for that special-
ized support within university hospitals. This underlines a specific focus for academic 
expertise centers: patients with decisional conflict and/or higher information need.
future Prospects
We live in the so-called Information Age: the Internet serves as an easily accessible 
worldwide network with increasing capabilities for information storage and spread.229 
This goes hand in hand with the health care wide call for shared decision-making4: in 
a 2014 eHealth monitor by Nictiz and NIVEL, 65% of Dutch health care users reported 
having looked online for health information in the past year, of whom 39% used this to 
decide whether or not to consult a doctor.230 eHealth services are increasingly important 
to patient self-care, and such patient engagement in their own health care may lead to 
better health care outcomes.231
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Our online referral tests which guide clinicians in familial cancer risk assessment201 may 
therefore also be suitable for direct use by patients and the general public. In fact, when 
these referral tests were initially made available as self-tests to the general public for a 
short period of time, 256 users filled in an online questionnaire in which the majority 
of 71% reported the self-test provided them with more certainty and/or reassurance 
regarding their familial risk of hereditary cancer: only 3% was less reassured by the self-
test.200 Results from the DNA-direct procedure (Chapters 3-5) also suggest that patients 
are capable of handling such genetic information with less face-to-face time. The self-
test could potentially act as a filter for questions regarding hereditary cancer: only those 
with a moderate or high risk are advised to go to their general practitioner, while the 
majority at low risk is reassured. However, there are concerns about triggering adverse 
psychological effects among unsuspecting healthy individuals and the self-test was 
therefore modified into a professional-aimed referral test. Studies are currently ongoing 
to evaluate the effect of these self-tests on participants in cancer population screening 
programs, as a step towards renewed public availability of the self-tests.
However, as pointed out earlier, genetic factors only explain a minority of all cancers.195 
There is also a wide range of lifestyle risk factors which can be influenced by patients 
themselves, such as smoking, diet and physical activity. Better awareness of these fac-
tors may lead to more patient empowerment through better-informed self-care.231 This 
may be especially important in those already at high risk through genetic predisposi-
tions, as literature consistently suggests that especially smoking and a high body mass 
index further increases CRC risk in Lynch syndrome patients.232 Further studies will be 
performed to assess the knowledge of lifestyle factors among Lynch syndrome patients 
and evaluate the effects of information about these lifestyle factors on both knowledge 
and behavior.
final Considerations
These are exciting times for cancer genetics, as many different evolutions are ongoing 
simultaneously. This includes (but is not limited to) “P5” health care for integration of 
predictive, personalized, preventive, participatory and psychocognitive aspects202,203; 
more patient empowerment and shared decision making4, higher demands for genetic 
services leading to the need to develop and evaluate new service delivery models5 and 
novel technologies showing higher diagnostic yield in different patient groups.2. All the 
more reason to bring all these different developments together into a joint culmination 
of more transparent and multidisciplinary cooperation in the development of future 
health care innovations, taking into account the necessary perceptions for successful 
clinical implementation.7 To do this, we must let go of our professional (or otherwise) 
assumptions and follow our scientific instincts to test these hypotheses instead: only 
then can we prove or disprove the acceptability of these innovations.
Finally, Albert Einstein stated many decades ago: “Intellectuals solve problems, geniuses 
prevent them.” In other words: our priority in oncologic care should not only be curing 
cancer, but preventing cancer from ever happening as well!

Chapter 10
Summary/samenvatting
“Don’t fear failure so much that you 
refuse to try new things. The saddest 
summary of a life contains three 
descriptions: could have, might have, 
and should have.”
(Louis E. Boone)
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SUMMAry
Approximately 5 to 10% of all cancers are based on a hereditary predisposition. The pro-
cess of identifying these families with hereditary cancer can be split into three stages: 
Stage i) recognition & referral
Stage ii) Genetic testing & Counseling
Stage iii) follow-up & Prevention
Considering increased demands for cancer genetic services, this three-stage process 
has become subject to a variety of innovations. Some were borne from technical 
advancements, whereas others were meant to achieve more patient-centered health 
care. Chapter 1 describes each stage within the cancer genetic diagnostic process and 
provides background for specific subjects of attention with associated research needs. 
These needs are addressed by the studies further described in this thesis.
Hereditary cancer syndromes such as Lynch syndrome (LS) or BRCA-mutations remain 
under-recognized. To improve detection of LS, experts had recommended raising the 
age limit for tumor genetic testing in colorectal cancer (CRC) patients from diagnosis 
at age 50 years or below (current practice) to age 70 years or below (experimental strat-
egy). This recommendation was based on expert opinion alone, therefore Chapter 2 
provides scientific evidence that this novel strategy is indeed cost-effective and results 
in fourfold increased detection of LS patients (i.e. LS mutation carriers). Implementation 
is important to find family relatives of those LS patients currently missed and to offer 
them life-saving surveillance. A new version of the Dutch national guideline “Hereditary 
colorectal cancer” is currently being developed to include the new age limit of 70 years. 
This novel strategy greatly simplifies the process of LS identification: half of all CRC cases 
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is diagnosed at 70 years or below and can therefore be immediately tested prior to clini-
cal genetic referral based on a single criterion.
To identify BRCA-mutations, currently no tumor genetic test exists. Therefore an alterna-
tive pathway to improve detection of these families must be found. The face-to-face 
consultation has long been the golden standard, but is not the most effective method of 
providing information: 40% to 80% of verbal medical information is immediately forgot-
ten by patients. Therefore Chapters 3-5 describe a novel procedure for breast cancer (BC) 
genetic diagnostics, where BC patients referred for genetic counseling could choose to 
replace the face-to-face intake consultation (DNA-intake) with telephone, written and 
digital information sent to patients’ homes (DNA-direct). More patients indeed opted 
for DNA-direct over DNA-intake to read pre-test information in the comfort of their own 
home without an additional hospital visit. Moving the first face-to-face contact to only 
post-test also allowed the genetic counselor to immediately discuss personal conse-
quences of BRCA-results for patients and their families. Less consultation time was lost 
covering basic information about BC and heredity, allowing more space for psychosocial 
aspects. Patients were highly satisfied and reported no increased distress on either short 
or long term.
Testing for adult-onset genetic cancer susceptibility such as LS or BRCA-mutations is 
generally not performed on minors below 18 years of age. But concerns have also been 
expressed about testing those from age 18 years, but still younger than the surveillance 
age of 25 years. This could leave a considerable time gap between learning of their he-
reditary predisposition and being able to act upon this knowledge. However, Chapter 6 
demonstrates that almost none of these young adults reported regret of their choice to 
test between 18 and 25 years. Standardized psychosocial support for all young adults 
is time-consuming especially with a growing number of patients seeking out cancer 
genetic services. Our quantitative analysis revealed that some young adults who expe-
rienced decisional conflict, especially those leaning towards a monitoring coping style 
or with paternal inheritance, and may be the appropriate target group for such support. 
This study did not introduce a new element to cancer genetic diagnostics, but instead 
removed the mandatory “one size fits all” pre-test consultation with a social worker or 
psychologist. This support can be more effective when focused on individual patients in 
need of such support, identified by genetic counselors.
A major technological advancement in genetics is so-called next generation sequenc-
ing (NGS) such as whole exome sequencing, allowing the exons of all genes to be 
sequenced simultaneously rather than conventional single-gene testing. Although 
these technologies show great promise, ethical concerns about possible unsolicited 
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or unclear findings led to hesitation to offer these novel techniques in clinical diag-
nostics. The Radboudumc was among the first to implement exome sequencing in a 
clinical diagnostic setting. Chapter 7 describes early patient experiences, showing high 
satisfaction and no increased distress following results of targeted gene panel analysis, 
comparable to conventional single-gene testing. Our study was the very first to quantify 
experiences of a larger group of patients using standardized and validated psychologi-
cal questionnaires. These study results, combined with higher diagnostic yield proven in 
other studies, supported local expansion of eligible diseases and a change in informed 
consent procedure. This change allowed patients to opt out of exome-wide analysis, 
limiting to targeted gene panels to avoid higher probabilities of unsolicited or unclear 
findings.
The last phase within the cancer genetic diagnostic process concerns follow-up and pre-
vention. Once a BRCA-mutation has been identified, these mutation carriers can choose 
to be supported for follow-up care in a regional or university hospital. Chapter 8 evalu-
ates differences between these two groups of BRCA-mutation carriers. BRCA-mutation 
carriers previously diagnosed with BC were more likely to go or return to regional 
hospitals, whereas women supported by UMCs had higher decisional conflict and/
or information need and/or were more likely presymptomatic. This matched regional 
specialists’ preference for a one-time consultation between the UMC expert team and 
BRCA-mutation carriers to discuss consequences for the patient and her family relatives 
(usually presymptomatic) and cancer prevention recommendations. This led to the 
conclusion that both regional and university hospitals fulfill different patient needs in 
the follow-up of BRCA-mutation carriers. Regional collaboration is therefore essential to 
ensure that the individual BRCA-mutation carrier receives optimal care at the appropri-
ate location.
Finally, Chapter 9 summarizes the principal findings of the aforementioned studies, 
as well as the clinical implications and future prospects following from these findings. 
Many ongoing evolutions – “P5” health care, shared decision making, new genetic 
service delivery models, novel genetic technologies – should be brought together into 
a joint culmination of more transparent and multidisciplinary cooperation in the devel-
opment of health care innovations concerning hereditary cancer. Professionals should 
take care not to assume, but to test their suspicions as scientific hypotheses. Oncologic 
care should focus not only on curing those already struck by illness, but also primary 
prevention as the most effective way to fight cancer.
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SAMenvAttinG
Ongeveer 5 tot 10% van alle kanker gevallen wordt veroorzaakt door een erfelijke 
aanleg. De procedure om deze families met erfelijke kanker te herkennen kan worden 
opgesplitst in drie fasen:
fase i) herkenning & verwijzing
fase ii) Genetisch testen & Counseling
fase iii) follow-up & Preventie
De vraag naar kanker genetische zorg neemt toe, waardoor deze drie-fase proce-
dure onderhevig is aan verschillende innovaties. Sommigen komen voort uit technische 
vooruitgangen, terwijl anderen bedoeld zijn om meer patiëntgerichte zorg te bereiken. 
hoofdstuk 1 omschrijft elke fase van de kanker genetische diagnostische procedure 
en geeft de achtergrond weer voor specifieke aandachtspunten met de bijbehorende 
onderzoek behoeften. Deze behoeften vormen de basis voor de wetenschappelijke 
studies die vervolgens in dit proefschrift worden omschreven.
Erfelijke kanker syndromen zoals Lynch syndroom (LS) of BRCA-mutaties worden nog 
steeds niet voldoende herkend. Om de herkenning van LS te verbeteren, hadden 
experts aanbevolen om de leeftijdsgrens voor tumor genetisch testen in patiënten 
met colorectaal carcinoom (CRC) van een maximale diagnoseleeftijd 50 jaar (huidige 
praktijk) te verhogen naar een maximale diagnoseleeftijd van 70 jaar (experimentele 
strategie). Deze aanbeveling was alleen gebaseerd op de opinie van experts. Daarom 
verschaft hoofdstuk 2 wetenschappelijk bewijs dat deze nieuwe strategie inderdaad 
kosteneffectief is en leidt tot de diagnose LS bij viermaal zoveel patiënten. Implemen-
tatie is belangrijk omdat de familieleden van de patiënten met LS die nu nog worden 
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gemist, daarmee kunnen profiteren van preventie of vroegdiagnostiek van een CRC. Een 
nieuwe versie van de Nederlandse richtlijn “Erfelijke darmkanker” wordt momenteel 
ontwikkeld, inclusief deze nieuwe leeftijdsgrens van 70 jaar. Deze nieuwe strategie 
zal het diagnostisch proces bij LS versimpelen, omdat patiënten met een colorectaal 
carcinoom tot en met 70 jaar meteen worden getest op basis van dit enkele criterium 
voorafgaand aan verwijzing door een klinisch geneticus.
Momenteel bestaat er geen tumor genetische test om BRCA-mutaties te identificeren. 
Om herkenning van deze families te verbeteren, moet daarom gezocht worden naar een 
alternatief. Het persoonlijke (face-to-face) consult is al lange tijd de gouden standaard, 
maar blijkt niet de meest effectieve vorm van informatievoorziening: 40% tot 80% van 
verbale medische informatie wordt direct door patiënten vergeten. Daarom beschrijven 
hoofdstukken 3-5 een nieuwe procedure voor borstkanker (BK) genetische diagnostiek, 
waarbij patiënten met BK die verwezen worden voor genetische counseling, de keuze 
krijgen om het face-to-face intake gesprek (DNA-intake) te vervangen met telefonisch, 
schriftelijke en online informatie om thuis te ontvangen (DNA-direct). Meer patiënten 
kozen inderdaad DNA-direct in plaats van DNA-intake om pre-test informatie op eigen 
gemak thuis door te nemen zonder een extra ziekenhuisbezoek. Door het eerste face-
to-face contact alleen post-test te laten plaatsvinden, kon de genetisch counselor ook 
direct de persoonlijke gevolgen van de BRCA-uitslag voor de patiënt en haar familie 
bespreken. Minder consult tijd ging verloren aan de uitleg van algemene informatie 
over BK en erfelijkheid, zodat meer ruimte overbleef voor psychosociale aspecten. Pa-
tiënten waren zeer tevreden en rapporteerden geen verhoging van distress op korte of 
lange termijn.
Het testen van erfelijke aanleg voor kanker wat zich uit op volwassen leeftijd, zoals LS 
of BRCA-mutaties, wordt over het algemeen niet gedaan bij minderjarigen jonger dan 
18 jaar. Echter zijn er ook zorgen over het testen van personen vanaf 18 jaar, die nog 
jonger zijn dan de surveillance leeftijd van 25 jaar. Mogelijk betekent dit een aanzienlijk 
tijdsgat tussen het weten dat zij een erfelijke aanleg hebben en de mogelijkheid om 
op deze kennis actie te ondernemen. Echter, hoofdstuk 6 laat zien dat bijna geen van 
deze jongvolwassenen spijt hebben van hun keuze om zich te laten testen tussen 18 en 
25 jaar. Standaard psychosociale ondersteuning voor alle jongvolwassenen is tijdrovend, 
vooral gezien het groeiend aantal patiënten voor kanker genetische zorg. Onze kwanti-
tatieve analyse liet zien dat sommige jongvolwassenen wel moeite met besluitvorming 
(decisional conflict) ervoeren, vooral degenen met een actieve informatiezoekende 
verwerkingsstijl of paternale overerving. Dit vormt mogelijk de juiste doelgroep voor 
dergelijke ondersteuning. Deze studie betrof niet het introduceren van een nieuw 
onderdeel in kanker genetische diagnostiek, maar nam juist het verplichte “one size fits 
Chapter 10
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all” pre-test consult met een maatschappelijk werker of psycholoog weg. Deze onder-
steuning is meer effectief als deze gericht is op individuele patiënten met behoefte aan 
deze begeleiding, herkend door de genetische counselors.
Een enorme technische vooruitgang binnen de genetica is het zogenaamde next gene-
ration sequencing (NGS) zoals exoom sequencing, waarmee de exonen van alle genen 
tegelijkertijd bekeken worden in tegenstelling tot traditioneel enkel-gen testen. Hoe-
wel deze technieken veelbelovend zijn, leiden ethische zorgen rondom ongevraagde 
of onduidelijke bevindingen tot terughoudendheid bij het aanbieden van deze nieuwe 
technieken in klinische diagnostiek. Het Radboudumc was een van de eerste centra die 
exoom sequencing implementeerde in een klinisch diagnostische setting. hoofdstuk 
7 omschrijft de eerste patiëntervaringen, met hoge tevredenheid en geen verhoogde 
distress na de uitslagen van gerichte genenpanels, vergelijkbaar met traditionele enkel-
gen testen. Onze studie was de allereerste die deze ervaringen van een grote groep 
patiënten kwantificeerde, gebruikmakend van gestandaardiseerde en gevalideerde 
psychologische vragenlijsten. Deze studieresultaten, tesamen met de hogere diagnosti-
sche opbrengst aangetoond in andere studies, leidden tot lokale uitbreiding van ziekten 
die in aanmerking komen voor exoom sequencing en een verandering van het informed 
consent beleid. Door deze verandering kunnen patiënten kiezen om geen exoom-brede 
analyse uit te voeren (opt-out), om zich te beperken tot gerichte genenpanels en hogere 
kansen op ongevraagde of onduidelijke bevindingen te vermijden.
De laatste fase binnen de kanker genetische diagnostische procedure betreft follow-up 
en preventie. Als een BRCA-mutatie eenmaal is ontdekt, kunnen deze mutatiedraagsters 
kiezen voor follow-up begeleiding in een regionaal ziekenhuis of een universitair me-
disch centrum (UMC). hoofdstuk 8 evalueert verschillen tussen deze twee groepen van 
BRCA-mutatiedraagsters. BRCA-mutatiedraagsters gediagnosticeerd met borstkanker 
gingen vaker (terug) naar de eigen regio, terwijl vrouwen begeleid in een UMC vaker 
hoger decisional conflict (oftewel moeite met besluitvorming rondom borstkanker pre-
ventie) en/of meer informatiebehoefte hadden, en/of vaker presymptomatisch waren. 
Dit kwam overeen met de voorkeur van regionale specialisten voor een eenmalig con-
sult tussen het UMC expertiseteam en BRCA-mutatiedraagsters, om gevolgen voor de 
patiënt en haar familieleden (veelal presymptomatisch) en kanker preventiemaatrege-
len te bespreken. Dit leidde tot de conclusie dat regionale ziekenhuizen en UMC’s ieder 
verschillende patiëntbehoeften vervullen bij de follow-up van BRCA-mutatiedraagsters. 
Regionale samenwerking is daarom van uiterst belang om te zorgen dat de individuele 
BRCA-mutatiedraagster de juiste zorg krijgt op de juiste plaats.
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Tot slot geeft hoofdstuk 9 een samenvatting van de hoofdbevindingen van de voorge-
noemde studies, als ook de klinische implicaties en toekomstperspectieven ten gevolge 
van deze bevindingen. Vele voortgaande evoluties – “P5” gezondheidszorg, gedeelde 
besluitvorming, nieuwe modellen voor genetische dienstverlening, nieuwe genetische 
technieken – zouden bijeen gebracht moeten worden tot een gezamenlijk hoogtepunt 
van meer transparante en multidisciplinaire samenwerking in de ontwikkeling van 
zorginnovaties rondom erfelijke kanker. Professionals moeten uitkijken voor het maken 
van aannames, maar hun verdenkingen juist toetsen als zijnde wetenschappelijke 
hypothesen. Oncologische zorg moet zich richten niet alleen op het beter maken van 
reeds zieke personen, maar ook primaire preventie als de meest effectieve manier om 
kanker te bestrijden.
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Als kind had ik drie voornaamste dromen: dokter, schrijver en rockster worden. Het 
eerste om “net als papa” mensen te kunnen helpen, de rest vanwege mijn creatieve 
kant. Nu blijken tot mijn verwondering de eerste twee hiervan gelukt! (Mijn nieuwe 
doelstelling is dus duidelijk: ik moet “alleen nog maar” rockster worden.) De afgelopen 
vier jaren zijn voorbij gevlogen met de nodige pieken en dalen, maar hier is dan toch 
eindelijk dit boekwerk als resultaat. Ik heb dan ook veel personen om te bedanken voor 
alle bijdragen in al die jaren.
Om te beginnen alle patiënten als kern van mijn onderzoeken: invullen van vragenlijs-
ten, meedoen aan interviews, discussiëren in focusgroepen. Zonder al die welwillende 
input had ik nooit iets kunnen zeggen over deze “patient experiences”.
Geachte prof. dr. Hoogerbrugge, beste Nicoline: het beeld van de stoffige academicus 
die ik ooit had, had jij binnen no time weggevaagd! Jouw enorme drive om de zorg 
te verbeteren was bijzonder aanstekelijk. Hartelijk dank voor jouw vertrouwen in mijn 
kwaliteiten: mede hierdoor durfde ik uiteindelijk te kiezen voor de wetenschap boven 
directe patiëntenzorg. Wat ben ik blij dat wij de aankomende jaren blijven samenwerken!
Geachte prof. dr. Prins, beste Judith: ook jij was een fantastisch rolmodel voor mij als 
jonge vrouwelijke onderzoeker! Van jou heb ik vooral de zorgvuldigheid meegekregen, 
waarmee jij als klinisch psycholoog tot allerlei inzichten rondom deze patiëntervaringen 
kwam, die wij als clinici soms net over het hoofd zagen. Jij maakte die brug tussen het 
medische en het menselijke in al die jaren mogelijk, heel erg bedankt!
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Geachte prof. dr. Massuger, prof. dr. Speckens en prof. dr. van Asperen: hiermee wil ik u 
als leden van de manuscriptcommissie hartelijk bedanken voor de tijd en moeite om 
mijn proefschrift te beoordelen en met mij van gedachten te wisselen. Geachte prof. dr. 
van Goor, prof. dr. van Krieken, prof. dr. Westert, dr. Kets en dr. Bleiker, ook aan u als leden 
van de oppositiecommissie mijn oprechte dank voor uw bijdragen aan deze bijzondere 
plechtigheid.
Dit proefschrift heb ik alleen kunnen voltooien met de hulp van een hele reeks aan 
collega’s binnen het Radboudumc, vooral van mijn eigen afdeling Genetica maar ook 
daarbuiten. Ik wil dan ook iedereen bedanken die direct of indirect heeft bijgedragen, 
maar ook een aantal mensen specifiek noemen:
Margot: fantastisch dat je mij als paranimf bijstaat! Juist in de stressvolle eindspurt van 
mijn promotietraject, hield jij mij goed in de gaten voor de nodige lunch pauzes en 
vrijdagmiddag borrels... wat ontzettend fijn en leuk dat je mij ook bij deze speciale dag 
wilde steunen. Ik ben je nog heel wat koekjes verschuldigd!
Alle huidige maar ook voormalige collega’s van de Klinische Genetica, vooral binnen de 
oncogenetica: ik heb in allerlei combinaties met velen van jullie mogen samenwerken, 
maar ook ontzettend veel plezier gehad aan de simpele collegialiteit van allemaal. In 
het bijzonder bedank ik allereerst mijn oud-kamergenootjes voor al het gedeelde lief 
en leed: Peggy, Marjolein, Anneke, Janneke, Nicky, Corrie, Gea en Lieke. Peggy, wat een 
genot om onze liefdes voor Star Wars en street art te kunnen delen: bedankt voor al 
je geduldige antwoorden op mijn suffe statistiek-vraagjes. Nicky, wat heb ik je enorm 
moeten missen de laatste paar jaren: door jouw moedige voorbeeld durfde ik ook als 
arts in de wetenschap te blijven, en daarvoor blijf ik je enorm dankbaar. Corrie, jij met 
jouw mama-wijsheden waren een bijzondere steun bij mijn twijfels over patiëntenzorg 
of onderzoek, dank je wel voor jouw grote hart. Lieke, wat vliegen vier maanden snel 
voorbij met zoveel gezelligheid: nogmaals bedankt voor het helpen versturen van die 
zéér belangrijke enveloppen!
Verder wil ik bedanken voor de directe samenwerking in het onderzoek, maar ook de 
gezelligheid daarbuiten: Liesbeth, Wendy, Han, Marleen, Gwendolyn, Ilse, Erica, Maayke, 
Marsha, Martine en Nienke. Liesbeth, met jou is het altijd lachen om alle Facebook 
onbenulligheden, bedankt dat dit gewoon kon naast al het serieuze werk. Gwendolyn, 
dank je wel voor jouw praktische aanpak in alles wat je tegenkomt, af en toe zo’n frisse 
adem van al het academische om ons heen. En wat betreft die gezelligheid zijn dan 
ook zeker niet te vergeten: Lot, Arjen van E, Charlotte, Sonja, Marjolijn J, Marlies, Lianne, 
Yvonne, Esther, Leonie, Emine, Karen, Daphne, Yvette, Anne-Marie en Dinusha. Esther, 
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mijn partner in crime in volwaardige nerddom, we blijven elkaar gelukkig zien met alle 
fantasy fairs. Emine, dank je voor al het lief en leed die we konden delen, zelfs de IND 
frustraties die jij ook helemaal herkende. Lot, Charlotte, Leonie, Karen, Dinusha: onze 
diehard vrij/domiboco, fantastisch dat jullie altijd in zijn voor een borrel en/of etentje, 
bedankt voor alle leuke avonden. Arjen, zelfs als ANIOS was je al enthousiast over onze 
zorgvernieuwing, dat gaf mij een extra boost bij de laatste loodjes – bedankt en super 
dat jij die fakkel als nieuwe PhD student overneemt!
Ook mijn collega’s van de DNA-diagnostiek en research binnen de afdeling Genetica wil 
ik hartelijk bedanken voor alle bijdragen aan dit proefschrift, in het bijzonder Marjolijn 
L, Arjen M, Joris, Ingrid en Richarda. Marjolijn en Arjen: allebei bedankt voor die nauwe 
en bijzonder prettige samenwerking door alle jaren heen, deze brug tussen kliniek en 
lab was ook kenmerkend voor dit proefschrift van begin tot eind. Ingrid, wat een timing 
met onze proefschriften, heel veel succes als postdoc in de VS!
Verder wil ik nog bedanken: alle collega’s betrokken bij oncogenetisch onderzoek 
vanuit andere disciplines en afdelingen, vooral Annemiek, Joanne, Rosella en Eddy voor 
hun directe betrokkenheid bij mijn onderzoeken. Annemiek: wat was het enorm leuk 
om een tijdje samen met jou als maatje te werken – succes met jouw laatste promotie-
loodjes en jouw eigen postdoc project!
Ooit is mijn wetenschappelijke avontuur begonnen met een gewone onderzoeksstage 
bij de Gynaecologie & Obstetrie en Klinische Genetica in het UMCG. Marian, Truuske 
en Jan: hartelijk dank voor dat eerste zetje richting zowel de wetenschap als de onco-
genetica. Ook dank aan de “Amateur Gynaecologen” van kamer Y4.228 voor alle gezellige 
tijden toen en reünies nu: Annemarie, Froukje, Ilse, Ineke, Karin, Kim, Maaike, Maartje, 
Marloes, Mèlanie, Nina en Sophie.
Al mijn lieve familie, vrienden en vriendinnen, aan jullie mijn eeuwige dank voor alle 
steun en het aanhoren van mijn drukke onderzoekersleven waardoor ik zo weinig met 
jullie kon afspreken: Yuan, Michiel, Kylie, Jason, Stefanie, Dennis, Wendolien, Mirjam, 
Mirte, Amy, Tycho, Hilde, Jan, Elvira en Warnar. Yuan: mijn onofficiële kleine broertje, jij 
stond altijd voor mij klaar vooral tijdens perioden van onzekerheid, dank je wel voor 
al die steun. Kylie: bijzonder dat wij als nichtjes ongeveer hetzelfde pad bewandelen, 
met ons hart meer in de wetenschap dan alleen zorg… als mij dit lukt, lukt jou dat 
ook! Steffy: bedankt dat wij naast onze jarenlange vriendschap ook onze ervaringen 
in de medische wetenschap konden delen, dat gaf mij soms net die nodige moed en 
doorzettingsvermogen. And a special shout-out to all my international friends for their 
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support, from closeby or afar: Ajeng, Amber, Julia, Rafael, Tiscilla, Michelle, Jeroen, Erika, 
Cees-Jan, Frank, Gabi, Scott, Simon, Kayla, Mitchell, Stelian and Shawn.
Naturally, my thanks above also extends to my family-in-law in the US. Most importantly 
Elaine, Dean and Faith: thank you so much for always believing in me throughout these 
years and letting me be part of your family, long before we ever signed anything into 
law. I love y’all.
Lieve papa, lieve mama: ik heb dit alleen maar kunnen doen dankzij jullie liefdevolle 
steun en volste vertrouwen alle 30 jaren van mijn leven, dat ik – ondanks een studie en 
vervolgens carrière switch – wel op mijn pootjes terecht zou komen. Ik hou van jullie en 
ben jullie voor altijd dankbaar, voor dit en zoveel meer.
Lieve Guy: hoewel het academische wereldje jou niet ligt, kick je wel op tradities. En op 
zo’n speciale dag als deze, denk ik ook: wat moet ik toch zonder mijn grote broer? Dat 
jij mijn paranimf wilde zijn om deze mijlpaal met mij te delen, betekent dan ook enorm 
veel voor mij. Dank je wel voor al je lieve steun, broertjuh.
My dearest Ross: where to begin? A good part of this PhD project was all about breaking 
out of my comfort zone, and you were the one giving me the confidence to fly that high, 
with a safe haven to come home to. Thanks to your neverending love and support, I can 
follow my own path with you always by my side. I cannot imagine my life – either before 
or after this PhD – without you. Thank you for putting up with me throughout these 
years, both at my best and at my worst. I love you with all my heart.
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